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Project motivation  
 
A major focus of Professor Paul Freemont’s research group is nuclear organization in 
the cell. We are using PML and PML nuclear bodies (NBs) together with other 
nuclear compartments to investigate the relationships between the NBs and how they 
are organized. This means that functional studies of the PML protein and associated 
factors are important to us, and they have informed the thesis I have been working on. 
When I began to study the PML field around 20 years ago in Hans Will’s group in 
Hamburg, PML NBs were called ‘nuclear dots’ and it was only Sp100 that was 
known to localize to nuclear bodies. The second nuclear body protein to be identified 
was PML. PML was discovered as a fusion protein with the retinoid acid receptor in 
acute promyelytic leukaemia and is now probably the most prominent NB constituent 
of all. We now know that PML NBs contain more than 80 constituents, most of them 
showing only a partial and transient colocalisation. For many years research groups 
failed to distinguish between the various PML isoforms they were working with and 
naturally obtained diverse results. Around 10 years ago, when I joined Paul 
Freemont’s group in London, we wrote a review naming all the different PML 
isoforms and splice variants, making clear the high number of PML proteins 
expressed in the cell and hence the variety their functions. 
Today our main interest is the involvement of PML and PML NBs in apoptosis. There 
is no formation of PML NBs in PML -/- cells because PML is necessary for PML NB 
formation and SUMO is important for the formation of mature PML NBs.  
We are also interested in SUMO-modification of proteins and the regulatory functions 
where SUMO-modification is involved. Many research groups have speculated that 
SUMO-modification takes place within the PML NBs, partly because many of the 
constituents are being SUMO-modified but also because many of the constituents are 
part of the SUMO-modification machinery. PML has been shown to be a SUMO E3 
ligase and to bind to the SUMO-conjugating enzyme Ubc9.  
Our overall is aim to discover more about the function of PML NBs and PML NB 
constituents. This will give us a better insight into how the disruption of the 
organisation of PML NBs can cause human disease. After more than 20 years of 
investigation, PML NBs have turned out to be very complex – and extremely 
interesting. 
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Abstract 
 
PML nuclear bodies (NBs) consist of more than 80 constituents and are involved in 
many cellular processes such as apoptosis, DNA repair, cell cycle, transcriptional 
regulation and development. PML NBs are associated with the ‘nuclear matrix’ and 
vary in size from 0.3 to 1.0 µm in diameter. PML NBs came to prominence when 
PML, expressed as an oncogenic fusion protein with the retinoic acid receptor, was 
found in patients with acute promyelocytic leukaemia. PML is the major PML NB 
constituent and is involved in cellular activities such as apoptosis, growth 
suppression, antiviral defence and DNA repair, among many others. PML can be 
modified by the Small Ubiquitin-like MOdifier (SUMO) and contains a SUMO-
interacting motif (SIM). Both SUMO-modification and SUMO-interaction play an 
important role in the formation of PML NBs. 
The aim of this study is to gain deeper knowledge about PML, PML NBs and 
associated factors. Preliminary data show that PML is interacting with TRAF4-
associated factor 1 (TFAF-1). The TRAF family of proteins forms part of a signalling 
pathway via the TNF receptor and is implicated in growth regulation. When TFAF-1 
is expressed as a fusion protein with a red fluorescent protein it forms filamentous 
structures. These structures colocalise with death-effector filaments (DEFs). DEFs are 
formed by the Fas-associated death domain (FADD) and the prodomain of caspase-8.  
The main focus of this study was to discover more about how PML and PML NBs 
regulate apoptotic pathways, and thereby gain a better insight into the organisation of 
PML and PML NBs and how their disruption contributes to human disease. The 
association between TFAF-1, PML, PML NBs and DEFs was investigated further. 
DEFs were found to disrupt PML NBs and phosphorylation of FADD was found to be 
necessary for the disruption. Casein kinase 1 alpha (CK1 alpha) phosphorylates 
FADD at S194, which has been shown to regulate the apoptotic activities of FADD. 
Thus the regulation of the kinase activity and the phosphorylation of FADD, together 
with PML and PML NBs were investigated. Preliminary data shows that CK1 is 
modified by SUMO. This might take place at the PML NBs and adds a whole new 
aspect to the already very complex story of PML NBs and PML NB constituents. 
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AML  acute myeloid leukaemia 
APL   acute promyelocytic leukaemia 
ATRA  all-trans retinoid acid 
CARD  caspase recruitment domain 
CBs  cajal bodies 
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CK1  casein kinase 1 
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SUMO  small ubiquitin modifier 
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TNF  tumor necrosis factor 
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1 Introduction 
1.1 The mammalian nucleus 
1.1.1 The mammalian nucleus and subcompartments of the nucleus 
The most prominent organelle of the eukaryotic cell is the nucleus. It contains all the 
machinery essential for gene expression. It is surrounded by the nuclear envelope, 
which consists of two membranes. The two membranes are fused together at nuclear 
pores, which allow smaller molecules to diffuse freely while regulating the transport 
of larger molecules such as proteins. The nucleus contains all the genetic information 
necessary for division and maintenance of the cell. This information is stored on 
chromosomes. Chromosomes are packed into chromatin and their structure varies 
throughout the cell cycle. For example, chromosomes condense in the M phase of the 
cell cycle, whereas in interphase, specific regions of chromosomes decondense, 
becoming accessible for gene expression. Chromatin consists of DNA wrapped 
around histones, forming nucleosomes, and is organised into chromosome territories. 
The location of these territories relates to gene density and expression (Cremer and 
Cremer, 2001). Chromatin consists of the lesser-condensed, active euchromatin and 
the highly condensed, mostly inactive heterochromatin. Euchromatin is usually 
located on the interior of the nuclear space whereas heterochromatin is located at the 
nuclear periphery, often close to the nucleolus. Gene positioning might be self-
organising, dependent not only on expression but also on interactions between 
chromosomes, e.g. co-regulated genes and the association of regulatory elements with 
their target genes (Misteli, 2008). An overview of the mammalian nucleus and its 
organisation can be seen in Figure 1.1. 
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Figure 1.1. An overview of the mammalian nucleus and its organisation 
The nucleus is surrounded by the nuclear envelope, which contains nuclear pores. PML nuclear bodies 
(PML NBs), Cajal bodies (CBs) and nuclear speckles localise to the interchromatin compartment (IC) 
or interchromosomal domain compartment (ICD). This compartment forms outside the chromosome 
territories (CT), which are a major feature of nuclear organisation. Adapted from (Lanctot et al., 2007). 
 
 
1.1.2 Nuclear bodies and dynamics of the nuclear compartments 
Several studies have identified an increasing number of specialised domains within 
the nucleus (Lamond and Earnshaw, 1998). These compartments are often referred to 
as nuclear bodies. They are defined by distinct sets of residual proteins and include 
nucleoli, Cajal bodies (CBs), promyelocytic leukaemia nuclear bodies (PML NBs), 
nuclear speckles, active sites of transcription, polycomb group (PcG) bodies, gemini 
bodies (gems) and 53BP1 NBs, amongst many others. Nuclear compartments are non 
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membrane-bound, which was previously thought to lead to their random distribution. 
Although it is now known that the nucleus is highly organised, the formation of 
nuclear compartments is still not fully understood. In some cases, the domains have 
been shown to be dynamic structures and a rapid protein exchange occurs between 
them and the nucleoplasm (Misteli, 2001; Misteli, 2007). New microscopy techniques 
have helped in studying the systemic organisation of the nucleus, and further studies 
might help us to understand how disruption of this organisation can contribute to 
human disease (Misteli, 2010). How and why such nuclear structures form is far from 
clear, but two differing models have been discussed in the literature (Kaiser et al., 
2008; Matera et al., 2009; Mao et al., 2011). While both involve recruitment of 
components from the soluble nucleoplasmic pool, one model is ordered and built 
around a single scaffolding component and the other is stochastic: its components 
assemble in a random order. Although the assembly is stochastic, it can still be 
predicted through known interactions. Loss of one component of the complex can 
lead to the failure to incorporate another component and therefore to disruption of the 
nuclear organisation (Kaiser et al., 2008; Matera et al., 2009; Mao et al., 2011). 
 
1.2 PML and PML nuclear bodies 
1.2.1 Identification of PML and PML nuclear bodies 
PML NBs (also known as ND10 or PODs) were first identified over 50 years ago (de 
The et al., 1960) and comprise a multi-protein heterogeneous complex of over 80 
proteins (see Figure 1.2) that is implicated in numerous cellular activities such as 
ageing, apoptosis, the cell cycle, stress response, hormone signalling, transcriptional 
regulation and development (reviewed in Negorev and Maul, 2001; Lallemand-
Breitenbach and de The, 2010). Thirty years later, the first PML NB component, 
Sp100, was discovered using autoimmune sera from primary billiary cirrhosis (PBC) 
patients (Szostecki et al., 1990). PML NBs are associated with the ‘nuclear matrix’ 
and are found in nearly all cell types, varying both in size (from 0.3 to 1.0 µm in 
diameter) and number (10 to 30 structures per cell). PML NBs came to attention with 
the discovery that PML, a major protein constituent, was associated with acute 
promyelocytic leukaemia (APL), a type of cancer characterised by a reciprocal 
chromosomal translocation of chromosomes 15 and 17 resulting in a fusion protein 
comprising PML and the retinoic acid receptor α  (RARα)  (reviewed in Zelent et al., 
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2001). In APL patients, it is observed that PML NBs are disrupted into smaller and 
more dispersed bodies whereas in treated patients the bodies reform, suggesting that 
the integrity of PML is directly correlated with the APL disease phenotype (Koken et 
al., 1995; Le et al., 1996). 
In APL patients treated with arsenic trioxide the PML NBs reform. Arsenic trioxide 
binds to PML and PML/RARα in the B2-domain of PML and induces the formation 
of intermolecular disulfate bonds (Jeanne et al., 2010) followed by SUMO-
modification and degradation of PML (Lallemand-Breitenbach et al., 2008; Tatham et 
al., 2008); whereas the treatment with all-trans-retinoic acid causes mostly 
differentiation of the APL blasts but also degradation of of RARα and PML/RARα 
via the RARα moiety (reviewed in Dos Santos et al., 2013). 
 
Figure 1.2. A list of cellular proteins identified to localise to PML nuclear bodies 
PML and Sp100 are two major components of PML NBs and always co-localise. The other 
components are either recruited or localise transiently to the PML NBs under specific conditions. 
 
 
1.2.2 PML  
In the following sections and in my studies I concentrated on PML, Sp100, Daxx and 
SUMO because these are the major components of PML NBs and usually colocalise, 
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whereas many of the other PML NB components are either recruited or localise 
transiently to PML NBs under specific conditions. 
PML is the key organizer of PML NBs and it has been shown that PML -/- mice 
cannot assemble PML NBs (Zhong et al., 2000). The PML genomic locus is 
approximately 35 kb in length. It is subdivided into nine exons and a large number of 
alternative spliced transcripts are synthesized from the PML gene, resulting in a 
variety of PML proteins ranging in molecular weight from 48–97 kDa (Jensen et al., 
2001). The PML gene encodes six distinct groups of isoforms, all of which contain a 
conserved TRIpartite Motif or TRIM (Reymond et al., 2001), consisting of a RING 
finger, two B-boxes and a coiled-coil domain – also named the RBCC motif (Jensen 
et al., 2001). Studies of the RBCC/TRIM motif have included both biophysical and 
functional approaches, resulting in the first description of the structure of the PML 
RING-finger domain (Borden et al., 1995). By using this structure as strategy for 
further experiments, it was shown that point mutations in the RING finger had severe 
effects on the structure and integrity of PML NBs in vivo (Boddy et al., 1997). Further 
studies on the RBCC/TRIM motif showed that mutations in the B-box also disrupted 
PML NB formation in vivo and that homo-oligomerisation via the coiled-coil domain 
was not sufficient for NB formation (Borden et al., 1996). 
A yeast two-hybrid protein screen for PML led to the first description of PIC1 (PML 
interacting clone 1), now known as Small Ubiquitin-like Modifier (SUMO)-1 (Boddy 
et al., 1996). PML was the first NB protein shown to be modified by SUMO-1 
(Kamitani et al., 1998c, Muller et al., 1998, Sternsdorf et al., 1997). At least three 
lysine residues can serve as SUMO-1 modification sites in the PML protein (Duprez 
et al., 1999; Kamitani et al., 1998b). A detailed study showed one major modification 
site, K490, was part of the nuclear localisation signal (NLS) and another site, K65, 
was where the SUMO-specific E2 conjugating enzyme UBC9 interacted with PML 
via the RING finger domain (Duprez et al., 1999).  
PML is expressed as several different isoforms (Fagioli et al., 1992; Jensen et al., 
2001). The isoforms are divided into groups on the basis of sequence differences 
found at the C-terminus (Jensen et al., 2001). A further division into subgroups has 
been made which reflects the alternative splicing of exons 4, 5 and 6 (Fagioli et al., 
1992; Jensen et al., 2001). A NLS is located in exon 6 (Jensen et al., 2001) and two 
splice variants that lack exon 6, PML VIb and PML VIIb, have been identified 
(Reymond et al., 2001). PML I, the longest isoform, contains a nuclear export signal 
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(NES) (Henderson and Eleftheriou, 2000) and has a nuclear and cytoplasmic 
distribution when overexpressed in PML -/- cells (Condemine et al., 2006). All PML 
isoforms except for b/c variants (variants without exon 5 and 6 or exon 4, 5 and 6) 
contain the three SUMO modification sites and a NLS, suggesting that the 
functionality of these motifs is relevant to most PML isoforms. Another relevant 
motif in the PML protein is the SUMO interacting motif (SIM) (Shen et al., 2006). 
The SIM is localised in exon 7a and found in all PML isoforms except for PML VI 
(Brand et al., 2010). (See Figure 1.3 for an overview of the PML domain structure.) 
 
 
 
 
Figure 1.3. PML domain structure 
All PML isoform share the N-terminal domain containing the RBCC/TRIM motif. PML isoforms are 
made by alternative splicing at the C-terminus, resulting in altered sizes of each isoform. SUMO 
modification sites (S) are located at positions K65, K160 and K490. *Retained intron sequence. 
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1.2.3 Sp100 
A large number of cellular proteins have been identified as localising to PML NBs. 
All components, except for Sp100, localise transiently to PML NBs or are recruited to 
them under certain conditions. The Sp100 protein which was the first PML NB 
component identified (Szostecki et al., 1990) is expressed as many C-terminal- 
spliced variants (Guldner et al., 1999). Sp100, like PML, is an interferon-inducible 
protein (Guldner et al., 1992; Grotzinger et al., 1996b) and can also be modified by 
SUMO-1 (Sternsdorf et al., 1997). Interestingly, modification of Sp100 is dependent 
on a functional NLS but is not necessary for nuclear import or targeting to PML NBs 
(Sternsdorf et al., 1999). Sp100 has also been shown to interact with SUMO via a 
SUMO interaction motif. It was identified as a SUMO-1/2 interaction partner in a 
yeast two-hybrid assay (Hecker et al., 2006). Furthermore, the SIM in Sp100 is 
essential for in vivo Sp100 SUMO modification (Knipscheer et al., 2008). 
Sp100 is a PML NB component that links PML NBs to apoptosis. Caspase-8-binding 
FLICE-associated huge protein (FLASH) has been shown to interact with Sp100. 
FLASH localises to the nucleus in the PML NBs but is translocated to the cytoplasm 
upon CD95 activation, where it interacts with caspase-8 at the mitochondria and 
subsequently activates the mitochondrial apoptosis pathway (Milovic-Holm et al., 
2007). Sp100 has also been shown to contain a potential caspase recruitment domain 
(CARD) (Sanchez-Pulido et al., 2007), also known as the HSR domain (Grotzinger et 
al., 1996a; Sternsdorf et al., 1999). It has been speculated that Sp100 can interact with 
caspase-2 via this domain (Sanchez-Pulido et al., 2007). Caspase-2 also localises to 
PML NBs (Tang et al., 2005) and the CARD in procaspase-2 is modified by SUMO-1 
(Shirakura et al., 2005). It is possible that SUMO-1 modification might play a critical 
role in the maturation/activation and nuclear localisation of procaspase-2 (Shirakura et 
al., 2005). 
 
1.2.4 Daxx 
The death domain-associated protein (Daxx) was originally discovered as a Fas-
receptor interacting protein (Torii et al., 1999; Yang et al., 1997), and also links PML 
NBs to apoptosis. Daxx localises to the cytoplasm, as well as the nucleus where it is 
found as a component of PML NBs. It can be modified by SUMO-1 (Jang et al., 
2002) and has also been shown to interact with SUMO-modified PML (Ishov et al., 
 24 
1999). Localisation of Daxx to PML NBs correlates with the proapoptotic activity of 
Daxx, and Daxx mutants that fail to localise to PML NBs do not facilitate Fas-
induced cell death (Torii et al., 1999). Daxx is also found in the nucleoplasm and 
within heterochromatic regions of the nucleus in PML -/- cells, where it also fails to 
facilitate apoptosis (Ishov et al., 1999). Several studies suggest a role for Daxx in 
promoting apoptosis (Torii et al., 1999; Yang et al., 1997), which is in apparent 
conflict with the results obtained from mutation of the Daxx gene in vivo (Michaelson 
et al., 1999). Surprisingly, Daxx-deficient mice show extensive apoptosis and 
embryonic lethality. The role of Daxx in preventing and/or inducing apoptosis 
remains unclear (Salomoni and Khelifi, 2006). 
Daxx has also been shown to interact with SUMO (Ryu et al., 2000) and this 
interaction is necessary for SUMO-modification of Daxx (Lin et al., 2006). It has 
been speculated that the interaction with SUMO might target Daxx to PML NBs 
where it can be modified by SUMO, although levels of SUMO-modified Daxx did not 
change in cells transfected with PML siRNA (Lin et al., 2006). The SIM in Daxx is 
also important for transrepression of several SUMO-modified transcription factors 
(Lin et al., 2006). Recently it was shown that the Daxx SIM is phosphorylated by 
CK2 kinase (Chang et al., 2011). This phosphorylation promotes binding affinity 
towards SUMO-1 over SUMO-2/3 and results in Daxx interacting with SUMO-1-
modified proteins, implying a preference (Chang et al., 2011). 
At the moment there are two models proposed for the proapoptotic function of Daxx 
associated with PML NBs. The first suggests that Daxx represses expression of 
antiapoptotic genes at PML NBs and the second suggests that Daxx could act as a 
transcriptional coactivator of proapoptotic genes (Bernardi et al., 2008). Further 
studies will have to be performed to understand the role of Daxx and PML, and Daxx 
PML NBs in apoptosis. 
Recently Daxx has been shown to act as a chaperone for the H3.3 histone (Drane et 
al., 2010). H3.3 interacts with Daxx directly and Daxx is essential for targeting H3.3 
to PML NBs (Drane et al., 2010). The chromatin remodelling factor ATRX, which 
also interacts with Daxx and associates with PML NBs (Ishov et al., 2004) assists 
Daxx in targeting H3.3 onto pericentric DNA repeats (Drane et al., 2010). These 
findings open a whole new area for the function of Daxx and PML NBs (reviewed in 
Salomoni, 2013). 
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1.2.5 SUMO 
SUMO was simultaneously discovered by several laboratories in 1996 and given a 
variety of names: GMP-1, PIC1, Sentrin, HSMT3 and Ubl1 (Matunis et al., 1996; 
Boddy et al., 1996; Okura et al., 1996; Mannen et al., 1996; Shen et al., 1996). SUMO 
is now the most commonly used name. SUMO binds covalently to other proteins in a 
similar way to ubiquitin  (Figure 1.4) and is involved in several different cellular 
events, such as progression through the cell cycle, apoptosis, protein stability, 
transcriptional regulation, response to viral infection and DNA repair (Johnson and 
Blobel, 1999; Seeler and Dejean, 2003; Gareau and Lima, 2010; Wilkinson and 
Henley, 2010). SUMO contains a Gly–Gly motif at the C-terminus, which is essential 
for its conjugation to other proteins. SUMO binds to a lysine within the consensus 
sequence ΦKXE/D, where Φ is a hydrophobic amino acid, K the modified lysine, X 
any amino acid and E/D an acidic amino acid. SUMO-1 only shows 18% homology to 
ubiquitin but both proteins have a very similar three-dimensional structure (Bayer et 
al., 1998). The SUMO-1 protein does not contain a lysine residue that corresponds to 
lysine 48 in ubiquitin, which is responsible for forming ubiquitin chains (Bayer et al., 
1998). Therefore, SUMO-1 is unable to form SUMO chains. 
Soon after SUMO-1, two further familial proteins were discovered: SUMO-2 (also 
named SMT3A or Sentrin-3 (Lapenta et al., 1997); and SUMO-3 (SMT3B or Sentrin-
2) (Kamitani et al., 1998a). SUMO-2 and SUMO-3 share 95% sequence identity with 
each other but only 50% sequence identity with SUMO-1. SUMO-2 and SUMO-3 
contain the FKXE/D motif and – unlike SUMO-1 – can form SUMO chains (Tatham 
et al., 2001). Another difference is the flexible N-terminal extension of SUMO-1, 
which the other SUMO isoforms lack. This is probably important for protein/protein 
interactions (Bayer et al., 1998) and has been shown to be phosphorylated at serine 2 
(Matic et al., 2008). 
SUMO has also been shown to interact non-covalently with proteins via a SIM: motif 
1 h-h-X-S-X-S/T-a-a-a (h, hydrophobic; a, acidic) (Minty et al., 2000); motif 2 V/I/L-
X-V/I/L-V/I/L (Song et al., 2004); and motif 3 K-X3-5 –I/V-I/L-I/L-X3-D/E/Q/N-D/E-
D/E (Hannich et al., 2005; Hecker et al., 2006). Recently, RING domain-containing 
proteins possessing one or more SIMs have been shown to target SUMO-modified 
proteins for ubiquitin-mediated proteolysis (Prudden et al., 2007; Sun et al., 2007; 
Uzunova et al., 2007; Tatham et al., 2008; Lallemand-Breitenbach et al., 2008). 
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Figure 1.4. Schematic representation of the SUMO cycle 
The SUMO protease cleaves the SUMO precursor, leaving two essential glycine residues at the C-
terminus. SUMO is activated by formation of a thioester bond between the C-terminal glycine and a 
cysteine in the SUMO-activating enzyme E1. It is then transferred to the conjugating enzyme E2 and 
finally passed onto the ε–amino group of specific lysine residues in the target protein by a SUMO-
specific ligase E3. S (SUMO), E1 SUMO-activating enzyme (Uba2, Aos1), E2 conjugating enzyme 
(Ubc9) and E3 SUMO-specific ligase. 
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1.2.6 RNF4 
RNF4, also known as small nuclear RING-finger protein (SNURF), has been linked to 
transcriptional regulation (Moilanen et al., 1998) and shown to have ubiquitin E3 
ligase activity (Hakli et al., 2004). It localises partially to PML NBs (Hakli et al., 
2005) and is recruited to them when co-expressed with a specific PML isoform, PML 
IV, but not with PML III. The recruitment is enhanced by SUMO-1 (Hakli et al., 
2005). PML IV is able to repress the transcriptional activity of RNF4, probably by 
recruiting it to the bodies in a SUMO-dependent way (Hakli et al., 2005). Later it was 
discovered that RNF4 is a poly-SUMO-specific E3 ubiquitin ligase that is required for 
arsenic–induced degradation of PML and PML/RARα (Lallemand-Breitenbach et al., 
2008; Tatham et al., 2008). Arsenic induces SUMO-modification, ubiquitination and 
degradation of PML protein. Lysine 160, one of the major SUMO-modification sites 
in PML, is necessary for this process (Lallemand-Breitenbach et al., 2008). PML is 
modified by SUMO-1 and SUMO-2/3 after arsenic treatment and it is speculated that 
both SUMO-1 and SUMO-2/3 contribute to PML degradation but on different levels 
(Lallemand-Breitenbach et al., 2008). Lysine 160 primarily appears to be a site for 
SUMO-2 chains and RNF4 binding whereas Lysine 65, which is found in the RING-
finger domain of PML, could stabilise the RING-Ubc9 interaction (Knipscheer et al., 
2007) and/or stabilise RNF4 binding. 
RNF4 was found to bind to and ubiquitinate SUMO-2 chains (Tatham et al., 2008). 
Cells depleted for RNF4 have increased levels of PML and SUMO-2. PML fails to be 
degraded in arsenic-treated cells when RNF4 is depleted (Tatham et al., 2008). 
To find out more about arsenic-induced degradation of PML, stable cells lines were 
created (Percherancier et al., 2009; Geoffroy et al., 2010). After treating PML III-
expressing cells with arsenic, PML is recruited to the PML NBs, modified by SUMO 
and targeted for ubiquitin-mediated proteolysis (Geoffroy et al., 2010). Cells 
expressing PML III but depleted for RNF4 show an accumulation of PML in large 
bodies (Geoffroy et al., 2010). Depletion of RNF4 in a SUMO-2-expressing cell line 
treated with arsenic also results in formation of large PML-containing bodies 
(Geoffroy et al., 2010). RNF4 may interact with poly-SUMO-2 chains attached to 
PML, but not directly with PML, leading to ubiquitin-mediated degradation of PML 
(Geoffroy et al., 2010). 
By further investigation of the involvement of SUMO in RNF4-mediated degradation 
of PML, it was shown that the PML SIM is required for arsenic-induced degradation 
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of PML but not for the arsenic-enhanced SUMO-modification of PML (Percherancier 
et al., 2009). Serine phosphorylation sites next to the SIM are required for SIM-
dependent non-covalent interactions of PML with SUMO-modified partners but are 
not required for arsenic- and RNF4-induced degradation of PML (Percherancier et al., 
2009). Interestingly, this stretch of serines has also been shown to be important in 
CK2-dependent phosphorylation and ubiquitin-mediated degradation of PML 
(Scaglioni et al., 2006). 
 
1.3 PML nuclear body formation 
PML is essential for PML NB formation and required for NB localisation of other NB 
components such as Sp100, Daxx and SUMO-1 (Zhong et al., 2000). In PML -/- cells, 
Daxx and SUMO-1 show a speckled pattern whereas Sp100 forms large aggregates, 
probably by interacting with itself through the HSR domain. The normal NB pattern 
can be restored by co-transfection of PML (Zhong et al., 2000). PML has been shown 
to be covalently modified by SUMO (Sternsdorf et al., 1997) at three lysines: K65, 
K160 and K490 (Duprez et al., 1999; Kamitani et al., 1998b). PML I and PML IV are 
additionally C-terminally SUMO-modified at lysine K616 (Boutell et al., 2011; 
Cuchet-Lourenco et al., 2011). SUMO modification of PML is necessary for the 
formation of a mature PML NB (Lallemand-Breitenbach et al., 2001). SUMO-
modified PML forms a doughnut-like shape whereas the PML mutant PML-3K forms 
dense aggregates (Lallemand-Breitenbach et al., 2001). Both SUMO binding and 
modification are necessary for PML NB formation and a model for the assembly of 
PML NBs has been proposed (Shen et al., 2006; Bernardi and Pandolfi, 2007, Figure 
1.5). However, it has been shown that all PML isoforms, including PML VI, which 
does not contain a SIM, are able to form PML NBs in PML -/- cells (Brand et al., 
2010). Thus, the SIM is not essential for nuclear formation of PML but is probably 
critical for the recruitment of other PML NB components (Brand et al., 2010). 
The common feature of PML NB components, i.e. their ability to be modified by 
SUMO, has led to speculation about PML NBs being the site where SUMO-
modification takes place. Another feature is that many PML NB components or 
RBCC/TRIM proteins are SUMO E3 ligases, important for the SUMO-modification 
machinery (Chu and Yang, 2011). Some RBCC/TRIM proteins also bind the similarly 
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important SUMO-conjugating enzyme Ubc9 and enhance the transfer of SUMO from 
Ubc9 to the substrate (Chu and Yang, 2011). 
In mitotic cells, PML is de-SUMO-modified (Everett et al., 1999) and other NB 
components dissociate from PML. PML forms aggregates through multimerisation of 
the coiled-coil domain. During interphase, PML is modified again and the nucleation 
of PML NBs is triggered by the interaction of SUMO-modified PML and other 
SUMO-modified proteins, such as Sp100 and Daxx, through SUMO moieties and 
SUMO binding motifs (Shen et al., 2006). 
PML NBs localise to the interchromosomal domain compartment (ICD) in the cell 
(Bridger et al., 1998). This compartment forms outside the chromosomes and co-
localises not only with PML NBs but also with coiled bodies and specific nuclear 
RNAs (Bridger et al., 1998). 
The different PML isoforms have been shown to accumulate in various nuclear 
domains (Condemine et al., 2006). This difference in localisation might be due to 
variations in the C-terminus of the PML isoforms, resulting in interactions with 
different nuclear proteins. All PML isoforms colocalise when co-expressed due to 
PML protein interacting with itself through the coiled-coil domain (Condemine et al., 
2006). This results in the PML NBs appearing to be uniform but recent evidence 
shows that they are structurally and functionally heterogeneous structures (Bernardi 
and Pandolfi, 2007; Weidtkamp-Peters et al., 2008). It has also recently been shown 
that the C-terminus of PML II and V can form PML NBs independently of their N-
terminus and that the PML NBs formed by PML V can recruit other PML NB 
components like Sp100 and Daxx (Geng et al., 2012). This suggests that the C-
terminus of PML V is important for PML NB formation and adds to the complexity of 
the assembly of PML NBs (Geng et al., 2012). PML NB formation seems to be 
influenced by many different mechanisms, including SUMO-modification and SUMO 
interactions, PML isoform interactions and the presence of other PML NB 
components (Weidtkamp-Peters et al., 2008). (See Figure 1.5 for a suggested model 
for PML NB assembly.) 
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Figure 1.5. A model for the assembly of PML NBs 
Many PML NB components are not only covalently modified by SUMO but also contain a SIM. PML 
NB components interact with themselves or with SUMO, which can subsequently be covalently 
attached to another PML NB component. (Adapted from Bernardi and Pandolfi, 2007). 
 
 
1.4 Proposed PML functions 
Given the heterogeneous mix of proteins found in PML NBs, the function of the NBs, 
and thus PML itself (since PML is essential for the formation of PML NBs) (Zhong et 
al., 2000), has remained elusive. They have been linked to many different functions 
such as transcriptional regulation, tumour suppression, the regulation of apoptosis, the 
antiviral response and DNA damage (Bernardi and Pandolfi, 2007; Lallemand-
Breitenbach and de The, 2010). 
Several models for PML NB function have emerged. One proposes that PML NBs act 
as ‘nuclear depots’ where proteins, including those covalently modified by SUMO-1, 
can be recruited and, under certain conditions, released at sites of action elsewhere 
(Negorev and Maul, 2001). Support for this model comes from the non-essential 
nature of the bodies such as their existence as aggregations of concentrated proteins 
and the discrepancy between functions of NB proteins. Another model suggests that 
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PML NBs act as sites of nuclear protein turnover, supported by the observations that 
proteasomes, associated co-factors and mis-folded viral proteins are localised to the 
bodies under certain conditions (Anton et al., 1999; Lallemand-Breitenbach et al., 
2001). As mentioned earlier, the SUMO-dependent ubiquitin ligase RNF4 was found 
to colocalise to PML NBs (Hakli et al., 2005), which fits this model very well. RNF4 
has been shown to target the arsenic-induced SUMO-modified lysine 160 in PML for 
polyubiquitination and proteasome-mediated degradation in PML NBs (Tatham et al., 
2008). Neither of these models is mutually exclusive and many other functions of 
PML NBs have also been suggested, which is unsurprising when taking into account 
the many different proteins that localise to PML NBs. However, it is clear that PML 
NBs form a part of a nuclear/cellular defence mechanism against viral attack and 
other external insults. Many viruses have been shown to alter the levels, modification 
and localisation of PML (reviewed in Geoffroy and Chelbi-Alix, 2011). 
 
1.4.1 PML forms part of an anti-viral response 
It has emerged that PML nuclear bodies are the targets of viral infection (reviewed in 
(Everett, 2001). For nuclear replicating DNA viruses, including herpesviruses, 
adenoviruses and papovaviruses, the viral genome associates with PML NBs, and 
initial sites of transcription and replication are frequently close to PML NBs (Everett, 
2001). In addition, several viral regulatory proteins disrupt PML NB structure and 
these events are directly correlated with the efficiency of infection. For RNA viruses, 
including the hepatitis delta virus, lymphocytic choriomeningitis virus and rabies 
virus, PML NBs are disrupted by a range of mechanisms including the relocalisation 
of PML NBs to the cytoplasm (reviewed in Regad and Chelbi-Alix, 2001). 
Interestingly, the PML gene contains interferon response elements, and PML 
expression is upregulated by interferon α, β, and γ treatment, resulting in an increase 
in the number of PML NBs per cell (Stadler et al., 1995; Lavau et al., 1995; Chelbi-
Alix et al., 1998). Several studies have shown that PML expression enables resistance 
to viral infection and that PML NBs form part of a cellular antiviral response (Chelbi-
Alix et al., 1998; Djavani et al., 2001; Bonilla et al., 2002). 
One PML isoform, PML II, has been shown to interact directly with adenovirus type 5 
E4 Orf3 protein (Hoppe et al., 2006). This interaction is isoform specific as only PML 
II was rearranged by E4 Orf3 (Hoppe et al., 2006). The PML II interacting sequence 
has been mapped to aa 645-684 in exon 7b (Leppard et al., 2009). E4 Orf3 has been 
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shown to self-associate to mediate the formation of nuclear tracks, and PML is not 
necessary for E4 Orf3 track formation (Hoppe et al., 2006). The E4 Orf3 protein 
inhibits the cellular viral response, as do many other viral proteins, by disrupting PML 
NBs (Ullman et al., 2007). 
It has been speculated that cytoplasmic PML consists of either newly made 
cytoplasmic PML or nuclear PML that has been recruited to the cytoplasm (McNally 
et al., 2008). A PML splice variant lacking exon 5 and 6, PML Ib accumulates in the 
cytoplasm in HSV-1-infected cells, sequestering ICP0 and thereby decreasing viral 
gene expression (McNally et al., 2008). 
Different viruses use different mechanisms to regulate PML and PML NBs. Some 
disrupt the bodies by changing the SUMO-modification of PML, thus changing the 
stability and localisation of PML. Viruses probably disrupt PML NBs to avoid 
cellular defence mechanisms (reviewed in Everett and Chelbi-Alix, 2007; Reineke 
and Kao, 2009). 
 
1.4.2 Acute promyelocytic leukaemia 
Acute promyelocytic leukaemia (APL) belongs to the acute myeloid leukaemia 
(AML) family of cancers and is classified as AML-M3 in the old French-American-
British (FAB) system and AML with characteristic genetic abnormalities in the newer 
World Health Organization (WHO) system. APL accounts for 10% of adult AML 
patients and currently 90% of APL patients are disease free at 5 years. However, APL 
used to be a fatal disease with a severe prognosis. APL is the most malignant form of 
acute leukaemia with severe bleeding tendency and a very rapid fatal course of only a 
few weeks. Cells from APL patients contain a reciprocal translocation of chromosome 
15 and 17 which fuses the PML gene and the RARα (de The et al., 1991; Goddard et 
al., 1991; Kakizuka et al., 1991; Pandolfi et al., 1991). This translocation generates 
the PML-RARα fusion protein and accounts for 99% of all cases. (See Figure 1.6 for 
an overview of the breakpoints in PML and RARα.) Four other genes have been 
described as rare fusions with RARα in APL: promyelocytic leukaemia zinc finger 
(PLZF) (Chen et al., 1993), nucleophosmin (NPM) (Redner et al., 1996), nuclear 
mitotic apparatus (NuMA) (Wells et al., 1997) and signal transducer and activator of 
transcription 5b (STAT5b) (Arnould et al., 1999).  While the RARα gene always 
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breaks within the same intron and the reciprocal translocations X-RARα and RARα-
X are expressed in the APL blasts, X does not bear any structural similarities. 
 
 
 
Figure 1.6. Breakpoints in RARα and PML 
The PML breakpoint positions are located between exons 3 and 4 and between exons 6 and 7. All 
PML-RARα fusion proteins contain the RBCC/TRIM motif. The RARα gene always breaks within the 
second intron. (Adapted from Tussie-Luna et al., 2006). 
 
 
1.4.3 Treatment of acute promyelocytic leukaemia 
The prevalence of most cancers increases with age, due to the accumulation of 
mutations in cells. However, the prevalence of APL appears to remain constant with 
age, suggesting that it is caused by a single, rate-limiting genetic event (Vickers et al., 
2000). APL can be treated with all-trans retinoid acid (ATRA) in association with 
chemotherapy, with arsenic alone or with arsenic and ATRA.  
ATRA induces differentiation of APL blasts (Castaigne et al., 1990) and proteasome-
mediated degradation of PML/RARα (Zhu et al., 1999). Degradation of PML/RARα 
allows for the restoration of PML NBs (Zhu et al., 1997). Only a few patients are 
cured with ATRA alone (Castaigne et al., 1990) and a combination therapy of ATRA 
with chemotherapy is often used (Fenaux et al., 1999). Clinical trials have shown that 
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arsenic on its own delivers a 70% cure rate whereas arsenic and ATRA gives a 90% 
cure rate (Lallemand-Breitenbach et al., 2012). Arsenic degrades PML/RARα by 
targeting PML (Zhu et al., 1997) whereas RARα degrades through ATRA (Zhu et al., 
1999). Arsenic recruits diffuse PML to PML NBs (Zhu et al., 1997) where PML is 
then modified by SUMO and targeted for arsenic-induced proteolysis (Lallemand-
Breitenbach et al., 2001; Geoffroy et al., 2010). Recently it has been shown that PML 
gets poly-sumoylated and targeted by RNF4, a SUMO-dependent ubiquitin ligase, 
then polyubiquinated and degraded by the proteasome (Tatham et al., 2008). 
Recruitment of PML to the bodies is not dependent on RNF4, but RNF4 follows 
shortly after and interacts with SUMO, though not with PML, at the NBs (Geoffroy et 
al., 2010). 
Despite there being several different treatments for APL, the main therapies used are 
ATRA together with chemotherapy, arsenic alone, or arsenic together with ATRA 
(reviewed in de The and Chen, 2010). Recently a study showed that degradation of 
PML/RARα, and not differentiation of the APL blasts, as often thought, is responsible 
for curing APL (Nasr et al., 2008). 
 
1.4.4 PML and cancer 
PML has been shown to be involved in tumour suppression (Koken et al., 1995) and 
increasing evidence suggests that PML expression is altered in various tumours. Loss 
of PML expression is often associated with increased grade and progression in many 
tumour types. 
Tissue microarrays with samples from normal tissue and cancer tissue were analysed 
for PML expression and it was found that PML protein expression was lost in 17% of 
colon adenocarcinoma, 21% of lung carcinoma, 28% of prostate adenocarcinoma, 
32% of breast carcinoma, 49% of central nervous carcinoma, 48% of germ cell 
tumours, 0% of thyroid carcinoma, 0% of adrenal cortical carcinoma and 68% of non-
Hodgkin’s lymphoma (Gurrieri et al., 2004) tumours. Complete loss of PML 
expression is often associated with advanced cancers in breast, prostate and central 
nervous system tumours (Gurrieri et al., 2004). PML mRNA was detected in cells 
negative for PML protein expression and samples were tested for mutations at the 
PML locus. However, the PML gene was rarely mutated and was not subject to loss of 
heterozygosity (Gurrieri et al., 2004). In a germ cell tumour line where PML protein 
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expression was partially lost, two other NB components, SUMO and Daxx, were 
found at normal protein levels but with an aberrant nuclear localisation pattern. 
Furthermore, PML mRNA was expressed at normal levels and the PML gene was not 
mutated (Gurrieri et al., 2004). The proteasome inhibitor MG132 was used to treat 
cancer cell lines in order to investigate the effects of proteasome-dependent 
mechanisms on PML protein expression. After treatment with MG132, the normal NB 
pattern of PML was restored and SUMO-1 and Daxx were found in the NBs once 
again (Gurrieri et al., 2004). This suggests that the stability of PML is regulated in a 
proteasome-dependent way (Gurrieri et al., 2004).  
Other studies have also shown that PML protein expression is altered in cancers. An 
almost complete loss of PML protein was demonstrated in small-cell lung carcinomas 
(Zhang et al., 2000) and gastric cancers (Lee et al., 2007; Kim et al., 2011). In gastric 
cancers, PML loss was associated with greater lymphatic invasion and a lower 
survival rate (Lee et al., 2007; Kim et al., 2011). Loss of PML protein expression can 
also be used as an independent prognostic marker in patients with oesophageal 
squamous cell carcinoma (Yen et al., 2011). Different levels of PML expression in 
cancer cells might mirror the stage and aggressiveness of the tumour. 
Other groups have even found overexpression of PML protein in some cancer cells 
(Chan et al., 1998; Gambacorta et al., 1996; Yoon and Yu, 2001). When PML is 
highly expressed in chronic myeloid leukemia (CML) it has been shown to result in a 
less favourable outcome (Ito et al., 2008). PML/RARα is able to act as a potential 
oncogene and the SUMO-modifaction site lysine 160 in PML is essential for 
transcriptional repression and transformation (Zhu et al., 2005). It seems to be clear 
that PML can act as a tumor suppressor in many cancers but in other cases also 
facilitate cancer cell survial (Martin-Martin et al., 2013). 
For immunostaining of PML the monoclonal antibody PG-M3 is often used (Falini et 
al., 1997). This is a species-specific and fixative-resistant antibody that detects the N-
terminal region of PML (Flenghi et al., 1995), which is present in all known PML 
splice variants. It is often used for rapid diagnosis for APL (Alayed et al., 2013), 
recognising all APL cases characterised by the three major breakpoints bcr1, bcr2 and 
bcr3. 
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1.4.5 Cytoplasmic PML 
Nuclear PML has most commonly been studied but accumulating evidence shows that 
PML also seems to play a role in the cytoplasm. PML was shown to be involved in 
TGF-β-signalling (Lin et al., 2004). TGF-β induces senescence in wild-type mouse 
embryonic fibroblasts whereas in PML -/- cells this effect is completely abrogated. It 
was only possible to partially restore the activity of TGF-β in PML -/- cells by 
expressing PML IV, a nuclear PML isoform, whereas expression of PML IV ∆NLS or 
PML RBCC rescued the transcriptional activity of TFG-β. Cytoplasmic PML (cPML) 
interacts with the signalling proteins SMAD2/3 and SARA (Smad anchor for receptor 
activation), regulating their localisation (Lin et al., 2004). Also PML/RARα is able to 
disrupt the complex and thereby interfere with the TGF- β signalling (Lin et al., 
2004). 
Cytoplasmic PML has also been found to associate with the endoplasmatic reticulum 
(ER) and the mitochondria-associated membranes (MAMs) (Giorgi et al., 2010). 
These domains are involved in calcium-dependent apoptotic cell death. PML -/- cells 
treated with endoplasmic reticulum stress inducers are less responsive to apoptosis 
when compared with PML +/+ cells (Giorgi et al., 2010). Expression of a PML 
chimera that localises to the outer surface of the ER restores the mitochondrial 
calcium signals and the sensitivity to apoptosis (Giorgi et al., 2010). This shows that 
cytoplasmic PML regulates apoptosis at the ER by controlling calcium release (Giorgi 
et al., 2010). 
APL-associated PML mutations (1272delAG and IVS3-IG-A) cause both of these 
mutant PML proteins to localise to the cytoplasm and form doughnut-shaped 
cytoplasmic bodies (Bellodi et al., 2006). The cytoplasmic PML mutants interact with 
PML/RARα and counteract differentiation induced by retinoic acid (RA). A 
PML/RARα mutant that localises to the cytoplasm also inhibits RA-dependent 
transcription and differentiation. These results suggest that the cytoplasmic 
localisation of PML/RARα might contribute to transformation. The same PML 
mutants have been used to study the relationship between cPML and p53 (Bellodi et 
al., 2006). It has been shown that cPML sequesters nuclear PML to the cytoplasm, 
disrupts the NBs and inhibits p53’s transcriptional, growth suppressive and apoptotic 
functions (Bellodi et al., 2006). Further studies will hopefully bring more insight to 
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the function of cPML (reviewed in Salomoni and Bellodi, 2007; Carracedo et al., 
2011). 
 
1.5 PML and regulation of apoptosis 
PML has been involved in many apoptotic pathways such as a caspase-independent 
and -dependent pathways.  PML has been shown to be an important regulator of p53-
dependent and -independent apoptotic pathways and PML recruits p53 to the PML 
NBs upon certain stimuli. As mentioned earlier, PML is able to regulate apoptosis at 
ER-mitochodria sites showing it has a function outside the PML NBs.  
The literature on PML and apoptosis is vast and therefore only relevant aspects – 
those involving PML and death receptor-mediated apoptosis – have been included 
here, as this was the main interest of my studies. 
 
 
1.5.1 PML knockout mice 
The availability of embryonic fibroblasts from PML -/- mice has provided 
opportunities for studying the functional role of PML and PML NBs (Wang et al., 
1998a). Homozygous mice for the PML mutation are fertile, born with the expected 
Mendelian frequency and are indistinguishable at the phenotypic level from PML +/+ 
mice. However, PML -/- mice are extremely susceptible to bacterial infections, 
suggesting that PML may indeed play a role in an anti-infection response. PML -/- 
MEFs grow faster than PML +/+ MEFs and show loss of contact inhibition, 
suggesting that PML is involved in cell growth control (Wang et al., 1998a). PML -/- 
mice and cells are protected from the lethal effects of ionizing radiation and anti-Fas 
antibodies and PML is required for caspase-1 and caspase-3 activation (Wang et al., 
1998b). It has also been shown that PML is crucial for the induction of apoptosis by 
Fas, TNF α, ceramide and type I and II interferons (IFNs) (Wang et al., 1998b). This 
might also explain the resistance of APL cells to Fas-, TNF- and IFN-induced 
apoptosis with a lack of caspase-3 activation. 
PML -/- MEFs do not show any PML nuclear staining, and other PML NB 
components such as Sp100, Daxx and SUMO-1 fail to localise to PML NBs in the 
absence of PML. However, the normal localisation of the other PML NB components 
can be restored by transfection of PML (Zhong et al., 2000). This shows that PML is 
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required for the proper nuclear compartmentalisation of other NB components and 
therefore NB formation (Zhong et al., 2000). 
 
1.5.2 CD95/Fas-mediated apoptosis and death-effector filaments 
The CD95/Fas death receptor triggers apoptosis following its activation through the 
binding of Fas ligand (FasL) (Nagata, 1999). CD95/Fas ligation leads to formation of 
a death-inducing signalling complex (DISC) by recruitment of Fas-associated death 
domain (FADD) to its intracellular death domain (DD) (Kischkel et al., 1995). 
Interaction of the death-effector domain (DED) of FADD and caspase-8 (Boldin et al., 
1996) leads to recruitment and proteolytic activation of procaspase-8 at the DISC 
(Medema et al., 1997). 
FADD forms a 3:3 complex with the CD95/Fas receptor via the DD but it has been 
suggested that the DED in FADD is involved in forming the complex as well (Sandu 
et al., 2006). Self-association of FADD through the DED is required for the formation 
of a stable complex with the CD95/Fas receptor (Sandu et al., 2006). After the 
formation of the complex, procaspase-8 binds to FADD via their respective DEDs and 
it has been suggested to be a preferential interaction with one of the DEDs in 
procaspase-8 (Carrington et al., 2006). 
CD95/Fas triggers apoptosis via two signalling pathways, which are determined by 
the amount of caspase-8 activated at the DISC (Scaffidi et al., 1998). In type I cells, a 
large amount of caspase-8 is activated at the DISC, causing activation of caspase-3 
and resulting in apoptosis. In type II cells, the activation of caspase-8 is low and these 
cells depend on the mitochondrial pathway to activate caspase-3 (Scaffidi et al., 
1998). Low concentrations of caspsase-8 results in cleavage of Bid which produces 
tBid. tBid translocates to the mitchondria where it activates Bax/Bak. This results in 
cytochrome c being released to the cytosol and activation of the apoptosome follows 
(Sessler et al., 2013). For a review please see Tourneur and Chiocchia, 2010. An 
overview of PML NBs and death-receptor-mediated apoptosis is presented in Figure 
1.7.  
DED-containing proteins such as FADD and the prodomain of caspase-8 can cause 
apoptosis by forming death-effector filaments (DEFs) (Siegel et al., 1998). DEFs 
recruit and activate pro-caspase zymogens (Siegel et al., 1998) and viral DED- 
containing proteins can inhibit apoptosis by preventing formation of the DEFs. The 
data show that assembly of apoptosis-signalling complexes can occur intracellularly 
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as well as at the plasma membrane (Siegel et al., 1998). 
FADD has been shown to be phosphoryalted at S194 by casein kinase 1 alpha (CK1 
alpha) (Alappat et al., 2005). Phosphorylation of FADD correlates with the cell cycle 
(Scaffidi et al., 2000) and non-phosphorylated FADD is found in G1/S whereas 
phosphoryalted FADD is found in G2/M (Scaffidi et al., 2000). Phosphorylation of 
FADD is important for the regulation of cell cycle progression as phosphorylation of 
FADD was found to be necessary for G2/M cell cycle arrest in non-tumour cell lines 
(Alappat et al., 2003), and overview in Figure 1.8). This suggests that FADD might 
not only affect apoptosis by binding to the death receptors but also by interfering with 
the cell cycle.  
 
 
 
Figure 1.7. PML nuclear bodies and death receptor-mediated apoptosis 
Many proteins shown to be part of the death-receptor-mediated apoptotic pathway also localise to the 
nucleus and some of them partially to PML NBs. Often, post-translational modifications like 
phosphorylation or SUMO-modification affect the localisation of the proteins. 
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Figure 1.8. Phosphorylation of FADD is important for G2/M arrest in non-tumour cell lines 
FADD needs an intact phosphorylation site to arrest cells in G2/M. FADD but not the mutant FADD 
S194A arrests cells in GS/M. G2/M is an important checkpoint before mitosis. G1/S is important 
before chromosome duplication. 
 
 
1.5.3 PML and death receptor-mediated apoptosis 
Mounting evidence suggests PML NBs and PML NB components play a very 
important role in the death receptor-induced cell-death pathway, including CD95-
mediated apoptosis (Wang et al., 1998b; Torii et al., 1999).  
In addition to Daxx, another protein called tumor necrosis factor receptor (TNFR) 
type 1-associated death domain (TRADD) has been shown to localise to both the 
cytoplasm and the nucleus. TRADD contains an NLS and an NES domain and is able 
to shuttle between the cytoplasm and the nucleus (Morgan et al., 2002). It localises to 
PML NBs in the nucleus in the absence of export and the DD in TRADD has been 
shown to be responsible for the localisation. At PML NBs, the DD in TRADD can 
activate PML- and p53-dependent apoptosis. The apoptotic pathway induced by 
TRADD-DD is not sensitive to caspase inhibitors (Morgan et al., 2002). 
A third protein, known as HIPK3, has also been shown to localise to both the PML 
NBs and the cytoplasm. It was initially identified as a Fas-interacting protein and has 
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also been shown to interact with Daxx and FADD (Rochat-Steiner et al., 2000). 
Interestingly, overexpression of HIPK3 did not show any effect on Fas-induced 
apoptosis. 
Recently, PML and PML/RARα have also been identified as Fas-associated proteins 
(Tao et al., 2011). PML and PML/RARα bind to Fas through the B-box domain in 
PML, and the DD in Fas is necessary for Fas/PML and Fas/PML/RARα complex 
formation (Tao et al., 2011). The Fas/PML/RARα complex formation recruits the 
anti-apoptotic regulator c-FLIP and inhibits Fas-mediated apoptosis. In addition, 
PML/RARα prevents binding of the Fas ligand and agonistic antibody CH-11 to the 
Fas receptor (Tao et al., 2011). The authors speculate that PML might stabilise the 
Fas-FADD-procaspase-8 complex or destabilise the Fas-FADD-cFLIP complex, with 
PML/RARα having the opposite effect. This is an important discovery as many 
cancers feature altered PML expression, which could then result in defective Fas 
signalling. 
 
1.5.4 PML and SUMO-modified caspases 
PML has been shown to be involved in apoptosis via a caspase-independent pathway 
(Quignon et al., 1998). Caspase inhibitors do not prevent PML-induced cell death and 
caspase-3 is not activated upon PML overexpression (Quignon et al., 1998), although 
there is now growing evidence to support a connection between PML/PML NBs and 
caspases. One initiator caspase, caspase-2, has been shown to localise to PML NBs 
(Tang et al., 2005) and to be modified by SUMO (Shirakura et al., 2005). SUMO-
modification of procaspase-2 at lysine K60 is necessary not only for nuclear 
localisation but also for activation/maturation of procaspase-2 (Shirakura et al., 2005). 
Another initiator caspase, caspase-8, can also be modified by SUMO. Caspase-8 can 
be SUMO-modified at lysine 156, and in this case although the modification is also 
associated with nuclear localisation it does not seem to interfere with the processing 
of caspase-8 (Besnault-Mascard et al., 2005). 
One effector caspase, caspase-7, has also been shown to be modified by SUMO 
(Hayashi et al., 2006). While it is unclear if caspase-7 localises to PML NBs directly, 
it does co-localise with SUMO-1 (Hayashi et al., 2006). The results suggest that it is 
indeed PML NBs caspase-7 localises to but this requires further investigation. This is 
also the case with the role PML and PML NBs play in caspase-dependent apoptosis. 
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1.5.5 Tumor necrosis factor receptor (TNF-R)-associated factor (TRAF) 
The TRAF family of proteins is involved in cell survival, proliferation, differentiation 
and apoptosis. The proteins were originally identified as signalling adaptors binding 
to the cytoplasmic region of of the receptor of the TNF-R family (Ha et al., 2009). 
TRAF proteins are characterised by the presence of a TRAF domain at the C- 
terminus. The TRAF domain consists of a coiled-coil domain followed by a 
conserved TRAF-C domain. The C-domain interacts with the TNF-R family whereas 
the coiled-coil domain allows for oligomerisation of TRAF proteins. The N-terminus 
of TRAF proteins, except for TRAF1, contains a RING finger and several zinc finger 
motifs that are important for signalling downstream events (Aggarwal, 2003; Arch et 
al., 1998; Bradley and Pober, 2001; Chung et al., 2002). All TRAFs, apart from 
TRAF4, have benn identified by yeast two-hybrid screening using a cytoplasmic 
domain of various members of the TNFR family. TRAFs can act as E3 ubiqutin 
ligases and are involved in the pathogenesis of human diseases such as cancers 
(reviewed in Xie, 2013). 
 
 
1.6 Aims 
Taken together, these results strongly suggest that PML acts as a cell growth regulator 
and is involved in apoptosis. The interplay between PML protein and PML NBs 
remains unresolved, as does the recruitment of PML NB components and cellular 
function. A small fraction of PML protein is soluble within the nucleoplasm (N. 
Boddy, PhD thesis, Univ. London, 1996), suggesting that PML could have a 
functional role separate from that of insoluble PML NBs.  
The overall aims and objectives of this PhD project were to elucidate further 
functional data on PML in relation to its role in apoptosis, and more specifically to 
explore: 
 
• The role of PML and PML NBs in FADD-mediated apoptosis 
o Specific aims: 
 To identify new PML-interacting components 
 To explore the connection between PML NBs and DEFs 
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 To determine the role of PML in FADD phosphorylation 
 To determine the role of PML NBs in regulating FADD 
phosphorylation
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2 Materials and methods 
2.1 Materials 
 
Table 2.1. Media for bacterial growth  
LB broth 1% (w/v) bactotryptone, 1% (w/v) NaCl, 0.5% (w/v) bacto-
yeast extract 
SOC 20 mM glucose, 0.01 mM MgCl2, 0.0025 mM KCl, 2% (w/v) 
bactotryptone, 0.05% (w/v) NaCl, 0.5% (w/v) bacto-yeast 
extract 
LB-agar LB broth, 1.2% (w/v) agar 
 
 
Table 2.2. DNA electrophoresis 
TAE 40 mM Tris-acetate, 1 mM EDTA 
Gel loading buffer (6x) 10 mM EDTA, 50% Glycerin, 0.1% Bromphenolblue 
Agarose gel 1% agarose in TAE, 0.0006% (v/v) GelRed 
 
 
Table 2.3. Protein electrophoresis and detection 
SDS-gel reducing buffer 
(2x) 
100 mM Tris pH6.8, 200 mM DTT, 4% SDS, 
0.2% Bromphenolblue, 20% Glycerol 
SDS-gel running buffer 25 mM Tris, 192 mM Glycine, 0.2% (w/v) SDS, pH 8.3 
Resolving buffer (4x) 1.5 M Tris, pH 8.8 
Stacking buffer (4x) 0.5 M Tris, pH 6.8 
Resolving gel Acrylamide mix (8, 10, 12% (v/v)), 0.39 mM Tris (pH 8.8), 
0.1% (w/v) SDS, 0.1% (w/v) Ammonium persulphate (APS), 
0.04% (v/v) N,N,N’,N’-Tetramethylethylenediamine (TEMED) 
Stacking gel 4% (v/v) Acrylamide mix, 0.065 mM Tris (pH 6.8), 0.1% (w/v) 
SDS, 0.1% (w/v) APS, 0.04% (v/v) TEMED 
Coomassie stain 0.05% (w/v) Coomassie Blue R-250, 30% (v/v) Ethanol, 10% 
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(v/v) Acetic acid 
Coomassie destain 30% (v/v) Ethanol, 10% (v/v) Acetic acid 
Ponceau S 0.1% (w/v) Ponceau S, 5% (v/v) Acetic acid 
Electroblotting transfer 
buffer 
10mM 3-(cyclohexylamino)-1-propane sulfonic acid (CAPS), 
pH 11.0 
Blocking solution 5% (w/v) skimmed milk powder in dH2O 
dPBS 138 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4-7H2O, 1.47 
mM KH2PO4, pH 7.4 
dPBST PBS, 0.1% (v/v) Polyoxyethylenesorbitanmonolaurate (Tween 
20) 
 
 
Table 2.4. Bacterial strains  
Bacterial strain Genotype Source 
XL1-Blue recA1 endA1 gyrA96 thi-1 hsdR17 
supE44 relA1 lac (F’proAB 
lacIqZDM15 Tn10 (TetR))  
Electrocompetent 
Stratagene 
One Shot™ TOP10 F- mcrA D(mrr-hsdRMS-mcrBC) 
⎞80lacZ∆M15 ∆lacX74 recA1 
araD139 D(ara-leu)7697 galU galK 
rpsL (StrR) endA1 nupG 
Chemical competent 
Life Technologies 
LIBRARY EFFICIENCY® 
DH5α™ 
F- ⎞80lacZ∆M15 ∆(lacZYA-
argF)U169 recA1 endA1 hsdR17(rk- , 
mk+) phoA supE44 thi-1 gyrA96 relA1 
Chemical competent 
Life Technologies 
BL21-GOLD(DE3) E.coli B F- ompT hsdS(rß- mß-) dcm+ 
TetR galλ (DE3) endA Hte 
Electrocompetent and chemical 
competent 
Agilent 
SoluBL21 F- ompT hsdS(rß- mß-) gal dcm (DE3) 
(The SoluBL21 strain contains 
Genlantis 
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uncharacterised mutations obtained 
through special selection criteria. 
These mutations make the strain able 
to express insoluble proteins in soluble 
form, fully or partially, in most tests 
conducted). 
Electrocompetent. 
NEB 5-alpha fhuA2 ∆(argF-LacZ)U169 phoA gln44 
φ88∆ (lacZ)M15 gyrA96 recA1 relA1 
endA1 thi-1 hsdR17 
Chemical competent 
New England Biolabs 
 
 
Table 2.5. Mammalian cell lines 
Mammalian cell line Description Source 
MEF Mus musculus (mouse) 
adherent embryonic fibroblast 
(transfected with SV40 large T 
antigen) 
Prof. Hugues de The, Paris 
U2OS Homo sapiens (human) 
adherent osteosarcoma 
epithelial 
ICRF 
HT1080 Homo sapiens (human) 
adherent fibrosarcoma 
epithelial 
ICRF 
Saos-2 Homo sapiens (human) 
adherent osteosarcoma 
epithelial 
ICRF 
NIH/3T3 Mus musculus (mouse) 
adherent fibroblast 
ICRF 
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Table 2.6. Expression vectors 
Name Expression Source 
pSG5 Eukaryotic Agilent 
pSG5-FLAG Eukaryotic pSG5 modified with a FLAG tag (Sternsdorf 
et al., 1999). 
pSG5-LINK Eukaryotic pSG5 modified with a SV40 NLS and a 
FLAG tag (Sternsdorf et al., 1999). 
pSG5-LINK-EGFP Eukaryotic pSG5-LINK modified with EGFP 
pcDNA3 Eukaryotic Invitrogen 
pEGFP-C1,2,3 Eukaryotic Clontech 
pDsRed-N1 Eukaryotic Clontech 
pDsRed-C1 Eukaryotic Clontech 
pDsRed2-C1 Eukaryotic Clontech 
pMLV-plink2T Eukaryotic  
pET-28a/b Prokaryotic Novagen 
pProEX HTa,b Prokaryotic Invitrogen 
pGEX 6P-1 Prokaryotic GE healthcare 
 
 
Table 2.7. DNA Constructs 
cDNA Vector Tag/ 
Fusion 
Restriction 
sites used for 
cloning 
Source/relevant 
information 
FADD pcDNA3 AU1 KpnI/XhoI A kind gift from 
T.G. Hofmann 
FADD F25G pcDNA3 AU1   
FADD K35R pcDNA3 AU1   
FADD K33/35R pcDNA3 AU1   
FADD K125R pcDNA3 AU1   
FADD A174P pcDNA3 AU1   
FADD S194A pcDNA3 AU1   
FADD S194E pCDNA3 AU1   
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FADD S194D pcDNA3 AU1   
FADD DED (aa 1-80) pcDNA3 AU1 pcDNA3-AU1 
FADD digested 
KpnI/SalI and 
cloned into 
pcDNA3-AU1 
KpnI/XhoI 
 
FADD DN (aa 80- 208) pcDNA3 AU1  A kind gift from 
T.G. Hofmann 
FADD pEGFP EGFP  A kind gift from 
T.G. Hofmann 
Caspase-8 pEGFP EGFP  A kind gift from 
T.G. Hofmann 
Caspase-8 DED-AB pEGFP EGFP  A kind gift from 
T.G. Hofmann 
CrmA pcDNA3   A kind gift from 
T.G. Hofmann 
Caspase-8 (FLICE) pcDNA3 HA  A kind gift from 
T.G. Hofmann 
CK1 alpha (isoform 1) or  
CK1 alpha LS 
pSG5-
FLAG 
FLAG HindIII/BamHI  
CK1 alpha LS K46R pSG5-
FLAG 
FLAG HindIII/BamHI  
CK1 alpha LS K138R pSG5-
FLAG 
FLAG HindIII/BamHI  
CK1 alpha LS K46/138R pSG5-
FLAG 
FLAG HindIII/BamHI  
CK1 alpha LS K22/46/138R pSG5-
FLAG 
FLAG HindIII/BamHI  
CK1 alpha LS K46/257R pSG5-
FLAG 
FLAG HindIII/BamHI  
CK1 alpha LS K46/260R pSG5-
FLAG 
FLAG HindIII/BamHI  
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CK1 alpha LS K46/257/260R pSG5-
FLAG 
FLAG HindIII/BamHI  
CK1 alpha LS K46R/ 
V273A/E274A 
pSG5-
FLAG 
FLAG HindIII/BamHI  
CK1 alpha LS V273A/ 
E274A 
pSG5-
FLAG 
FLAG HindIII/BamHI  
CK1 alpha LS K22/46/138R, 
V273A/E274A 
pSG5-
FLAG 
FLAG HindIII/BamHI  
CK1 alpha LS 
K46/257/260R, 
V273A/E274A 
pSG5-
FLAG 
FLAG HindIII/BamHI  
E4 Orf3 pcDNA3 HA  A kind gift from 
H. Will 
SUMO-1 pEGFP EGFP  A kind gift from 
H. Will 
SUMO-2 pEGFP EGFP  A kind gift from 
H. Will 
SUMO-3 pEGFP EGFP  A kind gift from 
H. Will 
SuPr-1 pEGFP EGFP  A kind gift from 
H. Will 
SuPr-1 C466S pEGFP EGFP  A kind gift from 
H. Will 
SUMO-1 pSG5-
LINK-
EGFP 
FLAG- 
EGFP 
SUMO-1 
XmaI/BamHI 
and gSG5-
LINK-EGPF 
XmaI. 5’ ends 
filled in with 
Klenow. 
 
SUMO-1 pMLV-
plink2T 
MYC  (Duprez et al., 
1999) 
TFAF-1 (aa 79-316) pSG5- FLAG EcoRI/BamHI  
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FLAG 
TFAF-1 (aa 79-316) pSG5-
LINK 
FLAG EcoRI/BamHI  
TFAF-1 (aa 79-316) pEGFP EGFP EcoRI/BamHI  
TFAF-1 (aa 79-316) pDsRed-
N1 
DsRed EcoRI/BamHI  
TFAF-1 (aa 79-316) pDsRed-
C1 
DsRed EcoRI/BamHI  
TFAF-1 full-length DsRed-C1 DsRed EcoRI/BamHI  
TFAF-1 full-length pDsRed-
N1 
DsRed EcoRI/BamHI  
TFAF-1 full-length pSG5-
FLAG 
FLAG EcoRI/BamHI  
PML III pSG5-
LINK-
EGFP 
FLAG-
EGFP 
EcoRI/BamHI  
PML IV pSG5-
LINK-
EGFP 
FLAG-
EGFP 
EcoRI  
PML IV pSG5-
FLAG 
FLAG EcoRI  
CK1 alpha (isoform 1) or 
CK1 alpha LS 
pProEx 
HTb 
His BamHI/XhoI  
CK1 alpha (isoform 1) or 
CK1 alpha LS 
pGEX-6P-
1 
GST BamHI/XhoI  
CK1 alpha (isoform 1) or 
CK1 alpha LS 
pET-28a His BamHI/XhoI  
CK1 alpha (aa 1-301) pProEx 
HTb 
His BamHI/XhoI Mr. Gene 
GmbH Codon 
optimised for 
expression in E. 
coli 
CK1 alpha (aa 1-301) pGEX-6P- GST BamHI/XhoI Mr. Gene 
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1 GmbH Codon 
optimised for 
expression in E. 
coli 
CK1 alpha (aa 1-301) pET-28a His BamHI/XhoI Mr. Gene 
GmbH Codon 
optimised for 
expression in E. 
coli 
CK1 alpha (aa 1-325) pET-28a His BamHI/XhoI Mr. Gene 
GmbH Codon 
optimised for 
expression in E. 
coli 
CK1 alpha (aa 1-325) 
(S313G) 
pET-28a His BamHI/XhoI  
CK1 delta (isoform 1) pSG5-
FLAG 
FLAG EcoRI/BamHI Imagenes 
GmbH. Clone 
name:IRQMp50
18F077D 
CK1 delta (isoform 1) pEGFP-
C2 
EGFP EcoRI/BamHI Imagenes 
GmbH. Clone 
name:IRQMp50
18F077D 
CK1 delta (aa 1-317) pProEx 
HTb 
His BamHI/XhoI Mr. Gene 
GmbH Codon 
optimised for 
expression in E. 
coli 
CK1 delta (aa 1-317) pGEX-6P-
1 
GST BamHI/XhoI Mr. Gene 
GmbH Codon 
optimised for 
expression in E. 
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coli 
CK1 delta (aa 1-317) pET-28a His BamHI/XhoI Mr. Gene 
GmbH Codon 
optimised for 
expression in E. 
coli 
CK1 delta (aa 1-317) ∆STOP pET-28a N- and 
C-
termina
l His-
tag 
BamHI/XhoI  
CK1 delta (aa 1-317) ∆STOP 
K38R 
pET-28a N- and 
C-
termina
l His-
tag 
BamHI/XhoI  
CK1 delta (aa 1-317) ∆STOP 
K221,224,263,294R 
pET-28a N- and 
C-
termina
l His-
tag 
BamHI/XhoI G-Block from 
IDT 
CK1 delta (aa 1-317) ∆STOP 
K130,140,221,224,263,294R 
pET-28a N- and 
C-
termina
l His-
tag 
BamHI/XhoI G-Block from 
IDT 
CK1 delta (aa 1-317) ∆STOP 
K14,130,140,221,224,263,29
4R 
pET-28a N- and 
C-
termina
l His-
tag 
BamHI/XhoI G-Block from 
IDT 
CK1 delta (aa 1-317) ∆STOP 
K14,38,130,140,221,224,263,
pET-28a N- and 
C-
BamHI/XhoI G-Block from 
IDT 
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294R termina
l His-
tag 
CK1 delta (aa 1-317) ∆STOP 
K38,130,154,155,171,217,22
1R 
pET-28a N- and 
C-
termina
l His-
tag 
BamHI/XhoI GeneArt String 
from GeneArt 
CK1 delta (aa 1-317) ∆STOP 
K14,130,140,154,217,221,22
4,263,294R 
pET-28a N- and 
C-
termina
l His-
tag 
BamHI/XhoI GeneArt String 
from GeneArt 
CK1 delta (aa 1-317) ∆STOP 
K14,38,130,140,154,217,221,
224,263,294R 
pET-28a N- and 
C-
termina
l His-
tag 
BamHI/XhoI Synthesised by 
GeneArt 
CK1 delta (aa 1-317) ∆STOP 
K14,38,130,140,154,155,171,
217,221,224,263,294R 
pET-28a N- and 
C-
termina
l His-
tag 
BamHI/XhoI GeneArt String 
from GeneArt 
AU(E1),Ubc9(E2), SUMO-
1/SUMO-3(S1/S3) 
pT-Trx   A kind gift from 
Hisato Saitoh 
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Table 2.8. Oligonucleotides 
(Oligonucleotides were ordered from Eurofins MWG Operon, Sigma-Aldrich, 
Integrated DNA Technologies (IDT) or Oligonucleotide Synthesis Service ICRF).  
Constructs Sequence 5’ – 3’ 
Fwd: CCG GAA TTC ATG ACC AGT GTG GTT 
AAG 
pSG5-LINK-TFAF-1 (aa 79-316),  
pSG5-FLAG-TFAF-1 (aa 79-316) 
and pEGFP-C2-TFAF-1(aa 79-316) Rev: CGC GGA TCC TTA CAT TTC TAA TAG 
CTG 
Fwd: CC GGA ATT CAG ATG ACC AGT GTG 
GTT AAG 
pDsRed1-N1-TFAF-1 (aa 79-316) 
Rev: CG CGG ATC CGC CAT TTC TAA TAG 
CTG CTC 
Fwd: CC GGA ATT CAG ATG GCG GCT CCC 
GAA G 
pDsRed1-N1-TFAF-1 (full-length) 
Rev: CG CGG ATC CGC CAT TTC TAA TAG 
CTG CTC 
Fwd: C GGG AAT TCT ATG ACC AGT GTG GTT 
AAG 
pDsRed1-C1-TFAF-1 (aa 79-316) 
Rev: CG CGG ATC CGC CAT TTC TAA TAG 
CTG CTC 
Fwd: C GGG AAT TCT ATG GCG GCT CCC 
GAA G 
pDsRed1-C1-TFAF-1 (full-length) 
Rev: CG CGG ATC CGC CAT TTC TAA TAG 
CTG CTC 
Fwd: CG GAA TTC ATG GCG GCT CCC GAA G pSG5-FLAG-TFAF 1 (full-length) 
Rev: CGC GGA TCC TTA CAT TTC TAA TAG 
CTG 
Fwd: CCC AAG CTT ATG GCG AGT AGC AGC 
GGC 
pSG5-FLAG CK1 alpha isoform 1 
or pSG5-FLAG CK1 alpha LS 
Rev: CG GGA TCC TTA GAA ACC TTT CAT 
GTT ACT CTT GG 
CK1 N-terminus Fwd: CCC AAG CTT ATG GCG AGT AGC AGC 
GGC 
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 Rev: C TAG CCA TGG CAG GCT GGT TC 
Fwd: C ATG CCA TGG CAA GGG CTA AAG CK1 C-terminus 
Rev: CG GGA TCC TTA GAA ACC TTT CAT 
GTT ACT CTT GG 
Fwd: GG AAA TAT AAA CTG GTA CGG AGG 
ATC GGG TCT GGC TCC 
pSG5-FLAG CK1 alpha K22R 
Rev: GGA GCC AGA CCC GAT CCT CCG TAC 
CAG TTT ATA TTT CC 
Fwd: C GAG GAA GTG GCA GTG AGG CTA 
GAA TCT CAG AAG G 
pSG5-FLAG CK1 alpha K46R 
Rev: C CTT CTG AGA TTC TAG CCT CAC TGC 
CAC TTC CTC G 
Fwd: G AAT TTT ATA CAC AGA GAC ATT AGA 
CCA GAT AAC TTC CTA ATG G 
pSG5-FLAG CK1 alpha K138R 
Rev: C CAT TAG GAA GTT ATC TGG TCT AAT 
GTC TCT GTG TAT AAA ATT C 
Fwd: GGG CTA AAG GCT GCA ACA AGG AAA 
CAA AAA TAT GAA AAG ATT AG 
pSG5-FLAG CK1 alpha K257R 
Rev: CT AAT CTT TTC ATA TTT TTG TTT CCT 
TGT TGC AGC CTT TAG CCC 
Fwd: G GCT GCA ACA AAG AAA CAA AGA 
TAT GAA AAG ATT AGT GAA AAG 
pSG5-FLAG CK1 alpha K260R 
Rev: CTT TTC ACT AAT CTT TTC ATA TCT 
TTG TTT CTT TGT TGC AGC C 
Fwd: GGG CTA AAG GCT GCA ACA AGG AAA 
CAA  
AGA TAT GAA AAG ATT AGT GAA AAG 
pSG5-FLAG CK1 alpha K257/260R 
Rev: CTT TTC ACT AAT CTT TTC ATA TCT 
TTG TTT CCT TGT TGC AGC CTT TAG CCC 
Fwd: GAA AAG AAG ATG TCC ACG CCT GCT 
GCA GTT TTA AAG GGG TTT CC 
pSG5-FLAG CK1 alpha 
V273A/E274A 
Rev: GG AAA CCC CTT TAA AAC TGC AGC 
AGG CGT GGA CAT CTT CTT TTC 
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Fwd: CG GAA TTC ATG GAG CTG AGA GTC 
GG 
 
pSG5-FLAG CK1 delta, 
pEGFP-C2 CK1 delta 
Rev: CG GGA TCC TCA TCG GTG CAC GAC 
AG 
 
Fwd: CAA CAG GCA GCG TCC TCT GGT GGA 
CAA GGT CAG CAA G 
CK1 alpha (aa 1-325) 
(S313G) 
Rev: C TTG CTG ACC TTG TCC ACC AGA GGA 
CGC TGC CTG TTG 
Fwd: G GAA CGT CTG CGC CAT GGA CTC 
GAG CAC CAC CAC CAC CAC C 
CK1 delta ∆STOP  
Rev: G GTG GTG GTG GTG GTG CTC GAG TCC 
ATG GCG CAG ACG TTC C 
Fwd: CT GGT GAG GAA GTC GCC ATT CGT 
CTG GAG TGT GTG AAA ACA AAA CAC 
CK1 delta K38R 
Rev: GTG TTT TGT TTT CAC ACA CTC CAG 
ACG AAT GGC GAC TTC CTC ACC AG 
Fwd: G CTG ACC GAG CTC AAG GGC CTA 
TGC CTC GGG CGC G 
pcDNA3-AU1 FADD F25G 
Rev: C GCG CCC GAG GCA TAG GCC CTT GAG 
CTC GGT CAG C 
Fwd: G CGC GTG GGC AAG CGC AGG CTG 
GAG CGC GTG CAG AG 
pcDNA3-AU1 FADD K35R 
Rev: CT CTG CAC GCG CTC CAG CCT GCG 
CTT GCC CAC GCG C 
Fwd: GC CTC GGG CGC GTG GGC AGG CGC 
AGG CTG GAG CGC G 
pcDNA3-AU1 FADD K33/35R 
Rev: C GCG CTC CAG CCT GCG CCT GCC CAC 
GCG CCC GAG GC 
Fwd: G CTC AAA GTC TCA GAC ACC AGG ATC 
GAC AGC ATC GAG GAC  
pcDNA3-AU1 FADD K125R 
Rev: GTC CTC GAT GCT GTC GAT CCT GGT 
GTC TGA GAC TTT GAG C 
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Fwd: CAG ATG AAC CTG CCT GAC CTG GTA 
CAA GAG 
pcDNA3-AU1 FADD A174P 
Rev: CTC TTG TAC CAG GTC AGG CAG GTT 
CAT CTG 
Fwd: C AGG AGT GGG GCC ATG GCC CCG 
ATG TCA TGG AAC TC 
pcDNA3-AU1 FADD S194A 
Rev: GA GTT CCA TGA CAT CGG GGC CAT 
GGC CCC ACT CCT G 
Fwd: C AGG AGT GGG GCC ATG GAA CCG 
ATG TCA TGG AAC TC 
pcDNA3-AU1 FADD S194E 
Rev: GA GTT CCA TGA CAT CGG TTC CAT 
GGC CCC ACT CCT G 
Fwd: C AGG AGT GGG GCC ATG GAC CCG 
ATG TCA TGG AAC TC 
pcDNA3-AU1 FADD S194D 
Rev: GA GTT CCA TGA CAT CGG GTC CAT 
GGC CCC ACT CCT G 
Fwd: GG GAA TTC CAT ATG GAA TTT ACA 
GAG GAC ATG G 
pET-28b SENP2 (aa 366-588) 
Rev: CCG CTC GAG CAG CAA CTG CTG GTG 
AAG 
 
 
Table 2.9. G-Blocks/GeneArt® strings 
Name Sequence Company  
CK1 delta gBlock1 K14R 
(BamHI/EcoRI) 
CGCGGATCCATGGAACTGCGTGTGGGTAA
TCGCTATCGTCTGGGGCGTCGCATTGGTAG
TGGCTCTTTCGGTGACATCTATCTGGGTAC
TGACATTGCTGCTGGTGAGGAAGTCGCCA
TTAAACTGGAGTGTGTGAAAACAAAACAC
CCTCAGCTGCACATTGAATCCAAAATCTAT
AAAATGATGCAAGGCGGTGTGGGAATTCC
GG 
IDT 
CK1 delta gBlock1 K14,38R 
(BamHI/EcoRI) 
CGCGGATCCATGGAACTGCGTGTGGGTAA
TCGCTATCGTCTGGGGCGTCGCATTGGTAG
TGGCTCTTTCGGTGACATCTATCTGGGTAC
TGACATTGCTGCTGGTGAGGAAGTCGCCA
TTCGTCTGGAGTGTGTGAAAACAAAACAC
IDT 
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CCTCAGCTGCACATTGAATCCAAAATCTAT
AAAATGATGCAAGGCGGTGTGGGAATTCC
GG 
CK1 delta gBlock2 
K130,140R 
(EcoRI/StuI) 
CCGGAATTCCGACAATTCGTTGGTGTGGT
GCCGAAGGTGATTATAACGTCATGGTTAT
GGAGCTGCTGGGTCCTTCTCTGGAAGATCT
GTTCAACTTCTGTAGCCGTAAATTCAGCCT
GAAAACCGTTCTGCTGCTGGCCGATCAGA
TGATTTCCCGTATCGAGTATATCCACTCTA
AAAACTTTATCCACCGTGATGTGCGTCCGG
ACAACTTTCTGATGGGACTGGGCCGTAAA
GGCAACCTGGTCTATATTATCGACTTCGGT
CTGGCGAAAAAATATCGTGACGCCCGTAC
TCATCAACACATCCCTTATCGTGAGAATAA
AAACCTGACCGGTACAGCACGCTATGCCT
CTATTAACACTCACCTGGGGATCGAACAA
TCTCGTCGTGATGATCTGGAAAGCCTGGGT
TATGTCCTGATGTATTTCAACCTGGGTTCT
CTGCCGTGGCAAGGCCTTTC 
IDT 
CK1 delta gBlock3 
K221,224,263,294R 
(StuI/XhoI) 
GAAAGGCCTGAAAGCTGCTACTCGCCGCC
AACGTTATGAGCGTATCAGCGAGAAAAAA
ATGAGCACCCCGATCGAGGTTCTGTGTAA
AGGTTATCCGAGCGAGTTTGCCACATATCT
GAACTTTTGCCGCTCACTGCGCTTTGACGA
CCGTCCGGACTATTCCTATCTGCGCCAACT
GTTTCGTAACCTGTTCCACCGTCAGGGA 
TTTTCGTATGACTATGTCTTTGACTGGAAT
ATGCTGCGTTTCGGTGCCTCTCGTGCCGCC
GATGATGCCGAACGTGAACGTCGTGACCG
TGAGGAACGTCTGCGCCATGGACTCGAGC
GGC 
IDT 
GeneArt string CK1 delta 
K130,140,154,155,171R 
(EcoRI/StuI) 
CCGGAATTCCGACAATTCGTTGGTGTGGT
GCCGAAGGTGATTATAACGTCATGGTTAT
GGAGCTGCTGGGTCCTTCTCTGGAAGATCT
GTTCAACTTCTGTAGCCGTAAATTCAGCCT
GAAAACCGTTCTGCTGCTGGCCGATCAGA
TGATTTCCCGTATCGAGTATATCCACTCTA
AAAACTTTATCCACCGTGATGTGCGTCCGG
ACAACTTTCTGATGGGACTGGGCCGTAAA
GGCAACCTGGTCTATATTATCGACTTCGGT
CTGGCGCGTCGTTATCGTGACGCCCGTACT
CATCAACACATCCCTTATCGTGAGAATCGT
AACCTGACCGGTACAGCACGCTATGCCTC
TATTAACACTCACCTGGGGATCGAACAAT
CTCGTCGTGATGATCTGGAAAGCCTGGGTT
ATGTCCTGATGTATTTCAACCTGGGTTCTC
TGCCGTGGCAAGGCCTTTC 
GeneArt 
GeneArt String CK1 delta 
K130,154,155,171,217,221R 
CCGGAATTCCGACAATTCGTTGGTGTGGT
GCCGAAGGTGATTATAACGTCATGGTTAT
GGAGCTGCTGGGTCCTTCTCTGGAAGATCT
GeneArt 
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(EcoRI/XhoI) GTTCAACTTCTGTAGCCGTAAATTCAGCCT
GAAAACCGTTCTGCTGCTGGCCGATCAGA
TGATTTCCCGTATCGAGTATATCCACTCTA
AAAACTTTATCCACCGTGATGTGCGTCCGG
ACAACTTTCTGATGGGACTGGGCAAAAAA
GGCAACCTGGTCTATATTATCGACTTCGGT
CTGGCGCGTCGTTATCGTGACGCCCGTACT
CATCAACACATCCCTTATCGTGAGAATCGT
AACCTGACCGGTACAGCACGCTATGCCTC
TATTAACACTCACCTGGGGATCGAACAAT
CTCGTCGTGATGATCTGGAAAGCCTGGGTT
ATGTCCTGATGTATTTCAACCTGGGTTCTC
TGCCGTGGCAAGGCCTGCGTGCTGCTACTC
GTCGCCAAAAATATGAGCGTATCAGCGAG
AAAAAAATGAGCACCCCGATCGAGGTTCT
GTGTAAAGGTTATCCGAGCGAGTTTGCCA
CATATCTGAACTTTTGCCGCTCACTGCGCT
TTGACGACAAACCGGACTATTCCTATCTGC
GCCAACTGTTTCGTAACCTGTTCCACCGTC
AGGGATTTTCGTATGACTATGTCTTTGACT
GGAATATGCTGAAATTCGGTGCCTCTCGTG
CCGCCGATGATGCCGAACGTGAACGTCGT
GACCGTGAGGAACGTCTGCGCCATGGACT
CGAGCGGC 
 
 
Table 2.10. Antibodies 
Primary Immunogen Species Titer Source 
FADD aa 94-208 Mouse 
Monoclonal
IgG1 
1:50 IF BD Transduction 
Laboratories 
Cat No. 610399 
FADD aa 28-209 Rabbit 
polyclonal 
IgG 
1:100 IF 
1:200 WB 
Santa Cruz 
Biotechnology, Inc. 
(H-181): sc-5559 
FADD N-terminal 
peptide 
Goat 
Polyclonal 
IgG 
1:100 IF Santa Cruz 
Biotechnology, Inc. 
(S-18): sc-6035 
FADD Full-length 
FADD 
Rabbit 
polyclonal 
IgG 
1:200 WB Upstate 
Biotechnology 
Cat No. 06-711 
Phospho-FADD Synthetic Rabbit 1:50 IF Cell Signaling 
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(Ser 194) 
(Human Specific) 
phosphopeptide 
corresponding to 
residues 
surrounding Ser 
194 of human 
FADD 
Polyclonal 
IgG 
Technology 
Cat No. 2781 
Phospho-FADD 
(Ser 191) 
(Mouse Specific) 
Synthetic 
phosphopeptide 
corresponding to 
residues 
surrounding Ser 
191 of mouse 
FADD 
Rabbit 
Polyclonal 
IgG 
1:200 IF Cell Signaling 
Technology 
Cat No. 2785 
CK1 alpha C-terminus of 
human CK1 alpha 
Goat 
Polyclonal 
IgG 
1:25 IF Santa Cruz 
Biotechnology, Inc. 
(C-19): sc-6477 
SUMO  Rabbit 
polyclonal 
1:200 IF (Boddy et al., 1997) 
SUMO-1 Full-length 
SUMO-1 
Mouse 
Monoclonal 
IgG1 
(Clone 
21C7) 
1:50 IF Zymed laboratories 
Inc. 
Cat No. 33-2400 
from Invitrogen 
 
SUMO-1 Peptide specific 
for SUMO-1 
Rabbit 
polyclonal 
1:100 IF Cell Signaling 
Technology 
Cat No. 4930 
SUMO-2/3 C-terminal 
peptide of human 
SUMO2/3 
Rabbit 
polyclonal 
IgG 
1:100 IF Abcam plc. 
Cat No. (ab3742) 
PML  Rabbit 
polyclonal 
1:200 IF (Borden et al., 1995) 
PML aa37-51 of the 
human PML 
Mouse 
Monoclonal 
1:100 IF Santa Cruz 
Biotechnology, Inc. 
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IgG (PG-M3): sc-966 
PML N-terminal 
peptide of human 
PML 
Goat 
polyclonal 
IgG 
1:200 IF Santa Cruz 
Biotechnology, Inc. 
(N-19): sc-9862 
Sp100  Rabbit 
polyclonal 
1:200 IF A kind gift from H. 
Will 
Daxx aa 727-739 of the 
mouse Daxx 
Mouse 
Monoclonal 
IgG2a 
1:100 IF Santa Cruz 
Biotechnology, Inc. 
(H-7): sc-8043 
Daxx aa 627-739 Rabbit 
Polyclonal 
IgG 
1:50 IF Santa Cruz 
Biotechnology, Inc. 
(M-112): sc-7152 
p53 aa 1-393 Rabbit 
Polyclonal 
IgG 
1:50 IF Santa Cruz 
Biotechnology, Inc. 
(FL-393):sc-6243 
FLAG FLAG peptide Mouse 
Monoclonal
IgG1 
1:200 IF 
1:2000 WB 
Sigma-Aldrich 
Cat No. F 3165 
FLAG FLAG peptide Rabbit 
polyclonal 
IgG 
1:800 IF Cell Signaling 
Technology 
Cat No. 2368 
TFAF-1 Peptide 1 (aa 2-
16)  
Rabbit 
polyclonal 
1:200 IF Eurogentec 
TFAF-1 Peptide 2 (aa 96-
110) 
Rabbit 
polyclonal 
1:200 IF Eurogentec 
Keratin 18 
(K18) 
A-431 and MCF-
7 cells 
Mouse 
monoclonal 
IgG1 
1:200 IF Sigma-Aldrich 
Cat No. C8541 
His Synthetic peptide 
containing six His 
residues 
Mouse 
monoclonal 
IgG1 
1:1000 WB Invitrogen 
Cat No. 37-2900 
His Recombinant 
poly-histidine 
Mouse 
monoclonal 
1:10000 
WB 
Sigma-Aldrich 
Cat No A7058 
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tagged fusion 
protein 
IgG2a 
HA Internal peptide 
from the HA 
protein 
Mouse 
Monoclonal 
IgG2a 
1:50 IF Santa Cruz 
Biotechnology, Inc. 
(F-7): sc7392 
AU1 BPV-1. Detects 
epitope DTYRYI. 
Mouse 
monoclonal 
IgG3 
1:1000 IF Covance 
Caspase-8 C-terminal 
peptide of human 
Caspase-8 
Mouse 
monoclonal 
IgG1 
1:50 IF Cell Signaling 
Technology 
Cat No. 9746 
HIPK3 Synthetic peptide 
within aa100-200 
Rabbit 
polyclonal 
IgG 
1:100 IF Abgent 
Cat No. AP7540c 
Lamin B C-terminal 
peptide of mouse 
Lamin B  
Goat 
polyclonal 
IgG 
1:100 IF Santa Cruz 
Biotechnology, Inc. 
(M-20): sc-6217 
Nucleolus B23 purified from 
rat 
Mouse 
monoclonal 
IgG1 
1:50 IF Zymed laboratories 
Inc. (Invitrogen) 
Cat No. 32-5200 
 
Cajal bodies aa 363-481 of 
human coilin 
Mouse 
monoclonal 
IgG1 
1:125 IF Abcam plc. 
Cat No. (ab11822) 
 
  
Table 2.11. Secondary Antibodies 
Secondary Antigen Titer Source 
FITC-conjugated Donkey 
Anti-Rabbit 
Rabbit IgG 1:100 Jackson ImmunoResearch 
Laboratories, Inc. 
Cy3-conjugated Donkey 
Anti-Rabbit 
Rabbit IgG 1:200 Jackson ImmunoResearch 
Laboratories, Inc. 
FITC-conjugated Donkey Mouse IgG 1:100 Jackson ImmunoResearch 
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Anti-Mouse Laboratories, Inc. 
Cy3-conjugated Donkey 
Anti-Mouse 
Mouse IgG 1:200 Jackson ImmunoResearch 
Laboratories, Inc. 
FITC-conjugated Donkey 
Anti-Goat 
Goat IgG 1:100 Jackson ImmunoResearch 
Laboratories, Inc. 
Cy3-conjugated Donkey 
Anti-Goat 
Goat IgG 1:200 Jackson ImmunoResearch 
Laboratories, Inc. 
Polyclonal Goat Anti-Rabbit 
HRP conjugated 
Rabbit IgG 1:2000 Dako 
Polyclonal Goat Anti-
Mouse HRP conjugated 
Mouse IgG 1:2000 Dako 
Polyclonal Rabbit Anti-Goat 
HRP conjugated 
Goat IgG 1:2000 Dako 
Polyclonal Goat Anti-Rabbit 
HRP conjugated 
Rabbit IgG 1:4000 Sigma-Aldrich 
 
 
Table 2.12. Enzymes 
Reagent  Source 
BamHI New England Biolabs Inc. 
DpnI New England Biolabs Inc. 
EcoRI New England Biolabs Inc. 
HindIII New England Biolabs Inc. 
KpnI New England Biolabs Inc. 
SalI New England Biolabs Inc. 
StuI New England Biolabs Inc. 
XbaI New England Biolabs Inc. 
XhoI New England Biolabs Inc. 
XmaI New England Biolabs Inc. 
T4 DNA Ligase New England Biolabs Inc. 
T4 Polynucleotide Kinase  New England Biolabs Inc. 
Benzonase® Merck 
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Pfu Ultra II DNA Polymerase Agilent 
PfuTurbo DNA Polymerase Agilent 
Shrimp Alkaline Phosphatase Roche Diagnostics 
 
 
Table 2.13. Kits 
Reagent  Source 
QIAprep Spin MiniPrep Kit Qiagen 
QIAfilter Plasmid Midi Kit Qiagen 
QIAquick Gel Extraction Kit Qiagen 
QIAquick PCR Purification Kit Qiagen 
RNeasy Mini Kit Qiagen 
Zero Blunt PCR Cloning Kit Invitrogen 
E.coli T7 S30 Extract System for Circular DNA Promega 
RTS 100 E.coli HY Kit 5 PRIME 
ADP-GloTM Kinase Assay Promega 
Nuclear/Cytosol Fractionation Kit BioVision 
 
 
Table 2.14. Antibiotics  
Reagent  Source 
Ampicillin Sigma-Aldrich 
Kanamycin Sigma-Aldrich 
Chloramphenicol Sigma-Aldrich 
Tetracycline Sigma-Aldrich 
 
 
Table 2.15. DNA and protein ladders 
Reagent  Source 
1Kb Plus DNA Ladder Invitrogen 
PageRuler Prestained Protein ladder Fermentas 
Rainbow Molecular Weight Marker  GE Healthcare 
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Table 2.16. Miscellaneous reagents 
Reagent  Source 
Novex 4-20% Tris-Glycine Gels Life Technologies 
ECL detection reagent Amersham/GE Healthcare 
Whatman 3MM blotting paper Whatman/GE Healthcare 
dNTPs Roche Diagnostics 
Hybond ECL nitrocellulose membrane Amersham/GE Healthcare 
Amersham Hyperfilm ECL Amersham/GE Healthcare 
iBlot® Transfer Stack, nitrocellulose Life Technologies  
Tween 20 Sigma-Aldrich 
SIGMAFAST Protease inhibitor cocktail tablets, 
EDTA-Free 
Sigma-Aldrich 
 
 
Table 2.17. Commonly used reagents in tissue culture 
Reagent  Source 
DMEM Gibco® 
Foetal Bovine Serum (FBS or FCS) Gibco® 
L-Glutamine 200 mM 100X Gibco® 
Penicillin (50 IU/ml)/streptomycin (50 µg/ml) Gibco® 
0.05%Trypsin-EDTA Gibco® 
dPBS Gibco® 
DMSO Merck 
16% Formaldehyde TAAB laboratories 
Triton X-100 Sigma-Aldrich 
Citifluor Citifluor Ltd 
DAPI Roche Diagnostics 
Propidium Iodide Roche Diagnostics 
RNase A Sigma-Aldrich 
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Chemicals and reagents 
All chemicals and reagents were obtained from the following companies: Sigma-
Aldrich, Roche Diagnostics, Merck, VWR and Fisher Scientific unless otherwise 
stated. 
 
2.2 DNA and DNA manipulation methods 
2.2.1 Amplification of full-length TFAF-1 and assembly of constructs 
A human testis cDNA library (Origene Technologies Inc.) was screened by PCR and 
a full-length TFAF-1 clone was obtained. The following primers were used to screen 
the library: 5’-oligonucleotide CCA GAA GTT GAC TGA AAC TCA G and 3’-
oligonucleotide ACT GTA GAA ATT GTT TTC ATT CTG G. 
Subfragments of TFAF-1 were also generated by polymerase chain reaction 
amplification with specific oligonucleotides, which contained EcoRI (5’-
oligonucleotides) and BamHI (3’-oligonucleotides) restriction sites at their respective 
5’- or 3’-ends. Fragments were inserted into plasmids pSG5-LINK, pSG5-FLAG, 
pEGFP-C2, pDsRed1-N1, pDsRed1-C1 or pDsRed2-C1 (Clontech) for localisation 
studies.  
 
2.2.2 Amplification of full-length CK1 alpha isoform 1 (CK1 alpha LS) 
Full-length CK1 alpha LS was not available from RZPD/Imagenes so the full-length 
clone was constructed using PCR fragments from two different clones: one clone 
containing the N-terminus of CK1 alpha and the other containing the C-terminus of 
CK1 alpha. The N-terminus (aa 1-249) was amplified from clone 
IRALp962M1925Q2 (RZPD/Imagenes) using primers with the restriction sites 
HindIII and NcoI at the 5’ and the 3’ end respectively. The C-terminus (aa 248-365) 
was amplified from IMAGp998A2212114Q1 (RZPD/Imagenes) using primers with 
the restriction sites NcoI and BamHI at the 5’ and the 3’ end respectively. The PCR 
fragment containing the N-terminus of CK1 alpha was digested with HindIII and NcoI 
and the PCR fragment containing the C-terminus of CK1 alpha was digested with 
NcoI and BamHI. Both fragments were PCR-purified and ligated in the NcoI site. The 
ligation products were used as a template and a further PCR was performed to obtain 
the full-length clone using the 5’ HindIII primer and the 3’ BamHI primer. Full-length 
CK1 alpha LS was cloned into pSG5-FLAG. 
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2.2.3 Amplification of the SUMO-specific protease SENP2 
The active domain of SENP2 (aa 366-588) was amplified from the I.M.A.G.E full-
length cDNA clone IRAVp968H0878D (RZPD/Imagenes) using primers with the 
restriction sites NdeI and XhoI at the 5’ and the 3’ end respectively. The protease was 
cloned into pET-28b (Novagen) containing a N- and C-terminal 6xHis-tag. 
 
2.2.4 Polymerase chain reaction (PCR)  
For PCR, a single block (OmniGene (Hybaid)) or RoboCycler Gradient 40 
(Stratagene) PCR machine was used. The PCR was performed in 25 µl reactions 
consisting of: 1 x Pfu Turbo reaction buffer, 100 ng each of forward and reverse 
primer, 2% (vol/vol) DMSO, 0.2 mM dNTPs, 1.25 units Pfu Turbo DNA polymerase, 
10-30 ng DNA. 
The following program was used if the primers had restriction sites at the 5’ end for 
cloning purposes: 1 cycle at 95 ˚C for 30 sec, 10 cycles at 95 ˚C for 30 sec, 50-68 ˚C 
for 45 sec, 68 ˚C for x min (1 min/kb), 20 cycles at 95 ˚C for 30 sec, 50-68 ˚C for 45 
sec, 68 ˚C for x min (1 min/kb), 1 cycle at 68 ˚C for 5 min. 
After the PCR, samples were analysed by agarose gel electrophoresis.  
PCR products were purified for primers, nucleotides and polymerases using the 
QIAquick PCR Purification kit according to manufacturer’s protocol. 
 
2.2.5 Site-directed mutagenesis 
The protocol for site-directed mutagenesis was based on the Stratagene QuikChange 
protocol. Primers used for site-directed mutagenesis were designed taking the 
following into consideration:  
1. Both primers must contain the mutation. 
2. The primers should be around 35-40 nucleotides long with the mutation in the 
middle.  
3. The melting temperature of each site of the mutation (around 15-18 nucleotides) 
should be adjusted to the same temperature (usually around 50-55 ˚C).  
4. The nucleotide at the 3’ end of the primer should be a C or a G. 
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The following protocol was used for site-directed mutagenesis (25 µl reactions): 1 x 
Pfu Turbo reaction buffer, 100 ng each of forward and reverse primer, 2% (vol/vol) 
DMSO, 0.2 mM dNTPs, 1.25 units Pfu Turbo DNA polymerase, 10-30 ng DNA. 
A negative control without primers was always included. It was used to check the 
efficiency of the DpnI digest of the methylated non-mutated parental DNA. 
The following program was used on the RoboCycler Gradient 40 (Stratagene) PCR 
machine: 1 cycle at 95 ˚C for 30 sec, 16 cycles at 95 ˚C for 30 sec, 48-54 ˚C for 45 
sec, 68 ˚C for x min (1 min/kb). 
After the PCR, samples were analysed by agarose gel electrophoresis. If there was a 
visible band on the DNA gel, DpnI was added to the PCR to digest the methylated, 
non-mutated, parental DNA at 37 ˚C for 1-2 hours. 
DNA was transformed into competent cells where the nicks in the mutated plasmid 
were repaired. 
 
2.2.6 Agarose gel electrophoresis 
Agarose gels (0.6% to 1.2% w/v in TAE) with addition of GelRed (10,000X) were 
prepared, and run in TAE buffer. Resolved DNA fragments were visualised by using 
a UV transilluminator, or Gene Genius (Syngene). 
 
2.2.7 Restriction enzyme digestion of plasmid DNA and PCR products 
Plasmid DNA or PCR products were digested with ~5 units of restriction enzyme/mg 
of DNA for 1-2 hrs. The enzyme concentration did not exceed 10% v/v and glycerol 
was kept below 5% v/v. Restriction enzymes were obtained from New England 
Biolabs (NEB) and addition of BSA and choice of buffer were in accordance to the 
manufacturer’s protocol. Digests were analysed by agarose gel electrophoresis. 
 
2.2.8 PCR purification of DNA 
PCR products and PCR products digested with restriction enzymes were purified from 
primers, nucleotides, salt, polymerases and restriction enzymes using the QIAquick 
PCR Purification kit according to the manufacturer’s protocol. 
 
2.2.9 Extraction of DNA fragments from agarose gels 
DNA was extracted from gel slices, following the agarose gel electrophoresis 
purification of restriction fragments and excision under long wave UV (~360nm). 
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Isolation of DNA from gel slices was performed using QIAquick Gel Extraction Kit 
(Qiagen) according to the manufacturer’s protocol. 
 
2.2.10 Dephosphorylation of DNA 
To prevent self-ligation of the vector DNA, dephosphorylation of 5’ phosphates from 
DNA was carried out using the Shrimp alkaline phosphatase (Roche Diagnostics) 
according to the manufacturer’s protocol. 
 
2.2.11 Phosphorylation of DNA 
T4 polynucleotide kinase (NEB) was used according to the manufaturer’s protocol to 
phosphorylate 5’ hydroxyl end of double-stranded DNA prior to ligation. 
 
2.2.12 Ligation of DNA 
Ligations were carried out in 10 µl volumes using T4 DNA ligase (NEB). The DNA 
ligase forms a phosphodiester bond between 5’ phosphate and the 3’ hydroxyl end of 
DNA. For cohesive end ligation a ratio of 1:3 pmol vector to insert was used and for 
blunt end ligation a ratio of 1:6 pmol vector to insert was used. The concentration of 
the DNA was estimated on an agarose gel. 25 ng of the vector was always used for 
ligations and the concentration of the insert adjusted accordingly. 
 
2.2.13 Transformation of E.coli 
Electroporation of electrocompetent cells was routinely used for the transformation of 
E.coli with plasmid DNA. E.coli (XL1-BLUE and BL21-GOLD(DE3)) were prepared 
for electroporation using the following protocol: cells were grown to mid-log phase 
(A600 = 0.4-0.6) in LB broth with 20 µg/ml tetracycline at 37 oC, pelleted (4000 rpm, 
15 minutes at 4 oC), and washed with chilled dH2O, repelleted, and then resuspended 
in 10% (v/v) glycerol in dH2O. Finally cells were resuspended in 1/400 volume of 
10% (v/v) glycerol in dH2O, and stored in single use aliquots of 50 µl at -80 oC. 
 Cells were transformed in a 0.1cm electrode gap cuvette using a BioRad Gene Pulsar 
(settings: 1.67 kV, 25 mF, 200 Ω). Post-electroporation, cells were suspended in 450 
µl LB or SOC media and incubated at 37 oC for 30-45 minutes, before they were 
plated on LB-agar (LB with 1.2% w/v agar) containing appropriate antibiotic. Plates 
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were incubated at 37 oC overnight. SoluBL21 were transformed according to the 
manufacturer’s protocol. 
Bacterial cells (TOP10, LIBRARY EFFICIENCY® DH5a™, BL21-GOLD(DE3) and 
NEB 5-alpha) were chemically transformed. Cells were incubated with plasmid DNA 
on ice for 30 minutes, transformed by incubation at 42 oC for 45 seconds and on ice 
for 2 minutes. Cells were resuspended in 450 µl SOC, and incubated at 37 oC for 30-
45 minutes, then plated on LB-agar plates containing appropriate antibiotic, and 
incubated at 37 oC overnight. 
 
2.2.14 Isolation of plasmid DNA 
Isolation of plasmid DNA from varying amounts of bacteria-inoculated media was 
performed using a modified alkaline lysis method (Birnboim and Doly, 1979). Small-
scale plasmid purification followed the QIAprep Miniprep protocol (Qiagen). For 
larger scale isolations the QIAfilter plasmid Midi/Maxi Kit (Qiagen) was used 
according to the manufacturer’s protocol. 
 
2.2.15 Quantification of plasmid DNA  
Concentration of plasmid DNA was determined by using one of the following 
methods: 
A. DNA concentration was determined using 1:100 dilutions of stock plasmid DNA 
according to the formula: absorbance of one A260 unit approximately equates to 50 
ng/µl of double-stranded DNA. 
B. DNA concentration was determined using the Thermo Scientific NanoDropTM 
1000 Spectrophotometer according to the manufacturer’s protocol. 
C. DNA concentration was determined using the NanoPhotometer® P-Class from 
IMPLEN GmbH according to the manufacturer’s protocol. 
 
2.2.16 Sequencing of plasmid DNA 
1 µg of purified DNA was prepared in a 1.5 ml tube in either dH20 or 5 mM Tris-
HCL (pH 8-9) to a total volume of 15 µl including 15 pmol of sequencing primer. 
Samples were sent to Eurofins MWG Operon for sequencing. 
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2.3 Tissue culture 
 
2.3.1 Mammalian cell lines 
MEFs, U2O-S, Saos-2 and HT1080 cells were grown in T25 or T75 flasks in 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% FCS (foetal 
calf serum), 2 mM glutamine, 50 IU/ml penicillin and 50 mg/ml streptomycin (Life 
Technologies). Cells were passaged by removing media, washed with PBS and 
incubated with Trypsin-EDTA (0.05% Trypsin, 0.5 mM EDTA) for ~2 minutes, 
adding 5X of complete growth media to neutralise the trypsin and replated at a 
dilution of 1:5-1:20. 
 
2.3.2 Freezing of cell lines 
Cells were grown in a T75 flask until they were 80-90% confluent. Media was 
removed from the cells, washed with PBS and incubated with trypsin-EDTA (0.05% 
Trypsin, 0.5 mM EDTA) for ~2 minutes, then 5X of complete growth media was 
added to neutralise the trypsin. Cells were spun down for 5 minutes at 1000 rpm. 
Cells were resuspended in 5 ml of supplemented DMEM containing 10% DMSO and 
divided into 5 cryo tubes (Nunc). Tubes were wrapped in paper towels and put in a 
small styrofoam box and stored at -80 ˚C for 2 days. This was to allow slow cooling. 
Vials were then transferred to liquid nitrogen for long-term storage. 
 
2.3.3 Thawing of cell lines 
Vials containing the cells were removed from liquid nitrogen and immediately put 
into a 37 ˚C waterbath. This was to ensure fast thawing of the cells. Cells were added 
into pre-warmed media and spun down for 5 minutes at 1000 rpm. Media containing 
the DMSO was removed and cells were resuspended in supplemented DMEM and 
grown in a T25 flask. 
 
2.3.4 Transient transfection of mammalian cells 
U2OS or HT1080 cells were transiently transfected using SUPERFECT (Qiagen) or 
FuGENE 6 (Roche Diagnostics) according to the manufacturer’s protocol. 
U2OS or HT1080 cells were plated out (~3x105 cells/well) and grown overnight in a 
6-well plate (FALCON) containing a glass coverslip (22mm x 22mm). When 
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SUPERFECT was used for the transfection, a mix of DNA (2 µg), DMEM (700 µl) 
and Superfect (10 µl) was applied to every well and incubated for 3 hours at 37 oC. 
After 3 hours, cells were washed with PBS, and then 2ml DMEM containing 
supplements was added. Cells were incubated for 24-40 hours. 
When FuGENE 6 was used for the transfection a mix of DNA (2 µg), DMEM (94 µl) 
and FuGENE 6 (6 µl) was applied to every well and incubated for 18 hours. Then the 
media was removed and replaced with fresh media. Cells were incubated another 6-24 
hours. 
 
2.3.5 Fixation and permeabilisation of mammalian cells 
After incubation, media was removed from the cells. Cells were washed with PBS 
then fixed in 4% parafomaldehyde in PBS for 10 minutes. Paraformaldehyde was 
removed and cells were washed again with PBS, then permeabilised in 0.5% Triton 
X-100 in PBS for 20 minutes. Triton X-100 was removed and cells were washed 
twice with PBS. Fixed cells were stored at 4 ˚C until required. 
 
2.3.6 Immunofluorescence studies 
Primary antibodies in PBS at an appropriate dilution were added to cells fixed on 
coverslips and incubated for 30-60 minutes. Coverslips were then washed in PBS, (3 
x 10 minutes). Secondary antibodies (50 µl) in PBS at an appropriate dilution were 
added to the coverslips and incubated in the dark for 30-60 minutes. Coverslips were 
washed in the dark in PBS, (3 x 10 minutes). DNA was stained with propidium iodide 
(0.5 µg/ml (Roche)) or DAPI (0.25 µg/ml (Roche)) and cells were viewed on a 
confocal microscope (Zeiss LSCM 510) with a Zeiss objective Plan-Apochromat 
63x/1.40 oil DIC. 
 
2.3.7 Propidium iodide staining 
To outline the nuclear volume only, cells were washed with PBS, treated with 
Ribonuclease (100 µg/ml RNase (Roche)) for 20 minutes at 37 oC and DNA was 
stained with propidium iodide (0.5 µg/ml). 
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2.3.8 Preparation of total cellular protein extracts 
After incubation, media was removed from the cells. Cells were washed with PBS and 
then lysed directly in the plate with 150 µl 2 x SDS sample buffer containing 0.75µl 
Benzonase® (100U/µl) for 5-10 minutes on ice. Cell extracts were incubated 5 
minutes at 95 ˚C, then centrifuged for 5 minutes at 13000 rpm and stored at -20 ˚C 
until required. 
 
2.3.9 Nuclear/cytoplasmic fractionations 
Nuclear and cytoplasmic fractionations were isolated from mammalian cells 
according to the manufacturer’s protocol (BioVision). The fractionation was 
performed using untransfected or transfected mammalian cells. 
 
2.3.10 SDS polyacrylamide gel electrophoresis (SDS-PAGE), western blotting 
and chemiluminescent detection of proteins 
Preparation of total cellular protein extracts and SDS-polyacrylamide electrophoresis 
was carried out according to standard protocols (Sambrook, 1989). Gels used were 
either commercially available or made. Samples were lysed in SDS gel-reducing 
buffer, boiled and loaded onto an appropriate % Tris-Glycine polyacrylamide gel. 
Proteins were then transferred to Hybond ECL nitrocellulose membrane (Amersham 
Pharmacia) using the Hoefer Semiphor semi-dry transfer procedure or the iBlot® gel 
transfer device (Life Technologies) and then blocked overnight in 5% (w/v) skimmed 
milk powder in dH20.  
Blocked membranes were probed with an antibody diluted appropriately in blocking 
solution. Membranes were washed twice with PBST and once with PBS. Membranes 
were then incubated with horseradish peroxidase conjugated IgG antibody (Dako) 
diluted in blocking solution. Membranes were again washed twice with PBST and 
once with PBS. Binding of secondary antibodies was detected using ECL (Amersham 
Pharmacia). 
 
2.3.11 Production of polyclonal antisera against the TFAF-1 protein 
Two polyclonal antibodies 822 and 823 against the TFAF-1 protein were made by 
immunizing rabbits with two synthetic TFAF-1 peptides (residues 2-16 and 96-110) 
coupled to the carrier protein Hemocyanin (Eurogentec). Both antibodies detected 
exogenous TFAF-1 protein as described in Results. 
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2.4 Protein expression and purification methods 
 
2.4.1 Cell-free protein expression 
Cell-free protein expression is used for fast protein synthesis. It can be used for toxic 
gene products and can be a rapid way of mapping PCR-generated mutations. It can be 
used with PCR-generated templates or used with circular plasmids depending on the 
kit. The cell-free protein expression kits use coupled transcription/translation for in 
vitro protein synthesis. 
 
2.4.2 RTS 100 E.coli HY Kit 
The RTS kit (5 PRIME) requires a DNA template where the gene is under control of a 
T7 promoter. The DNA is transcribed into mRNA by the T7 polymerase followed by 
translation into protein by the ribosomal machinery. 
The manufacturer’s protocol was amended slightly. Instead of running the experiment 
in 50 µl reactions it was scaled down to 20 µl. 
The following protocol was used and the expression was tested at 16 ˚C, at room 
temperature and at 28 ˚C. 
 
4.8 µl E.coli lysate 
4.0 µl Reaction mix 
4.8 µl Amino acids 
0.4 µl Methionine 
2.0 µl Reconstitution buffer 
4.0 µl DNA (0.4 µg) in water 
 
Reactions were left overnight. Proteins were precipitated prior to SDS-PAGE using 
the following protocol: 
10 µl sample and 100 µl ice cold acetone was mixed and left on ice for 5 minutes. 
Samples were then centrifuged for 5 minutes at 13000 rpm. Supernatants were 
discarded and pellets air-dried for 10 minutes. The pellets were then dissolved in 20 
µl of SDS sample buffer, heated to 95 ˚C for 5 minutes and 15 µl was loaded onto a 
SDS gel. SDS page was followed by western blotting and chemiluminescent detection 
of the synthesised proteins. 
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2.4.3 E.coli T7 S30 Extract System for Circular DNA 
The T7 S30 Extract System for Circular DNA requires a circular DNA template 
where the gene is under control of a T7 promoter or an efficient E.coli promoter.  
Again the protocol was amended slightly. The reactions were scaled down to 25 µl 
instead of 50 µl. The following protocol was used and the expression was tested at 16 
˚C, at room temperature and at 28 ˚C. 
 
     1.25 µl Amino acid mixture minus methionine 
     1.25 µl Amino acid mixture minus cysteine 
10.0 µl S30 Premix without amino acids 
     7.5 µl T7 S30 Extract, Circular 
     5.0 µl DNA template (1 µg) in water 
 
Reactions were left overnight. 10 µl was mixed with SDS sample buffer, heated up to 
95 ˚C for 5 minutes and 15 µl loaded on a gel. SDS page was followed by western 
blotting and chemiluminescent detection of the synthesised proteins. 
 
2.4.4 Test expression of recombinant proteins 
The plasmid containing the sequence with the protein of interest was transformed into 
BL21-GOLD(DE3) or SoluBL21. Cells were plated on LB-agar containing the 
appropriate antibiotic and incubated overnight. One colony was picked and added to 5 
ml of media containing antibiotics and grown overnight. The overnight culture was 
diluted 1:20 (500 µl + 9.5 ml) and grown for around 2 hours to an OD600 of 0.6. The 
culture was divided: 1 ml was left uninduced and IPTG was added to the remaining 9 
ml to induce expression of the protein of interest. Both cultures were left for 6 hours 
to grow. Samples were centrifuged for 10 minutes at 4000 rpm. Pellets were 
resuspended in lysis buffer (8 M Urea, 100 mM NaH2PO4, 10 mM Tris pH 8.0, (50 
µl/1 ml culture)) and left for 20 minutes at room temperature. Samples were mixed 
with SDS sample buffer and expression of the protein was checked on a Coomassie 
gel or by western blotting. 
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2.4.5 SUMO-modification in E. coli 
This method was first described by Uchimura et al., 2004. The authors developed a 
binary vector system where a synthetic SUMO conjugation pathway is introduced in 
E.coli. They made a tri-cistronic plasmid for over-expression of SUMO-E1 activating 
enzyme and -E2 conjugating enzyme and either SUMO-1 or SUMO-3 (pE1E2S1/3). 
This vector was used for expression of E1, E2 and either SUMO-1 or SUMO-3 and a 
protein of interest leading to efficient SUMO modification of the protein in E.coli. 
The following protocol was used for modification of our protein of interest. 
pE1E2S1/3 and pET-28 CK1 alpha LS, CK1 alpha 325 or CK1 alpha 301 or pET-28 
CK1 delta 317 were co-transformed into BL21-GOLD(DE3) or SoluBL21. Cells were 
plated on LB with the appropriate antibiotics and incubated overnight. One colony 
was picked and added to 10 ml of media containing antibiotics and grown overnight. 
The overnight culture was added to 500 ml of media containing antibiotics and grown 
to an OD600 of 1.0. The 500 ml culture was cooled to 15 ˚C for expression of CK1 
alpha protein or to 22 ˚C for expression of CK1 delta and IPTG was added to a final 
concentration of 0.2 mM. The culture was left to grow overnight or for 5 or 6 hours at 
the appropriate temperature and spun down for 15 minutes at 4500 rpm. The pellets 
were stored at -80 ˚C until required. 
 
2.4.6 Protein purification 
Protein purification of the casein kinases was done using a protocol from (Burzio et 
al., 2002) that was subsequently modified. 
Bacterial pellets were re-suspended in buffer A (50 mM HEPES pH 8.0, 500 mM 
NaCl, 10 mM Imidazole, 1% Triton X-100) containing a SIGMAFAST inhibitor 
protease cocktail and Lysozyme (1 mg/ml) and lysed on ice for 1 hour. Lysates were 
sonicated on ice for 4 minutes (2 seconds on, 2 seconds off, 50% amplitude) and 
centrifuged at 15000 rpm at 4 ˚C for 45 minutes. Lysates were loaded onto a 1 ml 
Nickel-affinity column or a 1 ml HIS-Select Cobalt Affinity Gel using an AKTA 
system at 4 ˚C at a flowrate of 0.5 ml/min and UV detection at 280 nm. The column 
was washed with 12 volumes buffer A without Triton X-100, then washed with 12 
volumes 15% buffer B (50 mM HEPES pH 7.5, 200 mM NaCl, 250 mM Imidazole) 
and eluted with 50% buffer B. The column was finally washed with 6 volumes 100% 
buffer B to clean the resin. 
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After visualizing on an SDS gel the eluted protein was concentrated and buffer 
exchanged using an Amicon Ultra centrifugal filter with a 10K MW cut-off using 
buffer (40 mM Tris pH 7.5, 20 mM MgCl2, 150 mM NaCl). 2 ml purifed protein was 
concentrated to 0.5-1.0 ml. The protein concentration was determined using the 
NanoPhotometer® P-Class from IMPLEN GmbH according to the manufacturer’s 
protocol. 
 
2.4.7 Expression and purification of SUMO-specific protease 
pET-28b SENP2 (aa 366-588) was transformed into BL21-GOLD(DE3). Cells were 
plated on LB-agar containing Kanamycin and incubated overnight. One colony was 
picked and added to 10 ml of media containing antibiotics and grown overnight. The 
overnight culture was added to 500 ml of media containing antibiotics and grown to 
an OD600 of 0.6. The 500 ml culture was cooled down to 22 ˚C and IPTG was added 
to a final concentration of 0.5 mM for induction of expression of the SUMO-protease. 
The culture was left to grow overnight at 22 ˚C and spun down for 15 minutes at 4500 
rpm. Pellets from a 500 ml culture were resuspended in 15 ml of buffer A (10 mM 
Tris pH 7.6, 0.5 M NaCl and 5 mM Imidazole), then sonicated on ice for 4 minutes (2 
seconds on, 2 seconds off, 50% amplitude) and centrifuged at 15000 rpm at 4 ˚C for 
45 minutes. Supernatant was loaded onto a 5 ml Nickel-affinity column using an 
AKTA system at 4 ˚C with a flowrate of 0.5 ml/min and UV detection at 280 nm. 
Column was washed with 10 volumes buffer A. Then washed with 10 volumes 10% 
buffer B (10 mM Tris pH 7.6, 0.5 M NaCl and 0.5 M Imidazole) and eluted with 
100% buffer B. The protein was concentrated and buffer-exchanged using an Amicon 
Ultra centrifugal filter with a 10K MW cut-off in 2 x storage buffer (1 x storage 
buffer: 25 mM Tris pH 8.0, 250 mM NaCl and 0.5 mM DTT). 7 ml of purified protein 
was concentrated to 3 ml. The concentrated SUMO protease was diluted in glycerol 
(50% final concentration) and stored at -20 ˚C. 
 
2.4.8 De-modification of CK1 delta 317/SUMO-1 
The concentrated purified proteins CK1 delta 1-317 and CK1 delta 1-317/SUMO 
modified were diluted to a concentration of 5 µg/100 µl in 1 x kinase buffer (40 mM 
Tris pH 7.5, 20 mM MgCl2) and 10 µl SUMO-specific protease (3 µg/µl) was added, 
mixed well and incubated at room temperature. The de-modified CK1 protein was 
used in the kinase assay to check the activity after protease treatment. 
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2.4.9 ADP-GloTM Kinase Assay 
The kinase assay was performed according to the manufacturer’s protocol with slight 
modifications. 
Kinase reaction buffer (5 ml 40 mM Tris pH 7.5, 20 mM MgCl2 + 50 µl BSA (10 
mg/ml)) was prepared and the following protocol used for the assay: 
2.6 µl CK1 (5 ng purified protein/µl) 
5 µl substrate CK1 peptide (pS7) 600 µM 
3.75 µl ATP 500 µM 
1.25 µl Kinase reaction buffer 
Incubated 10-30 minutes at room temperature 
Added 12.5 µl ADP-Glo reagent 
Incubated 40 minutes at room temperature 
Added 25 µl kinase detection reagent 
 
Luminescence measured on the POLARstar Omega (BMG LABTECH GmbH) 
Instrument settings: 
Measurement time 1 second 
Cycle time 60 seconds 
Cycles 40 minutes 
Gain Dependent on ADP concentration 
 
 
2.5 Prediction servers 
 
2.5.1 SUMO prediction server 
To predict where our protein of interest could be covalently modified by SUMO the 
following servers were used. 
SUMOplot: http://www.abgent.com/tools/sumoplot 
SUMOsp: http://sumosp.biocuckoo.org/  
seeSUMO: http://bioinfo.ggc.org/seesumo/  
PCI-SUMO: http://bioinf.sce.carleton.ca/SUMO/start.php  
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The following server was used to predict if our protein of interest contains a SUMO-
interacting motif (SIM), also called the SUMO-binding motif (SBM). 
GPS-SBM 1.0: http://sumosp.biocuckoo.org/  
 
2.5.2 PSIPRED secondary structure prediction server 
To predict the secondary structure of the TFAF-1 protein the following server was 
used. 
http://bioinf.cs.ucl.ac.uk/psipred/  
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3 Results 
3.1 Signal transduction pathways as part of a PML regulatory 
cascade 
3.1.1 Introduction 
In order to gain a better understanding of PML and PML NBs a yeast two-hybrid 
assay was previously carried out (Boddy et al., 1996). This is a well-established 
method for screening a large number of independent cDNAs encoding proteins, which 
might interact with a target protein. The isoform PMLVI was used as bait and 
preliminary data indicated that PMLVI interacted with TRAF4-associated factor 1 
(TFAF-1). This clone was of particular interest because the TRAF family of proteins 
is involved in cell survival, proliferation, differentiation and apoptosis. 
As discussed earlier TRAF proteins are characterised by the presence of a TRAF 
domain at the C- terminus. The TRAF domain consists of a coiled-coil domain 
followed by a conserved TRAF-C domain. The N-terminus of TRAF proteins, except 
for TRAF1, contains a RING finger and several zinc finger motifs that are important 
for signalling downstream events (Aggarwal, 2003; Arch et al., 1998; Bradley and 
Pober, 2001; Chung et al., 2002). All TRAFs, apart from TRAF4, were identified by 
yeast two-hybrid screening using a cytoplasmic domain of various members of the 
TNFR family. Even though TRAF4 has no known function in the signalling of TNF it 
was still worth investigating. One observation worth pointing out is that TRAF 
proteins share structural features with the PML protein (Arch et al., 1998). 
This interaction between PML and TFAF-1 was investigated further using 
colocalisation studies. 
 
3.1.2 Amplification of full-length TFAF-1 
A human testis cDNA library was screened by PCR and two TFAF-1 clones were 
obtained. TFAF-1 specific primers were used for the screening. Truncated TFAF-1 
constructs were used in some of the experiments as this was the only partial coding 
sequence known when the studies commenced. 
In Figure 3.1 an overview can be seen of the TFAF-1 clones used in this study. 
Predicted functional domains are also shown. 
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Figure 3.1. Schematic representation of the TFAF-1/SKAP constructs and predicted functional 
domains 
A: The TRAF-1 clone pulled out in the yeast-two hydrid screen (TFAF-1 aa 176-316).  
B: The truncated TFAF-1 aa 79-316 was used in some of the experiments as this was the only partial 
coding sequence known when the studies commenced.  
C: Full-length TFAF-1 construct. 
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3.1.3 Subcellular localisation studies of TFAF-1 
To study the subcellular localisation of TFAF-1, U2OS cells were transfected with a 
plasmid encoding the enhanced green fluorescent protein (EGFP), resulting in a 
EGFP-TFAF-1 fusion protein (pEGFP-TFAF-1 (aa 79-316)). TFAF-1 was excluded 
from the nucleus and showed a speckled distribution in the cytoplasm (Figure 3.2, A-
C). When TFAF-1 (aa 79-316) was expressed with a FLAG- tag it had a diffuse 
nuclear and cytoplasmic distribution (Figure 3.2, E-F). Expression of a FLAG-TFAF-
1 (aa 79-316) construct with an exogenous SV40-nuclear localisation signal (NLS) 
changed the cytoplasmic distribution. The FLAG-NLS-TFAF-1 (aa 79-316) protein 
showed a diffuse distribution in the nucleus (Figure 3.2, H-I). A red fluorescent 
TFAF-1 fusion protein expressed in U2OS cells resulted in a very distinctive 
cytoplasmic network (Figure 3.2, K-L). The TFAF-1 filaments appeared to link PML 
NBs (Figure 3.2L). The pDsRed-N1-TFAF-1 full-length protein showed a similar 
filamentous pattern in many of the transfected cells (Figure 3.3B). In some cells, the 
TFAF-1 full-length showed a speckled distribution that did not colocalise with PML 
NBs (Figure 3.3F). The vector pDsRed-N1 was used as a control and did not form 
filaments in transfected cells. 
 
3.1.4 Generation of an anti-peptide antibody against the TFAF-1 protein 
To characterise the subcellular localisation of endogenous TFAF-1 protein, two 
polyclonal antisera against two 15-residue synthetic peptides were made (residues 2- 
16 and 96-110). In Figure 3.4 the predicted secondary structure of the TFAF-1 protein 
is presented. The secondary structure was used to choose the most promising peptides 
of the TFAF-1 protein sequence against which to raise an antiserum. 
Neither preimmune sera recognised exogenous TFAF-1 protein. Only the two 
polyclonal antisera detected exogenous TFAF-1 protein (Figure 3.5). In non- 
transfected cells a diffuse pattern throughout the cytoplasm and the nucleus was seen 
using the rabbit polyclonal anti-TFAF-1 antisera. 
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Figure 3.2. Subcellular localisation studies of the TFAF-1 protein 
A-C: A green fluorescent protein (GFP)-TFAF-1 fusion protein localised to the cytoplasm in U2OS 
cells and showed a speckled distribution. Cells were stained with polyclonal rabbit anti-PML 
antibodies (red fluorescence). D-F: An N-terminal FLAG-tagged TFAF-1 protein showed a diffuse 
nuclear and cytoplasmic distribution in U2OS cells. Cells were stained with anti-FLAG mAb (red 
fluorescence) and with polyclonal rabbit anti-PML antibodies (green fluorescence). G-I: The FLAG-
TFAF-1 protein was redistributed to the nucleus in U2OS cells when it was expressed with an 
exogenous SV40-nuclear localisation signal (NLS). Cells were stained with an anti-FLAG mAb (red 
fluorescence) and with polyclonal rabbit anti-PML antibodies (green fluorescence). J-L: A red 
fluorescent TFAF-1 fusion protein showed a filamentous structure in U2OS cells. Cells were stained 
with polyclonal rabbit anti-PML antibodies (green fluorescence). 
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Figure 3.3. Localisation of red fluorescent TFAF-1 full-length fusion protein 
A-C: DsRed-TFAF-1 full-length fusion protein formed filaments in some of the transfected cells.  
D-F: In other cells it formed some kind of bodies that did not colocalise with PML NBs. 
U2OS cells transiently transfected with pDsRed-N1-TFAF-1 (full-length). Cells were stained with 
polyclonal rabbit anti-PML antibodies (green fluorescence). 
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Figure 3.4. Predicted secondary structure of the TFAF-1 protein using the PSIPRED protein 
structure prediction server 
References:  
The PSIPRED server:  
McGuffin LJ, Bryson K, Jones, D.T. (2000) The PSIPRED protein structure prediction server. 
Bioinformatics. 16, 404-405.  
PSIPRED:  
Jones, D.T. (1999) Protein secondary structure prediction based on position-specific scoring matrices. 
J. Mol. Biol. 292, 195-202. 
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Figure 3.5. Anti-peptide antibody against the TFAF-1 protein  
The anti-peptide antibody recognised TFAF-1. 
U2OS cells transiently transfected with pDsRed-N1-TFAF-1 (aa 79-316). Cells were stained with 
polyclonal rabbit anti-TFAF-1 antibodies (green fluorescence). 
 
 
 
Figure 3.6. TFAF-1 filaments are cytoplasmic filaments, part of the microtubule cytoskeleton 
A-C: U2OS cells transiently transfected with pDsRed-N1-TFAF-1 (aa 79-316). 
A: 20 hours after transfection cells were treated with Nocodazole (20 µM 2.5 hrs). Cells were stained 
with polyclonal rabbit anti-PML antibodies (green fluorescence). 
B: YOYO-1 dye-stained chromosomes (green fluorescence). 
C: Cells were stained with mouse monoclonal anti-Lamin A/C antibodies (green fluorescence). 
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3.1.5 TFAF-1 filaments are a part of the microtubule cytoskeleton 
To find out more about the TFAF-1 filaments, U2OS cells were transfected with 
pDSRed-N1-TFAF-1 (aa 79-316) and treated with Nocodazole (Figure 3.6A). 
Nocodazole induces microtubule depolymerization by inhibiting addition of tubulin 
monomers. In Figure 3.6A it can be seen that TFAF-1 filaments were disrupted after 
Nocodazole treatment. This means that TFAF-1 filaments are associated with the 
microtubule cytoskeleton. TFAF-1 filaments did not break down during mitosis 
(Figure 3.6B). In figure 3.6C it is very clear that TFAF-1 filaments are cytoplasmic 
filaments. Cells were stained with LaminA/C and captured as a z-stack. Some of the 
filaments might just touch the nucleus but they do not appear to go through it. 
 
3.1.6 Colocalisation studies of TFAF-1 and known cytoskeletal filaments 
To test whether TFAF-1 filaments colocalised with other known cytoskeletal 
filaments, double immunofluorescent studies were performed. Because it had been 
reported that TNFR-associated death domain (TRADD) could be found in the PML 
NBs in the absence of export (Morgan et al., 2002), and that overexpressed TRADD 
localised in K18 filaments (Inada et al., 2001), a subcellular distribution of TFAF-1 
and K18 was carried out (Figure 3.7, A-C). Overexpressed TFAF-1 did not colocalise 
with K18. 
The TFAF-1 protein contains a predicted coiled-coil domain. Coiled coils mediate 
both homo- and heterodimeric interactions. Another protein, TRIM 29, which also 
contains a coiled-coil domain and localises in cytoplasmic filaments (Reymond et al., 
2001), was tested for colocalisation with TFAF-1 (Figure 3.7, D-F). No colocalisation 
of TFAF-1 and TRIM 29 was found here either. 
A third structure, named death-effector filaments (DEFs), resembles cytoskeleton 
filaments although microtubule and microfilament proteins are not involved. DEFs 
are formed by overexpression of the Fas-associated death domain (FADD) or the 
prodomain of caspase-8 and usually assemble into structures orbiting around the 
nucleus (Siegel et al., 1998). Figure 3.7, G-I shows a partial colocalisation of DEFs 
and TFAF-1 filaments. These results suggested that the TFAF-1 protein might play a 
role in the Fas death-signalling pathway. 
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Figure 3.7. Colocalisation studies of TFAF-1 
TFAF-1 colocalised partially with death-effector filaments formed by FADD. 
A-C: The red fluorescent-TFAF-1 fusion protein did not colocalise with K18 in U2OS cells. Cells were 
stained with an anti-cytokeratin peptide 18 mAb (green fluorescence). 
D-F: The red fluorescent-TFAF-1 fusion protein did not colocalise with the green fluorescent protein 
(GFP)-TRIM29 in U2OS cells.  
G-I: The red fluorescent-TFAF-1 fusion protein partially colocalised with death-effector filaments in 
U2OS cells. Cells were stained with an anti-Fadd mAb (green fluorescence). 
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3.1.7 Summary 
• TFAF-1 interacted with PMLVI in a yeast two-hybrid assay 
• TFAF-1 did not colocalise to PML NBs but showed a diffuse distribution 
throughout the cell 
• TFAF-1 formed cytoplasmic filaments when expressed as a fusion protein 
with DsRed 
• The TFAF-1/DsRed filaments were a part of the cytoplasmic cytoskeleton 
• TFAF-1/DsRed filaments partially colocalised with DEFs formed by FADD 
 
 
3.1.8 Conclusion and hypothesis 
These results suggested that TFAF-1 might interact with a soluble fraction of PML 
outside PML NBs. TFAF-1/DsRed colocalised with DEFs in the cytoplasm and could 
be involved in Fas-mediated apoptosis. This association was investigated further 
using colocalisation studies with DEFs and PML NB components.  
Interaction studies between PML VI and TFAF-1 were repeated in a mammalian two-
hybrid system and in co-immunopreciptation experiments. However, it was not 
possible to reproduce the results from the yeast two-hybrid system. It was therefore 
speculated that it was possibly not a specific interaction between PML and TFAF-1 
but an unspecific interaction between the two coiled-coil domains in the 
corresponding proteins. 
 
 
3.2  PML nuclear bodies and death-effector filaments 
 
3.2.1 Introduction 
Studies in PML -/- cells show that PML might be involved in Fas-mediated apoptosis. 
PML -/- cells are less responsive to apoptotic inducers such as Fas and TNF ligands 
and PML plays a role in the response of caspase-1 and caspase-3 upon treatment with 
these ligands (Wang et al., 1998b). Another protein called TRADD, which shuttles 
between the cytoplasm and the nucleus where it localizes to PML NBs, links PML to 
death receptor-mediated apoptosis (Morgan et al., 2002). Furthermore the Daxx 
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protein, which interacts with SUMO-modified PML and localizes to PML NBs. was 
originally found as an interacting partner with the Fas receptor. 
FADD, which forms death-effector filaments, is also involved in death receptor-
mediated apoptosis and a working hypothesis could suggest that FADD is part of 
PML NBs and Fas-mediated apoptosis. 
 
3.2.2 Death-effector filaments modify the distribution of PML 
It was observed that in some of the U2OS cells expressing the DsRed-TFAF-1 fusion 
protein the pattern of endogenous PML was rearranged into fewer bodies (Figure 3.8). 
To find out if this was specific for the TFAF-1 filaments and to investigate the 
connection between DEFs and TFAF-1 filaments further, U2OS cells were transfected 
with a plasmid expressing the FADD protein. Interestingly, the distribution of PML 
NBs was also rearranged in some of the cells expressing the FADD protein (Figure 
3.9A). The bodies appeared to become elongated and formed tracks while in other 
cells PML NBs were associated with the DEFs (Figure 3.9B). DEFs are described as 
cytoplasmic structures (Siegel et al., 1998) and PML NBs are localised in the nucleus. 
To show that there was a physical connection between the DEFs and PML NBs, 
U2OS cells were transfected with FADD (Figure 3.9C and D). Figure 3.9C shows that 
the PML protein stays in the nucleus in smaller filaments or tracks after disruption. 
Figure 3.9D shows that DEFs are not only cytoplasmic structures but also travel 
through the nuclear envelope into the nucleus. This result was also confirmed by a 3D 
reconstruction of U2OS cells transiently transfected with FADD (Figure 3.10: 3D 
reconstruction with kind help from Dr Suhail Islam). In figure 3.10 it was very clear 
that the DEFs were not only cytoplasmic filaments but also nuclear and that PML was 
forming tracks on the filaments.  
 
3.2.3 Electron microscopy analysis of FADD death-effector filaments in the 
nucleus 
Electron microscopy was also used to confirm that the DEFs are nuclear as well as 
cytoplasmic filaments. U2OS cells were transfected with FADD and analysed by 
electron microscopy and immunogold labeling (Figure 3.11: Electron microscopy 
analysis with kind help from Dr Fabienne Beuron). The filaments seemed to penetrate 
the nuclear envelope (Figure 3.11B). 
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Figure 3.8.  TFAF-1 changes the pattern of PML nuclear bodies 
The red fluorescent-TFAF-1 fusion protein changed the distribution of the PML nuclear bodies in some 
of the transfected U2OS cells. Cells were stained with polyclonal rabbit anti-PML antibodies (green 
fluorescence). 
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Figure 3.9. Death-effector filaments change the distribution of PML nuclear bodies 
A: The death-effector filaments disrupted PML 24 hours after transfection of pcDNA3-AU1 FADD. B: 
PML colocalised with the death-effector filaments. U2OS cells were stained with polyclonal rabbit 
anti-PML antibodies (green fluorescence) and with an anti-FADD mAb (red fluorescence). C: PML 
stayed in the nucleus after transfection of pcDNA3-AU1 FADD. U2OS cells were stained with 
polyclonal rabbit anti-PML antibodies (green fluorescence) and propidium iodide. D: Death-effector 
filaments were not only cytoplasmic structures but also nuclear. U2OS cells were stained with an anti-
FADD mAb (green fluorescence) and propidium iodide. 
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Figure 3.10. Death-effector filaments are nuclear and change the distribution of PML nuclear 
bodies 
The death-effector filaments disrupted PML 24 hours after transfection of pcDNA3-AU1 FADD. PML 
colocalised with death-effector filaments. U2OS cells were stained with polyclonal rabbit anti-PML 
antibodies (green fluorescence) and with an anti-FADD mAb (red fluorescence). Lamin B was used to 
outline the nucleus and stained with goat anti-Lamin B antibodies  (blue fluorescence). 
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Figure 3.11. Preliminary electron microscope analysis of FADD death-effector filaments in the 
nucleus 
A: U2OS cells were tranfected with pCDNA3-AU1 FADD, analysed by electron microscopy and 
immunogold labelling. Death-effector filaments were localised in the cytoplasm and in the nucleus (see 
arrows) and the filaments penetrated the nuclear envelope. Higher magnification of a part of the cell is 
shown as B. 
Specimen preparation: sample high pressure frozen, embedded in resin and sectioned, followed by 
immunogold labelling. 
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3.2.4 Death-effector filaments modify other PML nuclear body components 
To see if the modification of the PML NBs by DEFs was specific for the PML 
protein, the patterns of three other PML nuclear body components, Sp100, SUMO-1 
and Daxx, were tested in cells expressing DEFs. Interestingly, the pattern of Sp100 
did not change until ~48 hours after transfection of FADD (Figure 3.12A), whereas 
the pattern of PML already changed ~24 hours after transfection. Sp100, like PML, 
also associated with the DEFs before becoming disrupted (Figure 3.12B). The 
SUMO-1 protein colocalised 24 hours after transfection (Figure 3.12C) although 48 
hours after FADD transfection the SUMO-1 protein completely overlaid the nuclear 
DEFs (Figure 3.12D), unlike PML and Sp100. A third nuclear body protein, Daxx, 
also showed association with the DEFs ~48 hours after transfection of FADD (Figure 
3.12, E-F). Figure 3.12G shows that the PML filaments/tracks colocalised with the 
SUMO-1 filaments. This result suggested that all disrupted PML nuclear body 
components localised to the same filamentous structure in the nucleus. 
Given that PML and PML NBs play an important role in apoptosis by regulating the 
activity of tumour suppressor p53, the localisation of p53 after FADD transfection 
was tested. The pattern of p53, however, did not change in cells transfected with 
FADD. Taken together these preliminary results showed that PML, SUMO-1, Sp100 
and Daxx formed part of nuclear DEFs or were recruited to these filaments after being 
formed. 
  
3.2.5 Death effector filaments do not modify other nuclear compartments 
To ensure that the disruption of the PML bodies was specific, three other nuclear 
compartments were stained after tranfection of FADD. HIPK2, Cajal bodies and 
nucleoli (Figure 3.13) were tested and none of the compartments was modified by 
DEF. This suggested that the disruption of the PML bodies might be specific and not 
just an event where the filaments randomly penetrated the nucleus and disrupted 
nuclear compartments. 
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Figure 3.12. Death-effector filaments change the distribution of other PML nuclear body 
components 
A: Death-effector filaments disrupted Sp100 in some of the U2OS cells 48 hours after transfection of 
pcDNA3-AU1 FADD and CrmA. B: Sp100 colocalised with the death-effector filaments. Cells were 
stained with polyclonal rabbit anti-Sp100 antibodies (green fluorescence) and with an anti-FADD mAb 
(red fluorescence). C: Death-effector filaments changed the pattern of SUMO-1 24 hours after 
transfection. D: The death-effector filaments recruited SUMO-1 into the filaments 48 hours after 
transfection of pcDNA3-AU1 FADD and CrmA. Cells were stained with polyclonal rabbit anti-SUMO 
antibodies (green fluorescence) and with an anti-FADD mAb (red fluorescence). E-F: The death- 
effector filaments recruited Daxx into the filaments 48 hours after transfection of pcDNA3-AU1 
FADD and CrmA. Cells were stained with polyclonal rabbit anti-Daxx antibodies (green fluorescence) 
and with an anti-FADD mAb (red fluorescence). G: PML filaments (green fluorescence) colocalised 
with SUMO-1 filaments (red fluorescence) 48 hours after transfection of pcDNA3-AU1 FADD and 
CrmA.  
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Figure 3.13. Death-effector filaments do not disrupt other nuclear substructures 
The DEFs did not disrupt nucleoli after transfection of pcDNA3-AU1 FADD. U2OS cells were stained 
with polyclonal goat anti-FADD antibodies (green fluorescence) and with an anti-nucleophosmin mAb 
(red fluorescence).  
 
 
 
Figure 3.14. Caspase-8 and death-effector filaments formed by the DED domains of Caspase-8 do 
not disrupt PML nuclear bodies 
A: U2OS cells transiently transfected with pEGFP-Caspase-8. Cells were stained with polyclonal 
rabbit anti-PML antibodies (red fluorescence). 
B: U2OS cells transiently transfected with pEGFP-Caspase-8 DED-AB. Cells were stained with 
polyclonal rabbit anti-PML antibodies (red fluorescence). 
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3.2.6 Relocalisation of PML nuclear bodies is independent of recruitment of 
caspases 
To see if filament formation and PML NB disruption were dependent on caspase-
recruitment the following experiments were performed. 
It has been reported that endogenous caspase-8 is recruited to DEFs (Siegel et al., 
1998). Overexpression of full-length caspase-8 did not lead to formation of DEFs 
(Figure 3.14A); only caspase-8 DED-AB and caspase-8 DED-B were able to form 
DEFs (Siegel et al., 1998). Full-length caspase-8 did not relocalise PML (Figure 
3.14A) neither did caspase-8 DED-AB (Figure 3.14B). 
Filament formation of PML and SUMO was still observed in U2OS cells treated with 
the caspase inhibitor z-VAD-fmk. 100 µM caspase inhibitor z-VAD-fmk was added 1 
hour before transfection and left on the cells 23 hours after transfection of FADD. The 
same result was obtained by co-transfection of FADD and the cowpox serpin cytokine 
response modifier A (CrmA). CrmA is a serpin-like protease inhibitor and blocks the 
activities of many caspases (group I caspases: caspase-1, 4 and 5 and group III 
caspases: caspase-8, 9 and 10).  
These results suggested that the disruption of the PML NBs by FADD was 
independent of caspase recruitment. 
 
3.2.7 Death-effector filaments and Ad5 E4 Orf3 
PML NBs are disrupted or targeted by many different viral proteins (Geoffroy and 
Chelbi-Alix, 2011). One of them, Ad5 E4 Orf3, is able to self-associate and form 
filaments/tracks (Hoppe et al., 2006) that disrupt PML NBs and also make PML form 
small tracks (Figure 3.15). The PML tracks formed by Ad5 E4 Orf3 appear similar to 
the PML tracks formed by death-effector filaments and it was tempting to think that 
they might be the same. In figure 3.16 it can be seen that the filaments formed by 
FADD showed a partial colocalisation with Ad5 E4 Orf3. These results suggested that 
track formation of PML NBs could be the same. 
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Figure 3.15. Adenovirus Type 5 E4 Orf3 rearrange PML NBs into tracks 
U2OS cells transiently transfected with pcDNA3-HA E4 Orf3. Cells were stained with polyclonal 
rabbit anti-PML antibodies (green fluorescence) and an anti-HA mAb (red fluorescence).  
 
 
 
Figure 3.16. Death-effector filaments and filaments formed by Adenovirus Type 5 E4 Orf3 show 
a partial colocalisation 
U2OS cells transiently transfected with pcDNA3-AU1 FADD and pcDNA3-HA E4 Orf3. Cells were 
stained with polyclonal rabbit anti-FADD antibodies (green fluorescence) and an anti-HA mAb (red 
fluorescence).  
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3.2.8 Death effector filaments colocalise with NLS/Vimentin 
DEFs were originally discovered by Siegel et al., 1998. In that paper the authors 
mention some resemblance to the Vimentin network. Vimentin is type III 
intermediate filament. NLS-Vimentin is engineered to translocate into the nucleus and 
outline the ICD compartment, which lies outside of the chromosome territories 
(Bridger et al., 1998). PML has been shown to localise to the interchromosomal 
domain compartment (ICD) (Bridger et al., 1998). To see if the DEFs localises to 
ICD, cells were co-transfected with human NLS-/YFP-Vimentin (9:1) and pcDNA3-
AU1 FADD (Figure 3.17: Data kindly provided by Hannah Stage and Hans Will, 
Hamburg). DEFs and NLS Vimentin showed a partial colocalisation in the nucleus. 
This result suggested that PML and DEFs were to be found in the same compartment 
in the cell nucleus in the ICD. 
 
3.2.9 Treatments of cells with apoptotic inducers 
It was important to see if DEFs could be found in cells without over-expression of the 
FADD protein. Apoptotic inducers were used to treat cells to induce the formation of 
the DEFs. 
It has previously been shown that endogenous FADD can form DEFs in Jurkat cells 
when treated with cyclohexamide (CHX) (Tang et al., 1999). Treatment with CHX 
(2.5 µg/ml 20 hours) took endogenous FADD into DEFs in HT1080 cells (Figure 
3.18B) and U20S cells (Figure 3.18D). In untreated HT1080 cells FADD localised to 
the nucleus and in small filaments, which could be DEFs (Figure 3.18A) and in 
untreated U2OS cells endogenous FADD localised mainly to the nucleus (Figure 
3.18C). Treatment with CHX did not change the PML bodies, although there might 
have been a slight decrease in PML bodies as CHX inhibits protein synthesis. 
Treatment with TNF (100 pg/ml for HT1080 and 1 ng/ml for U2OS 20 hours) and 
treatment with FasL (50 ng/ml for 20 hours HT1080 and U2OS cells or 100 ng/ml 
FasL + z-VAD-fmk 100 µM 6 hours or 24 hours for HT1080 cells) did not relocalise 
PML. 
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Figure 3.17. NLS-Vimentin and death-effector filaments localise (partially) in the same 
interchromosomal spaces  
HeLa cells transiently transfected with human NLS-/YFP-Vimentin (9:1) and pcDNA3-AU1 FADD. 
Cells were stained with an anti-FADD mAb (red flourescence). 
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Figure 3.18. HT1080 cells and U2OS cells treated with apoptotic inducers 
Endogenous FADD localised to small filaments (indicated by white arrows) in untreated HT1080 cells 
(A), treated HT1080 (B) and U2OS cells (A) which could be DEFs. 
A: HT1080 cells untreated.  
B: HT1080 cells treated with CHX (2.5 µg/ml 20 hours). 
C: U2OS cells untreated.  
D: U2OS cells treated with CHX (2.5 µg/ml 20 hours).  
Cells were stained with an anti-FADD mAb (red fluorescence). 
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3.2.10 Death effector filaments in PML -/- KO mice. 
To check whether PML and PML NBs are necessary for the formation of DEFs, PML 
-/- cells were transfected with pcDNA3-AU1 FADD and pEGFP-FADD. In Figures 
3.19 and 3.20 the various distributions of AU-FADD are shown. In Figure 3.21 the 
pattern of GFP-FADD in PML -/- cells is shown. There was a discontinuous 
formation of DEFs in PML -/- cells. These results suggested that PML NBs might be 
needed for the formation of DEFs. 
PML nuclear body components such as Sp100, Daxx and SUMO-1 fail to accumulate 
in the PML bodies in the absence of PML (Zhong et al., 2000). It is also known that 
SUMO-modification of PML is needed for the formation of mature PML NBs 
(Lallemand-Breitenbach et al., 2001). It was therefore interesting to see whether 
SUMO was necessary for a proper formation of DEFs by co-transfection of pEGFP-
FADD and pSG5-LINK-EGFP SUMO-1 in PML -/- cells. Co-expression of SUMO 
did not change the formation of DEFs in PML -/- cells. 
PML -/- KO mice and cells are protected from apoptosis induced by Fas and TNF 
(Wang et al., 1998b) and it is well known that FADD is important for signalling from 
the Fas and other TNF receptor family members (Chinnaiyan et al., 1996). 
Phosphorylation of FADD has been speculated to regulate its apoptotic properties by 
interfering with cell cycle progression (Alappat et al., 2003). To see whether there 
was a difference in phosphorylation of FADD in PML -/- cells and NIH/3T3 cells, 
cells were transfected with FADD and CrmA or FADD alone and western blotting 
was performed. More phosphorylated FADD was found in NIH/3T3 after co-
transfection of CrmA (Figure 3.22). This experiment was done using two different 
mouse cell lines as the corresponding PML wild type cells were not available to us 
and therefore the results might not be conclusive. 
This experiment was repeated in the PML-inducible cell line PML III cl.19 but no 
difference in the phosphorylation of transfected FADD before and after induction of 
PML III was observed. This might have been because it was only one PML isoform 
being expressed in the inducible cell line: a better experiment would have been 
depletion of PML. PML depletion using siRNA was attempted but at the time it was 
not possible to produce a stable cell line without PML.  
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Figure 3.19. Death-effector filaments in PML -/- cells 
There was no proper death-effector filament formation in PML -/- cells.  PML -/- cells transfected with 
pcDNA3-AU1 FADD. Cells were stained an anti-FADD mAb. 
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Figure 3.20. Death-effector filaments in PML -/- cells 
PML -/- cells transfected with pcDNA3-AU1 FADD and pcDNA3-CrmA. Cells were stained anti-
FADD mAb antibodies (green fluorescence) and with propidium iodide. 
 
 
 
Figure 3.21. Death-effector filaments in PML -/- cells 
Death-effector filaments formed by the fusion protein EGFP-FADD were slighter shorter in PML -/- 
cells. PML  -/- cells transfected with pEGFP-FADD and stained with propidium iodide. 
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Figure 3.22. FADD phosphorylation in PML -/- cells 
FADD seemed less efficiently phosphorylated in PML -/- cells.  
PML -/- cells and NIH/3T3 cells transfected with pcDNA3-AU1 FADD and pcDNA3-CrmA and 
pcDNA3-AU1 FADD alone and analysed by immunoblotting using anti-FADD antibodies. 
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3.2.11 Summary 
• SUMO and PML formed filaments/tracks which colocalised with 
DEFs 24 hours after transfection of FADD 
• Sp100 and Daxx formed filaments/tracks which colocalised with 
DEFs 48 hours after transfection of FADD 
• DEFs were not only cytoplasmic filaments but also went through 
the nucleus where they localised to the ICD 
• DEFs disrupted PML NBs when FADD was overexpressed 
• DEFs formed by endogenous FADD formed small filaments in the 
cytoplasm and these filaments did not disrupt the PML NBs 
• The disruption of the PML NBs by DEFs was independent of 
caspase recruitment 
• DEFs showed a partial colocalisation with filaments/tracks formed 
by Ad5 E4 Orf3 
• DEFs formed in PML -/- cells were non-continuous and appeared 
shard-like 
• FADD appeared to be less efficiently phosphorylated in PML -/- 
cells compared to NIH/3T3 cells. This result may be inconclusive 
as two cell lines from two different mouse strains were used 
 
3.2.12 Conclusion and hypothesis 
DEFs formed by FADD disrupted the PML NBs. The NBs associated with DEFs 
before forming filament/tracks colocalising with the DEFs. SUMO was the first 
protein to form filaments colocalising with the DEFs and PML then followed, 
forming tracks. Later, Sp100 and Daxx left the PML NBs, colocalising with the 
DEFs. PML might be necessary for the formations of DEFs and phosphorylation of 
FADD seemed to be altered in PML -/- cells. FADD is involved in death receptor-
mediated apoptosis and the hypothesis is that it could be a part of PML NBs and Fas-
mediated apoptosis. This led to the next set of experiments where the FADD domains, 
which are necessary for the disruption of PML NBs, were mapped. 
During my studies several different cell lines such as U2OS, SAOS-2 and HT1080 
were tested after tranfection of FADD and there was no difference in the 
track/filament formation of PML NBs observed. The track/filament formation was not 
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cell-type specific and all images shown here are representative of what was observed 
in the transfected cells. 
 
 
3.3 PML nuclear bodies and FADD  
3.3.1 Introduction 
FADD was originally discovered as an interacting partner with the Fas receptor in a 
yeast two-hydrid screen (Chinnaiyan et al., 1995). It contains an N-terminal death-
effector domain (DED) and a C-terminal death domain (DD). It interacts with the Fas-
receptor through the DD and with caspase-8 through the DED, forming the death-
inducing signalling complex (DISC). FADD is phosphorylated by casein kinase 1 
(CK1) alpha at a single residue serine 194 at the C-terminus. Phosphorylation af 
FADD and therefore the C-terminus of the FADD protein affects apoptosis not only 
binding to the death receptors but also by playing an important role in cell cycle 
progression (Alappat et al., 2003). As mentioned earlier, one of the main interests of 
this study is to try to find and explain the connection between Fas-mediated apoptosis 
and PML and PML NBs and thus explain the altered response to death receptor 
ligands in PML -/- KO mice and cells. This was tested by mapping the domains in the 
FADD protein, which are necessary for the disruption of PML NBs. 
 
3.3.2 Mapping of the FADD domain that modifies PML nuclear bodies 
Truncated FADD constructs and FADD mutants were made to test which domain was 
necessary for the disruption of the PML NBs (Figure 3.23).  
FADD DED, which is necessary for homo- and hetero-oligomerisation of DED-
containing proteins, is known to induce apoptosis and form smaller, more numerous 
filaments (Siegel et al., 1998). As seen in Figure 3.24, this domain is sufficient to 
change the localisation of PML and Sp100. PML and Sp100 both formed tracks after 
transfection of FADD DED. 
The FADD protein contains two different domains: the death-effector domain (aa 3-
81) and the death domain (aa 97-181). The FADD DN protein encodes for the C-
terminus of FADD aa 80-208 and binds to the DD of the Fas receptor, but is unable to 
bind to the DED in caspase-8 because of the missing FADD DED. Furthermore, the 
FADD DN does not form DEFs (Siegel et al., 1998). FADD DN showed a diffuse 
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localisation and changed neither PML (Figure 3.25A) nor Sp100 (Figure 3.25B). 
These results showed that DEFs and therefore the DED was necessary for the 
relocalisation of PML NBs.  
 
 
 
 
 
 
Figure 3.23. Structure and function of wildtype FADD and FADD mutants 
All the single residues were changed using site-directed mutagenesis. FADD DED was sufficient to 
disrupt PML NBs and FADD had to be phosphorylated to disrupt PML NBs. 
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Figure 3.24. The nuclear localisations of PML and Sp100 are modified by the FADD death-
effector domain 
The FADD DED was able to disrupt PML NBs.  
A: U2OS cells transfected with pcDNA3-AU1 FADD DED and stained with an anti-FADD mAb (red 
fluorescence) and polyclonal rabbit anti-PML antibodies (green fluorescence).  
B: U2OS cells transfected with pcDNA3-AU1 FADD DED and stained with an anti-FADD mAb (red 
fluorescence) and polyclonal rabbit anti-Sp100 antibodies (green fluorescence). 
 
 
 
 
 
Figure 3.25. The death domain is not sufficient to disrupt the PML bodies 
U2OS cells transiently transfected with pcDNA3-AU1 FADD DN. 
A: Cells were stained with polyclonal rabbit anti-PML antibodies (green fluorescence) and with an 
anti-FADD mAb (red fluorescence). 
B: Cells were stained with polyclonal rabbit anti-Sp100 antibodies (green fluorescence) and an anti-
FADD mAb (red fluorescence). 
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The FADD F25G mutant when expressed in cells induces low levels of caspase-3 
activity and reduced binding to caspase-8 (Kaufmann et al., 2002). F25 is in a 
hydrophobic region of FADD important for protein-protein interactions (Eberstadt et 
al., 1998). The FADD F25G mutant was able to form DEFs in some of the transfected 
cells and here SUMO was associated with the DEFs (Figure 3.26, A-C). In other cells 
the mutant showed a diffuse pattern and there was no PML NB disruption (Figure 
3.26, D-F). These results suggested that caspase activation was probably not 
necessary for the PML NB disruption. 
It could be SUMO-modified FADD that was detected in the immunofluorescence 
when SUMO colocalised with the DEFs. The FADD sequence contains two potential 
SUMO-modification sites, K35 and K125, where K35 is a part of a potential nuclear 
localisation signal. The mutants FADD K35R and FADD K125R still formed DEFs 
and SUMO was still associated with the filaments. This result suggested that it was 
probably not SUMO-modified FADD that was detected but another protein recruited 
to the filaments that was being modified by SUMO, or that FADD was being 
modified at a different lysine. To test if it was perhaps only nuclear FADD that was 
SUMO-modified, a western blot was prepared with nuclear and cytoplasmic fractions 
of cells (Figure 3.27). There was no higher migrating band detected in the nuclear 
fraction of FADD-transfected cells, which suggested that FADD was not SUMO-
modified. This is confirmed by the absence of any literature attesting to the fact. 
FADD DN A174P mutant has been shown not to bind to Fas and does not induce 
apoptosis (Morgan et al., 2001) although it can still bind to TRADD (Morgan et al., 
2001). The A174 is located in the kinase-binding domain of FADD and this mutant 
has been shown to be less phosphorylated than wild type (Alappat et al., 2005). The 
interesting thing about this mutant was that it showed a partial colocalisation with 
PML NBs (Figure 3.28, A-C). It was also able to form DEFs in a minority of the cells 
(Figure 3.28, D-F). 
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Figure 3.26. SUMO forms filaments in some of the cells tranfected with FADD F25G  
A-F: U2OS cells transiently transfected with pcDNA3-AU1 FADD F25G and CrmA. Cells were 
stained with polyclonal rabbit anti-SUMO antibodies (green fluorescence) and an anti-FADD mAb (red 
fluorescence). 
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Figure 3.27. Cytoplasmic and nuclear FADD 
There were no higher migrating bands detected after transfection of FADD. 
Lanes 1 and 2: Untransfected HT1080 cells. Lanes 3 and 4: HT1080 cells transfected with pSG5-
FLAG- CK1 alpha LS. Lanes 5 and 6: HT1080 cells transfected pcDNA3-AU1 FADD. 
Cytoplasmic and nuclear extracts were loaded onto a 4-20% polyacrylaminde gradient gel, transferred 
onto nitrocellulose stained with anti-FADD mAb antibodies to check for SUMO modification of 
FADD and with polyclonal anti-Lamin B antibodies as a control for the nuclear fraction.  
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Figure 3.28. The FADD A174P mutant shows a partial colocalisation with PML NBs 
A-F: SAOS-2 cells transfected with pcDNA3-AU1 FADD A174P and stained with polyclonal rabbit 
anti-PML antibodies (green fluorescence) and with an anti-FADD mAb (red fluorescence).  
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It has previously been shown that FADD is phosphorylated in the G2/M phase of the 
cell cycle and only non-phosphorylated FADD is found in G1/S phase (Scaffidi et al., 
2000; Alappat et al., 2005). The phosphorylation site has been mapped to S194 
(Scaffidi et al., 2000), and shown to be necessary for cell cycle arrest in G2/M in a 
non-tumour cell line (Alappat et al., 2005). For further experiments, the serine was 
mutated to alanine to have a phospho-dead mutant and to glutamic acid and aspartic 
acid to mimic phosphorylation as these mutations are chemically similar to a 
phosphorylated serine. 
U2OS cells transfected with pcDNA3-AU1 FADD S194A and pcDNA3-AU1 FADD 
S194E (Figure 3.29), showed no disruption of the PML bodies 24 hours after 
transfection. The DEFs formed by the phosphorylation mutants were not 
phosphorylated (Figure 3.30).  Endogenous phosphorylated FADD was not recruited 
to the filaments 24 hours after transfection but it was possible to detect 
phosphorylated FADD in some of the transfected cells after 48 hours. Different 
results were obtained in HT1080 cells, where it was already possible to detect 
endogenous phosphorylated FADD in the DEFs 24 hours after transfection, which 
resulted in a disruption of the PML NBs.  
These results showed that FADD had to be phosphorylated to disrupt the bodies and 
this raised the following question: were non-phosphorylated DEFs nuclear or only 
cytoplasmic filaments? In a 3D reconstruction (Figure 3.31: 3D reconstruction with 
kind help from Dr Suhail Islam) of FADD S194A it was possible to see that the non-
phosphorylated filaments went through the nucleus. This result was confirmed using 
another FADD mutant, FADD S194D as well as FADD S194A, in confocal 
microscopy (Figure 3.32). When comparing the DEFs, non-phosphorylated and 
phosphorylated, from transfected cells there was no obvious difference in the 
appearance of the filaments (Figure 3.33). The phosphorylation of the FADD protein 
appeared to be necessary for the observed disruption of PML NBs. 
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Figure 3.29. SUMO is not disrupted in cells transfected with FADD phosphorylation mutants 
A-C: U2OS cells transiently transfected with the FADD mutant pcDNA3-AU1 FADD S194A. 
D-F: U2OS cells transiently transfected with the FADD mutant pcDNA3-AU1 FADD S194E. Cells 
were stained with polyclonal rabbit anti-SUMO antibodies (green fliorescence) and with an anti-FADD 
mAb (red fluorescence).  
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Figure 3.30. FADD phosphorylation mutants are unable to be phosphorylated  
NIH/3T3 cells transfected with pcDNA3-AU1 FADD and FADD phosphorylation mutants pcDNA3-
AU1 FADD S194A/D/E. Whole cell extracts were loaded onto a 4-20% polyacrylamide gradient gel, 
transferred onto nitrocellulose and analysed by immunoblotting using anti-FADD antibodies.  
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Figure 3.31. DEFs formed by FADD S194A are nuclear as well as cytoplasmic 
Saos-2 cells transiently transfected with pcDNA3-AU1 FADD S194A.  
A: The non-phosphorylated death-effector filaments did not disrupt PML 24 hours after transfection.  
A-C: PML colocalised with the death-effector filaments.  
Cells were stained with polyclonal rabbit anti-PML antibodies (green fluorescence) and with an anti-
FADD mAb (red fluorescence). Lamin B was used to outline the nucleus and stained with goat anti-
Lamin B antibodies  (blue fluorescence). 
 
 
 
Figure 3.32. Non-phosphosphorylated filaments do penetrate the nucleus  
A: U2OS cells transiently transfected with pcDNA3-AU1-FADD S194A. Cells were stained with an 
anti-FADD mAb (green fluorescence) and with propidium iodide.  
B: U2OS cells transiently transfected with pcDNA3-AU1-FADD S194D.  
Cells were stained with an anti-FADD mAb (green fluorescence) and with propidium iodide. 
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Figure 3.33. No obvious difference in phosphorylated and non-phosphorylated DEFs 
A-J: U2OS cells transiently transfected with pcDNA3-AU1 FADD. 
K-T: U2OS cells transiently transfected with pcDNA3-AU1 FADD S194A. 
U-Y: PML NBs were not disrupted in untransfected cells. 
Cells were stained with polyclonal rabbit anti-PML antibodies (green fluorescence), and with an anti-
FADD mAb (red fluorescence). 
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3.3.3 Summary 
• The DED in FADD was sufficient for the disruption of PML NBs 
• Again, caspase activity did not seem to be necessary for the PML 
NB alteration 
• FADD was not modified by SUMO  
• FADD needed to be phosphorylated to disrupt PML NBs 
• DEFs formed by FADD phosphorylation mutants were 
cytoplasmic as well as nuclear 
• There was no obvious difference between DEFs formed by FADD 
and the FADD phosphorylation mutants 
 
3.3.4 Conclusion and hypothesis 
The DED domain and therefore filament formation appeared to be necessary for PML 
NB disruption and so did phosphorylation of FADD. The DEFs needed to be 
phosphorylated to disrupt the PML NBs. This suggested that the kinase 
phosphorylating FADD could be involved in the disruption of the PML NBs and this 
was investigated further. 
Again, different cell lines were tested after transfection of truncated FADD contructs. 
The track/filament formation of PML NBs was only observed when the constructs 
contained the DED domain and was able to be phosphorylated. This suggested the 
PML NB disruption was caused by the FADD domains and not by the transfection of 
the vector used in these experiments. Again all images shown here are representative 
of what was observed in the transfected cells. 
 
 
3.4 The role of PML in FADD phosphorylation 
 
3.4.1 Introduction 
Many research groups have failed to identity the kinase that phosphorylates FADD. 
First it was reported to be 70 kDa cell cycle-regulated kinase phosphorylating FADD 
at S194 (Scaffidi et al., 2000). Then almost in parallel a very interesting publication 
appeared which fitted well with the connection to PML NBs (Rochat-Steiner et al., 
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2000). In the paper, FADD was described as phosphorylated by HIPK3, which shows 
a partial colocalisation to PML NBs (Rochat-Steiner et al., 2000). Later, it was 
reported be to casein kinase 1 alpha phosphorylating FADD and thereby regulating 
non-apoptotic activities of FADD (Alappat et al., 2005). 
 
3.4.2 Phosphorylation of the FADD protein by HIPK3 
It has previously been shown that homeodomain-interacting protein kinase 3 (HIPK3) 
colocalises partially with PML NBs and is able to induce phosphorylation of FADD 
(Rochat-Steiner et al., 2000). Colocalisation studies with PML, HIPK3 and 
phosphorylated FADD are shown in Figure 3.34. Endogenous FADD showed a 
diffuse nuclear and cytoplasmic staining (Figure 3.34A). In contrast, endogenous 
phosphorylated FADD (phospho-FADD) showed a striking nuclear speckled pattern 
(Figure 3.33B) very similar to the pattern of HIPK3 (Figure 3.34C). 
Both endogenous HIPK3 and endogenous phosphorylated FADD showed a partial 
colocalisation with PML NBs (Figures 3.34D and E).  
These results suggested that FADD is phosphorylated in HIPK domains that 
colocalise with PML NBs. 
To try to confirm that FADD was phosphorylated by HIPK3 (Rochat-Steiner et al., 
2000) experiments were repeated by transfecting U2OS or HT1080 cells with HIPK3 
alone or FADD and HIPK3. No difference in phosphorylation of FADD was seen 
after co-transfection of HIPK3. Other groups like (Alappat et al., 2005) also tried and 
failed to reproduce the results from Rochat-Steiner et al., 2000. 
 
3.4.3 Phosphorylation of FADD by casein kinase 1 alpha 
Later casein kinase 1 (CK1) alpha was shown to phosphorylate FADD at S194 in vivo 
and in vitro (Alappat et al., 2005). It was shown that phosphorylated FADD 
colocalises with CK1 alpha at the spindle poles in metaphase (Alappat et al., 2005). 
CK1 alpha is expressed as four different splice variants, CK1 alpha, CK1 alpha L, 
CK1 alpha S and CK1 alpha LS (Fu et al., 2001; Burzio et al., 2002). All four splice 
variants are able to phosphorylate FADD (Alappat et al., 2005). CK1 alpha LS 
contains an L insert in the catalytic domain and an S insert at the C-terminus (Figure 
3.35). The alternative splicing results in different kinase activity and localisation of 
the four splice variants (Burzio et al., 2002). 
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Figure 3.34. PML, phospho-FADD and HIPK3 show a partial colocalisation 
A: Endogenous FADD in HT1080 cells. Cells were stained with an anti-FADD mAb (red 
fluorescence).  
B: Endogenous phosphorylated FADD in HT1080 cells. Cells were stained with polyclonal rabbit anti-
phospho-FADD antibodies (red fluorescence).  
C: Endogenous HIPK3 in HT1080 cells. Cells were stained with polyclonal rabbit anti-HIPK3 
antibodies (green fluorescence). 
D: HT1080 cells transfected with pSG5-LINK-EGFP PML IV and stained with polyclonal rabbit anti-
HIPK3 antibodies (red fluorescence).  
E: HT1080 cells transfected with pSG5-LINK-EGFP PML IV and stained with polyclonal rabbit anti-
phospho-FADD antibodies (red fluorescence).  
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Figure 3.35. Casein kinase 1 alpha (isoform 1)/ CK1 alpha LS 
L insert (shown in light blue): contains an contains a potential NLS 
S insert (in green) 
The splice variants containing the L and the LS inserts are targeted to the nucleus. 
 
 
 
Figure 3.36. Localisation of CK1 alpha LS in U2OS cells 
U2OS cells transiently transfected with pSG5-FLAG CK1 alpha LS. 
A: Endogenous and transfected CK1 alpha. Cells were stained with goat polyclonal anti-CK1 alpha 
antibodies. 
B: Transfected CK1 alpha cells were stained with an anti-FLAG mAb. 
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Full-length CK1 alpha LS was made from two I.M.A.G.E. (Integrated Molecular 
Analysis of Genomes and their Expression) clones using PCR and cloning methods. 
U2OS cells were transfected with FLAG-tagged full-length CK1 alpha and stained 
using immunofluorescence (Figure 3.36). When cells were stained with goat 
polyclonal anti-CK1 alpha antibodies, which stained endogenous and transfected 
CK1, CK1 alpha showed a diffuse localisation throughout the cell, whereas FLAG-
CK1 alpha LS showed a more speckled pattern. This has also been described earlier in 
the literature and the speckles are thought to be splicing speckles (Gross et al., 1999). 
To determine whether CK1 alpha was recruited to the DEFs, colocalisation studies 
were performed by co-transfecting pcDNA3-AU1 FADD and pSG5-FLAG CK1 
alpha LS into U2OS cells. Figure 3.37 shows a colocalisation of FADD and CK1 
alpha in the nucleus. A very interesting result is shown in Figure 3.38 where CK1 
alpha does not colocalise with FADD S194A. This experiment was repeated with 
pcDNA3-AU1 FADD S194D/E and pSG5-FLAG CK1 alpha LS and also here there 
was no colocalisation. This suggested that CK1 was only recruited to DEFs when 
FADD was able to be phosphorylated. It was also tested to determine if not only 
transfected but also endogenous CK1 alpha was recruited to the DEFs (Figure 3.39) 
and whether CK1 alpha colocalised with SUMO in the DEFs (Figure 3.39). SAOS-2 
cells were transfected with pcDNA3-AU1 FADD and stained for CK1 alpha and 
SUMO. Figure 3.39, A-C shows a colocalisation in the nucleus of CK1 alpha and 
SUMO. It was not always the case, as can be seen in Figure 3.39, D-F, where one of 
the transfected cells did not have SUMO localising to the DEFs. This suggested that it 
could be a cell cycle-dependent phenomenon or that CK1 alpha was SUMO-modified 
after phosphorylating the FADD protein. 
Earlier results showed that phosphorylation of FADD was necessary for the disruption 
of the PML NBs and SUMO filament formation. The next question was whether CK1 
alpha was the SUMO-modified protein detected on the DEFs. Using SUMO 
prediction servers, several potential SUMO-modification sites were identified in the 
CK1 sequence (Figure 3.40). 
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Figure 3.37. CK1 alpha LS colocalises with FADD in the nucleus 
U2OS cells transfected with pcDNA3-AU1 FADD and pSG5-FLAG CK1 alpha LS.  
A-C: Cells were stained with an anti-FADD mAb (green fluorescence) and with a polyclonal goat anti-
CK1 alpha (red fluorescence).  
D-F: Cells were stained a polyclonal rabbit anti-FADD antibody (green fluorescence) and with an anti-
Flag mAb (red fluorescence). 
 
 
 
Figure 3.38. CK1 alpha LS does not colocalise with FADD S194A in the nucleus 
U2OS cells transfected with pcDNA3-AU FADD S194A and pSG5-FLAG CK1 alpha LS. Cells were 
stained with an anti-FADD mAb (green fluorescence) and with a polyclonal goat anti-CK1 alpha 
antibody (red fluorescence). 
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Figure 3.39. Endogenous CK1 alpha colocalises with endogenous SUMO in the nucleus in the 
presence of DEFs formed by FADD 
SAOS-2 cells transiently transfected with pcDNA3-AU1 FADD and stained with polyclonal goat anti-
CK1 alpha antibodies (green fluorescence) and polyclonal rabbit anti-SUMO antibodies (red 
fluorescence). 
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Figure 3.40. SUMO site prediction of CK1 alpha LS 
Several SUMO prediction servers were used to predict potential SUMO modification sites in CK1 
alpha LS.  
SUMOplot: http://www.abgent.com/tools/sumoplot 
SUMOsp 2.0: http://sumosp.biocuckoo.org/ 
seeSUMO: http://bioinfo.ggc.org/seesumo/ 
GPS-SBM 1.0: http://sbm.biocuckoo.org/ 
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3.4.4 Summary 
• PML and endogenous phosphorylated FADD showed a partial 
colacalisation 
• Both endogenous and overexpressed CK1 alpha was recruited to 
the phosphoryalted DEFs 
• CK1 alpha was not recruited to the DEFs formed by the FADD 
phosphorylation mutants 
• SUMO colocalised with CK1 alpha in DEFs in many of the 
transfected cells 24 hours after transfection. This colocalisation 
increased over time and could be a cell cycle-dependent 
phenomenon 
 
3.4.5 Conclusion and hypothesis 
The results involving HIPK3 phosphorylation of FADD could not be reproduced. 
Instead the interaction with CK1 alpha was investigated further. FADD had to be 
phosphorylated to recruit CK1 alpha. CK1 alpha colocalised with SUMO in DEFs and 
this led to the next question: could CK1 alpha be the SUMO-modified protein 
observed in DEFs? 
 
 
3.5 The role of PML nuclear bodies in regulating FADD 
phosphorylation 
3.5.1 Introduction 
It has been speculated that SUMO-modification of proteins occurs at PML NBs. 
Could it be that CK1 alpha is SUMO-modified in order to regulate the activity of the 
kinase and its localisation? SUMO-modification can change protein-protein 
interactions. There have only been a few publications which show a regulation of 
SUMO-modification and kinase activity. One of them demonstrates that Glycogen 
Synthase Kinase 3ß is SUMO-modifed: SUMO-modification promotes nuclear 
localisation of GSK 3ß and is required for kinase activation (Eun Jeoung et al., 2008). 
In addition, SUMO-modified GSK 3ß regulates protein stability and apoptosis (Eun 
Jeoung et al., 2008). Another publication shows that Aurora B contains a SUMO-
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modification motif in the kinase domain and that mutating the lysine to an arginine 
increases the activity of the kinase slightly (Fernandez-Miranda et al., 2010). The 
authors speculate that SUMO-modification changes the activity and the localisation of 
the Aurora B. Recently it was shown that the yeast kinase SNF1 is not only SUMO-
modified but also contains a SUMO-interacting motif (SIM) near the active site 
(Simpson-Lavy and Johnston, 2013). The kinase activity of SNF1 is decreased upon 
SUMO-modification, perhaps by interacting with the SIM in the kinase domain and 
thereby stabilising the inactive form of the kinase. An SNF1 SUMO-interacting 
mutant is less stable and targeted for degradation by the SUMO-targeted ubiquitin 
ligase Slx8. 
The hypothesis here was that CK1 alpha is SUMO-modified and the modification 
takes place at the PML NBs, and that it regulates the activity and localisation of the 
kinase, thereby regulating the phosphorylation and the apoptotic activity of FADD. 
 
3.5.2 SUMO modification of CK1 alpha LS 
To see if a SUMO-specific protease could be recruited to the SUMO filaments and 
hydrolyse SUMO from them, cells were co-transfected with FADD and a SUMO-
specific protease called SuPr-1 (Best et al., 2002). This was done to find out if SUMO 
was necessary for the track/filament formation of PML NB components after 
transfection of FADD. EGFP-SuPr-1 seemed to associate with DEFs, as both wild 
type SuPr-1 and the inactive mutant SuPr-1 C466S colocalised to the death effector 
filaments (Figure 3.41). Interestingly but as expected, neither the wild-type SUMO 
protease nor the mutant SUMO protease colocalised with phosphorylation mutant 
FADD S194A (Figure 3.42). When EGFP-SuPr-1 colocalised with DEFs there was no 
track/filament formation of PML NBs. This means that SuPr-1 hydrolyses SUMO 
from the filaments and that SUMO is necessary for the track/filament formation. A 
summary for the many colocalisations studies is seen in Table 3.1.  
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Figure 3.41. Colocalisation studies of FADD and SuPr-1 
The SUMO specific protease SuPr-1 was recruited to the DEFS and hydrolysed SUMO from them. The 
mutant SuPr-1 C466S was also recruited to the DEFs. 
A-C: U2OS cells transiently transfected with pcDNA3-AU1 FADD and EGFP-SuPr-1. Cells were 
stained with an anti-FADD mAb (red fluorescence). 
D-F: U2OS cells transiently transfected with pcDNA3-AU1 FADD and EGFP-SuPr-1 C466S. Cells 
were stained with an anti-FADD mAb (red fluorescence). 
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Figure 3.42. No cocalisation of FADD S194A and SuPr-1/SuPr-1 C466S 
The SUMO specific protease SuPr-1 and the SuPr-1 mutant are not recruited to the non-phosphorylated 
DEFs. 
A-C: U2OS cells transiently transfected with pcDNA3-AU1 FADD S194A and pEGFP-SuPr-1. Cells 
were stained with an anti-FADD mAb (red fluorescence). 
D-F: U2OS cells transiently transfected with pcDNA3-AU1 FADD S194A and pEGFP-SuPr-1 C466S. 
Cells were stained with an anti-FADD mAb (red fluorescence). 
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Table 3.1. Colocalisation studies after transfection of FADD 
 
 
PML CK1 
alpha 
SUMO-
1 
SUMO-2/3 Sp100 Daxx SuPr-1 SuPr-1 
C466S 
FADD 
 
Partial92, 
93, 119 
Partial125 partial partial Partial96 Partial96 Full130 Full130 
FADD 
S194A 
None118, 
119  
None125 none none none none None131 None131 
PML 
 
------ partial 
(1) 
partial occasionally partial partial none partial 
(2) 
CK1 
 
------ ------- Almost 
full 
(3) 
almost none n/a n/a partial partial 
SUMO-
1 
------- ------- ------- partial n/a n/a none partial 
SUMO-
2/3 
------- ------- -------- ------- n/a n/a none partial 
Sp100 
 
------- ------- -------- --------- ------- n/a none few (4) 
Daxx 
 
------- ------- ------- --------- ------- ------- none few (4) 
 
Table 3.1. Colocalisation studies of endogenous PML, CK1 alpha, SUMO-1, SUMO-2/3, Sp100 
and Daxx after transfection of FADD and cotransfection of FADD and SuPr-1/SuPr-1 C466S 
1. PML was not yet disrupted but colocalised with CK1 filaments. 
2. Some PML formed tracks, which indicated that SUMO is needed for the disruption of the PML NBs. 
3. Almost 100 % colocalisation observed, but difficult to judge because many PML NB components 
are SUMO-modified, such as PML, Sp100 and Daxx. Colocalisation increased over time. 
4. Sp100 and Daxx disrupt later after transfection of FADD. 
Partial colocalisation implies that in some of the transfected cells PML colocalised with DEFs and was 
not yet disrupted. In other cells, PML was disrupted and had formed tracks. This disruption increased 
over time. Or CK1 colocalised with SUMO in some of the cells but not in all. This colocalisation also 
increased over time. 
The SUMO antibody used in the colocalisation experiments shown in my thesis detected SUMO-1/2/3. 
Only later during my studies were antibodies against SUMO-1 and SUMO-2/3 obtained and those 
results are shown in the above table. 
Numbers shown in superscript refer to page numbers. 
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Mammalian cells were transiently transfected with CK1 alpha LS and CK1 alpha LS 
with SUMO-1 to try to detect SUMO-modified CK1 alpha. Cells were lysed 24 hours 
after transfection and cell extracts were loaded onto a polyacrylamide gradient gel. In 
Figures 3.43 and 3.44 it is possible to see some higher migrating bands, which could 
potentially be SUMO-1-modified CK1 alpha. 
Another experiment was performed where U2OS cells were transiently transfected 
with CK1 alpha and CK1 alpha with pEGFP-SUMO-1,2,3 to see which SUMO-
modification it was. Often a SUMO-modified protein can be modified by any of the 
three SUMOs but often there is a preference (Figure 3.45). It was very difficult to 
detect a difference in SUMO-modification in western blot, and in parallel, several 
CK1 alpha LS mutants were made using site-directed mutagenesis (Figure 3.46) and 
transfected into U2OS and HT1080 cells. There was no major difference in the 
pattern detected by immunofluorescence. The only mutant that seemed to change was 
CK1 alpha LS K138R, where more SUMO filaments were detected when co-
transfected with FADD. It was very difficult to detect any changes in SUMO-
modification of CK1 alpha LS and CK1 alpha LS mutants in western blot. The reason 
for this could be that the CK1 alpha isoform used here contained the L insert, which 
has been shown to degrade more rapidly than the shorter isoform CK1 alpha (Burzio 
et al., 2002). CK1 alpha LS has a half life of 100 minutes compared to 400 minutes 
for the shorter isoform CK1 alpha. 
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Figure 3.43. CK1 alpha LS might be modified by SUMO-1  
Immunoblot analysis of U2OS cells transfected with pSG5-FLAG CK1 alpha LS +/- pEGFP-SUMO-1. 
Cell extracts were loaded onto a 4-20% polyacrylamide gradient gel. Proteins were transferred onto 
nitrocellulose membrane and the CK1 alpha protein was detected with polyclonal goat anti-CK1 alpha 
antibodies. 
 
 
 
Figure 3.44. CK1 alpha LS might be modified by SUMO-1  
Immunoblot analysis of  HT1080 cells transfected with pSG5-FLAG CK1 alpha LS, +/- MLV-SUMO-
1. Cell extracts were loaded onto a 4-20% polyacrylamide gradient gel. Proteins were transferred onto 
nitrocellulose membrane and the CK1 protein was detected with anti-FLAG mAbs. 
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Figure 3.45. Test expression of CK1 alpha LS and SUMO-1/2/3 
Immunoblot analysis of U2OS cells transfected with pSG5-FLAG CK1 alpha LS +/- pEGFP-SUMO-
1/2/3. Cell extracts were loaded onto a 4-20% polyacrylamide gradient gel. Proteins were transferred 
onto nitrocellulose membrane and the CK1 protein was detected with polyclonal goat anti-CK1 alpha 
antibodies. 
 
 
 
 
Figure 3.46. CK1 alpha LS SUMO mutants 
All mutants were made using site-directed mutagenesis and transfected into HT1080 and U2OS cells. 
SUMO modification was detected in western blot and immunofluorescence. CK1 K46R was still 
recruited to the DEFs, although the mutant was not active. CK1 alpha LS K138R results in more 
SUMO filaments localising to the DEFs. 
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3.5.3 SUMO-modification of CK1 alpha LS in E. coli 
It was decided to try to map the SUMO-modification sites in CK1 alpha LS in a 
system developed by Uchimura et al., 2004 (overview in Figure 3.47). CK1 alpha LS 
was cloned into several prokaryotic expression vectors either containing a His- or a 
GST-tag. BL21-Gold(DE3) were co-transformed with the plasmid expressing CK1 
alpha LS and the SUMO-modification machinery – Aos1 and Uba2 (AU) and Ubc9 – 
and SUMO-1 or SUMO-3. Various conditions were tested but it was not possible to 
detect any GST-tagged CK1 alpha LS expressed even with different conditions of 
IPTG and at different temperatures. The only test expression that showed any result 
was of His-tagged CK1 alpha LS induced with 0.5 mM IPTG for 6 hours at 37 ˚C 
(Figure 3.48). The expression was still very poor and the CK1 alpha LS protein was 
degraded. 
It was then decided to try in vitro protein synthesis using cell-free extract to express 
CK1 alpha LS to avoid the degradation and possible toxicity issues. No SUMO 
modification of CK1 alpha LS was observed when it was expressed together with 
SUMO-1 or SUMO-3 in the cell-free extract (Figure 3.49). RanGAP1, which has 
been shown to be SUMO-modified (Matunis et al., 1996) was used as a positive 
control. Two different cell-free extract kits were tested but neither gave a positive 
result when used for SUMO modification of CK1 alpha. This suggested that CK1 
alpha LS was insoluble and two new DNA constructs were ordered and synthesised 
by Mr Gene. The sequences chosen were based on past publications. A truncated 
variant of CK1 (Cki1∆298) from Schizisaccharomyces pombe has been successfully 
used in crystallisation studies (Xu et al., 1995). CK1 alpha S was aligned with Cki 
using the Clustal 2.1 multiple sequence alignment programme (Figure 3.50) and the 
construct CK1 alpha (aa 1-301) was chosen for expression experiments. Another CK1 
isoform lacking the C-terminal autoinhibitory region, CK1 delta (aa 1-317), has also 
been used in crystallisation studies earlier (Longenecker et al., 1996). This isoform 
was chosen for the expression studies as well. 
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Figure 3.47. Overproduction of eukaryotic SUMO-1- and SUMO-2/3-conjugated proteins in 
Escherichia coli 
A: One vector expresses the SUMO-modification machinery E1 and E2 + SUMO.  
B: Cotransformation of the vector expressing the SUMO modification machinery and a second vector 
that expresses the protein of interest. (Figure taken from Uchimura et al., 2004). 
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Figure 3.48. Test expression of CK1 alpha LS  
Immunoblot analysis of lysates from BL21-Gold(DE3) cells transformed with pProEx HTb CK1 alpha 
LS and pT-Trx-AU(E1)-Ubc9(E2)-SUMO-1/3, induced with 0.5 mM IPTG and left to grow 6 hours at 
37 ˚C. Lysates were loaded onto a 4-20% polyacrylamide gradient gel. Proteins were transferred onto a 
nitrocellulose membrane and the expressed CK1 protein was detected using an anti-His mAb. 
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Figure 3.49. Cell-free test expression of CK1 alpha LS with and without SUMO-1 and SUMO-3 
Immunoblot analysis from cell-free expression of CK1 alpha LS (CK1) with or without SUMO-1(S1) 
or SUMO-3(S3). SUMO-modified RanGAP1 was used as a positive control. Lysates were loaded onto 
a 4-20% polyacrylamide gradient gel. Proteins were transferred onto nitrocellulose membrane and the 
expressed proteins were detected using an anti-His mAb. 
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Figure 3.50. Alignment of CK1 sequences using Clustal 2.1 multiple sequence alignment 
A truncated variant of CK1 (Cki1∆298) from Schizisaccharomyces pombe has been successfully used 
in crystallisation studies (Xu et al., 1996). Based on the alignment above, the construct CK1 alpha aa 
1-301 was chosen for expression experiments (see arrow).  
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3.5.4 Expression of CK1 alpha 1-301 and CK1 delta 1-317 in E. coli 
CK1 alpha 1-301 and CK1 delta 1-317 were cloned into several different prokaryotic 
expression vectors with either a His- or a GST-tag. BL21-Gold(DE3) cells were 
transformed with the plasmids and test expression experiments were performed with 
0.2 mM IPTG  for 6 hours at 25 ˚C. The temperature was lowered from 37 ˚C to 25 ˚C 
to help protein folding and solubility. The expression was still poor for most 
constructs (Figure 3.51) but pET-28a seemed to give the best expression of CK1 
alpha 1-301. To check for protein solubility, another test expression experiment with 
pET-28a CK1 alpha 1-301 and pET-28a CK1 delta 1-317 was performed. This time 
the cells were grown to an OD600 of 1.0 at 37 ˚C, induced with 0.2 mM IPTG and left 
for expression overnight at 15 ˚C (Burzio et al., 2002). Only CK1 delta 1-317 was 
soluble under these conditions (Figure 3.52). Another test expression was done with 
pET-28a CK1 alpha 1-301 and as seen in Figure 3.53, CK1 alpha 1-301 was found in 
the pellet and was insoluble. The shortest CK1 alpha isoform has been used 
previously in biochemical studies (Burzio et al., 2002) and in autophosphorylation 
studies (Budini et al., 2009). This isoform (Figure 3.54) was now ordered and 
synthesised by Mr Gene. It was cloned into pET-28a and a test expression was 
performed; but again CK1 alpha was insoluble.  This was the smallest human CK1 
alpha isoform, CK1 alpha 1-325 without the L and S insert. The only difference in the 
sequence when compared to the clones used in the studies from Burzio et al., 2002 
and Budini et al., 2009, was the serine at position 313 (shown in red in Figure 3.54) 
which is a glycine in the CK1 alpha variants used in Burzio et al., 2002 and Budini et 
al., 2009. Serine 313 in CK1 alpha was mutated to glycine using site-directed 
mutagenesis and again test expression was repeated, but this time together with 
SUMO-1 (Figure 3.55) in the hope that SUMO-1 might make the CK1 alpha protein 
more soluble. Also under the new conditions the CK1 alpha protein was mainly found 
in the pellet and the small soluble portion detected was not SUMO-modified (Figure 
3.55).  
 142 
 
 
Figure 3.51. Test expression of CK1 alpha 1-301 and CK1 delta 1-317 
Transformed BL21-Gold(DE3) cells were induced with 0.2 mM IPTG and left to grow for 6 hours at 
25 ˚C. Cells were lysed and loaded onto a 4-20% polyacrylamide gradient gel and stained with 
Coomassie Blue.  
 143 
 
 
Figure 3.52. Test expression of CK1 alpha 1-301 and CK1 delta 1-317 
Transformed BL21-Gold(DE3) cells were induced with 0.2 mM IPTG and left to grow overnight at 15 
˚C. Proteins were purified and several fractions were loaded onto a 4-20% polyacrylamide gradient gel 
and stained with Coomassie Blue. Marker (M), Flow through (FT).  
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Figure 3.53. Solubility test of pET-28a CK1 alpha 1-301 
Transformed BL21-Gold(DE3) cells were induced with 0.2 mM IPTG and left to grow overnight at 15 
˚C. Protein was purified and several fractions were loaded onto a 4-20% gradient gel and stained with 
Coomassie Blue. Flow through (FT), Pellet (P), Load (L). 
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Figure 3.54. Shortest CK1 alpha isoform 
The shortest CK1 alpha isoform has been used in biochemical studies (CK1 alpha 1-325 (S313G) 
(Burzio et al. 2002) and in auto-phosphorylation studies (Budini et al. 2009).  The only difference is 
the serine at position 313 (in red) which is a glycine in the CK1 alpha variants mentioned in the studies 
above. 
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Figure 3.55. CK1 alpha 1-325 S313G is still insoluble  
BL21-Gold(DE3) cells co-transformed with pET-28a CK1 alpha 1-325 S313G and pT-Trx-AU(E1)-
Ubc9(E2)-SUMO-1 were induced with 0.2 mM IPTG and left to grow overnight at 15 ˚C. Protein was 
purified and several fractions were loaded onto a 4-20 % polyacrylamide gradient gel and stained with 
either (A) Coomassie Blue or (B). Proteins were transferred to a  nitrocellulose membrane and the 
expressed proteins were detected using an anti-His mAb. Load (L), Flow through (FT), Pellet (P), 
Marker (M). 
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Further test expression experiments with the various CK1 alpha constructs were also 
carried out in SoluBL21. SoluBL21 is a mutant strain of BL21(DE3) which has been 
optimised for expressing insoluble proteins in a soluble form, but here also CK1 alpha 
remained insoluble. It was then decided to continue mapping the SUMO-modification 
sites in the CK1 delta isoform. CK1 alpha is 76% identical to the amino acid level of 
CK1 delta (Gross and Anderson, 1998). 
 
3.5.5 Expression and SUMO modification of CK1 delta 1-317 in E. coli 
CK1 alpha LS and full-length CK1 delta were aligned using the Clustal 2.1 multiple 
sequence alignment programme. As can be seen in Figure 3.56, all of the predicted 
SUMO-modification sites in CK1 alpha LS are conserved in CK1 delta except for 
K363. To examine SUMO-modification of CK1 delta 1-317 in E. coli, BL21-
Gold(DE3) cells were transformed with pET-28a CK1 delta 1-317 with or without the 
SUMO-1/3 expressing plasmids. Again cells were grown to an OD600 of 1.0 at 37 ˚C, 
induced with 0.2 mM IPTG and left for expression overnight at 15 ˚C (Burzio et al., 
2002). Proteins were purified and loaded onto a 4-20% polyacrylamide gradient gel 
and stained with Coomassie Blue (Figure 3.57). Unfortunately, the SUMO-modified 
CK1 delta 1-317 was too weak to see properly in the Coomassie Blue-stained gel and 
a western blot was performed using an anti-His mAb and a polyclonal rabbit anti-
SUMO-2/3 antibody (Figure 3.58). CK1 delta 1-317 is SUMO-modified in E.coli. 
There are three very strong SUMO-modified bands and one weaker band detected 
with the SUMO-2/3 antibody. There is a weak band showing underneath the SUMO-
modified CK1 delta band in the western blot stained with the SUMO-2/3 antibody. 
This is contamination from the first detection with the His antibody. Preliminary data 
show that CK1 delta 1-317 can be modified by SUMO-1 and SUMO-3. 
It was decided to use SUMO-1 for future modification experiments. This would make 
it easier to interpret the results as the SUMO-1 protein does not contain the lysine 
residue that corresponds to lysine 48 in ubiquitin and therefore cannot make SUMO-
chains (Bayer et al., 1998). The CK1/SUMO higher molecular weight bands should 
each count for one SUMO-attachment. 
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Figure 3.56. Alignment of CK1 sequences using Clustal 2.1 multiple sequence alignment 
All the lysines predicted to be SUMO-modified in CK1 alpha LS are conserved in CK1 delta – K22/14, 
K46/38, K138/130, K257/221, K260/224 – except for K363. Conserved lysine positions are marked 
with an arrow. 
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Figure 3.57. Expression and SUMO-modification of CK1 delta 1-317 
BL21-Gold(DE3) cells transformed with pET-28a-CK1 delta 1-317 with or without pT-Trx-AU(E1)-
Ubc9(E2)-SUMO-1 were induced with 0.2 mM IPTG and left to grow overnight at 15 ˚C. Protein was 
purified and several fractions were loaded onto a 4-20% polyacrylamide gradient gel and stained with 
Coomassie Blue. Load (L), Flow through (FT), Marker (M). 
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Figure 3.58. SUMO-modification of CK1 delta 1-317 in E.coli 
BL21-Gold(DE3) cells transformed with pET-28a-CK1 delta 1-317 with or without pT-Trx-AU(E1)-
Ubc9(E2)-SUMO-1/3 and induced with 0.2 mM IPTG and left to grow overnight at 15 ˚C. Protein was 
purified and several fractions were loaded onto a 4-20% polyacrylamide gradient gel and proteins were 
transferred onto a nitrocellulose membrane and the expressed proteins were detected using an anti-His 
mAb (A) and polyclonal rabbit anti-SUMO-2/3 antibodies (B).  
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3.5.6 Optimisation of expression and SUMO modification of CK1 delta 1-317 in 
E. coli 
To optimise the expression and SUMO modification of CK1 delta 1-317 a few 
changes to plasmids and protocols were made. The vector pET-28a contains a 
potential N- and C-terminal His-tag. All constructs used in the preliminary 
experiments contained a STOP codon before the C-terminal His-tag. This was 
changed in pET-28a CK1 delta 1-317 using site-directed mutagenesis. The protein 
expressed using the new pET-28a CK1 delta 1-317 construct contained an N- and a 
C-terminal His-tag and had a much better affinity to the column during protein 
purification. This was not the only change made to the purification protocol. Instead 
of using a nickel-affinity column it was decided to try and use a cobalt-affinity 
column, which has very low non-specific binding. It was also noticed when using 
Triton X-100 in the elution buffer, as done by (Burzio et al., 2002), that a more 
indistinct band pattern was observed in western blot (Figure 3.59). Triton X-100 was 
therefore excluded from the elution buffer. To reduce unspecific background even 
further washing and elution conditions were tested (Supplementary Figure 6.1). When  
30 mM Imidazole was used in the wash buffer and 130 mM for elution there were still 
some contaminants in the elution. When 60 mM Imidazole was used in the wash 
buffer and 130 mM in the elution a part of the SUMO-modified CK1 was lost. It was 
decided to use 45 mM Imidazole in the wash buffer and 130 mM in the elution buffer. 
The temperature the cells were grown at overnight after induction was also changed 
from 15 ˚C to 22 ˚C for CK1 delta 1-317. A typical trace for the protein purification 
can be seen in Figure 3.60. 
 152 
 
 
Figure 3.59. Testing elution buffer for SUMO-modified CK1 delta 1-317  
BL21-Gold(DE3) cells transformed with pET-28a CK1 delta 1-317 with or without pT-Trx-AU(E1)-
Ubc9(E2)-SUMO-1, induced with 0.2 mM IPTG and left to grow overnight at 15 ˚C. Protein was 
purified and several fractions were loaded onto a 4-20% polyacrylamide gradient gel, transferred onto a 
nitrocellulose membrane, detected using an anti-His mAb. Please note that there seems to be a minor 
contamination of SUMO-modified CK1 in the lane on the left with CK1 eluted with Triton X-100, 
which could be a loading issue. 
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Figure 3.60. Typical purification profile for CK1 or SUMO-modified CK1 
Blue line: The first peak is the 15% wash, the second peak is the 50% elution and the third peak is the 
100% Imidazole wash. The green line shows the Imidazole concentrations 15%, 50% and 100%. 
The red triangles illustrate the fractions. 
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3.5.7 Mapping of the SUMO modification of CK1 delta 1-317 in E. coli 
Several different SUMO prediction servers were used to find potential SUMO-
modifications sites in CK1 delta 1-317 (Figure 3.61). Earlier during this study an 
alignment with CK1 alpha LS and CK1 delta was done to see if the predicted SUMO-
modification sites in CK1 alpha LS were conserved in CK1 delta (Figure 3.56). Now 
the predicted SUMO-modification sites from CK1 delta were compared to CK1 alpha. 
Most of the predicted sites in CK1 delta were conserved in CK1 alpha (Figure 3.62). 
The predicted lysines were mutated to arginines for mapping experiments of the 
potential SUMO sites in CK1 delta 1-317. Mutating lysines to arginines should keep 
the structure and charge balance of the CK1 mutants suited to the wild-type CK1. The 
CK1 delta 1-317 SUMO mutants were either made using site-directed mutagenesis, 
by cloning G-blocks/GeneArt strings in different combinations or by gene synthesis 
(Figure 3.63). All CK1 delta SUMO mutants were co-transformed into BL21-
Gold(DE3) cells together with the pT-Trx-AU(E1)-Ubc9(E2)-SUMO-1 plasmid, 
grown to an OD600 of 1.0, induced with 0.2 mM IPTG and left to grow overnight at 22 
˚C. The proteins were purified and detected in western blots using an anti-His mAb 
(Figures 3.64 and 3.65). It soon became clear that the SUMO-modification of CK1 
delta 1-317 was difficult to map using the system in E.coli because SUMO seemed to 
modify other lysines in the SUMO mutants. It was only when CK1 was mutated that 
SUMO modified unspecific lysines. It was always the same pattern detected in 
SUMO-modified wild-type CK1 delta 1-317 when expressed overnight. The only 
mutation that often showed a change in the band pattern was K38 (Figure 3.64). K38 
is the active site of CK1 delta and when mutated to arginine it results in a kinase dead 
mutant. It was decided to try and map the modified lysines in CK1 delta 1-317 using 
mass spectrometry. In parallel E.coli modification studies were continued with slight 
changes. The transformed cells were only grown to an OD600 of 0.6, induced with 0.2 
mM IPTG and left to grow at 22 ˚C but only for 5-6 hours. That improved the assay 
and the results were easier to interpret (Figures 3.66 and 3.67) but it was still not clear 
which lysines were SUMO-modified until the data was compared with the mass 
spectrometry analysis. 
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Figure 3.61. SUMO site prediction of CK1 delta  
Several SUMO prediction servers were used to predict potential SUMO-modification sites in CK1 
delta.  
SUMOplot: http://www.abgent.com/tools/sumoplot 
SUMOsp 2.0: http://sumosp.biocuckoo.org/ 
seeSUMO: http://bioinfo.ggc.org/seesumo/ 
GPS-SBM 1.0: http://sbm.biocuckoo.org/ 
PCI-Based Sumo Site Prediction Server: http://bioinf.sce.carleton.ca/SUMO/start.php 
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Figure 3.62. Alignment of CK1 sequences using Clustal 2.1 multiple sequence alignment  
The following predicted lysines from CK1 delta are conserved in CK1 alpha LS:  K14/22, K38/46 
K130/138, K154/190, K155/191, K221/257, K224/260, K294/330. 
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Figure 3.63. Overview of CK1 delta SUMO mutants 
The CK1 delta 1-317 SUMO mutants were made by using either site-directed mutagenesis, cloning G-
blocks/GeneArt strings in different combinations or by gene synthesis. 
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Figure 3.64. SUMO modification of CK1 delta 1-317 SUMO mutants  
BL21-Gold(DE3) cells co-transformed with pET-28a CK1 delta 1-317 SUMO mutants and pT-Trx-
AU(E1)-Ubc9(E2)-SUMO-1 were induced with 0.2 mM IPTG and left to grow overnight at 22 ˚C. 
Proteins were purified and several fractions were loaded onto a 4-20% polyacrylamide gradient gel, 
transferred onto a nitrocellulose membrane and the expressed proteins were detected using an anti-His 
mAb. 
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Figure 3.65. SUMO modification of CK1 delta 1-317 SUMO mutants  
BL21-Gold(DE3) cells co-transformed with pET-28a-CK1 delta 1-317 SUMO mutants and pT-Trx-
AU(E1)-Ubc9(E2)-SUMO-1 were induced with 0.2 mM IPTG and left to grow overnight at 22 ˚C. 
Proteins were purified and several fractions were loaded onto a 4-20% polyacrylamide gradient gel, 
transferred onto a nitrocellulose membrane and the expressed proteins were detected using an anti-His 
mAb. 
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Figure 3.66. Comparison of efficiency of SUMO-1 modification machinery in E.coli 
BL21-Gold(DE3) cells co-transformed with pET-28a CK1 delta 1-317 SUMO mutants and pT-Trx-
AU(E1)-Ubc9(E2)-SUMO-1 were induced with 0.2 mM IPTG and left to grow overnight or for 6 hours 
at 22 ˚C. Proteins were purified and several fractions were loaded onto a 4-20% polyacrylamide 
gradient gel, transferred onto a nitrocellulose membrane and the expressed proteins were detected using 
an anti-His mAb. 
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Figure 3.67. Comparison of efficiency of SUMO-1 modification machinery in E.coli 
BL21-Gold(DE3) cells co-transformed with pET-28a CK1 delta 1-317 SUMO mutant and pT-Trx-
AU(E1)-Ubc9(E2)-SUMO-1 were induced with 0.2 mM IPTG and left to grow overnight or for 5 hours 
at 22 ˚C. Protein was purified and several fractions were loaded onto a 4-20% polyacrylamide gradient 
gel, transferred onto a nitrocellulose membrane and the expressed proteins were detected using an anti-
His mAb. 
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3.5.8 Mass spectrometry of SUMO-modifed CK1 delta 1-317 from E. coli 
Mass spectrometry analysis was performed by Dr Paul Hitchen in the CISBIO Mass 
Spectrometry Core facility at Imperial College London. Samples for mass 
spectrometry were prepared by co-transforming BL21-Gold(DE3) cells with pET-28a 
CK1 delta 1-317 ∆STOP and pT-Trx-AU(E1)-Ubc9(E2)-SUMO-1 plasmids. 
Transformed cells were grown to an OD600 of 1.0, induced with 0.2 mM IPTG and 
left to grow overnight at 22 ˚C. Protein was purified and loaded onto a 4-20% 
polyacrylamide gradient gel and stained with Coomassie Blue (Figure 3.68). Two 
bands (Figure 3.68, marked with arrows) were cut out for mass spectrometry analysis, 
the lower unmodified band to check it is the right protein expressed and the higher 
migrating band where one SUMO should be covalently attached to CK1 delta. Under 
normal conditions in the mammalian cells there would probably be a preferential 
lysine in the protein but under the conditions in the E.coli the hope was to see a 
mixture of SUMO-modified bands. The protein was digested into peptides using 
trypsin, which cleaves at the carboxyl side of a lysine or an arginine except for when 
there is a proline present as the following amino acid. The expected CK1 delta and 
SUMO-1 peptides used in the analysis are shown in Tables 3.2 and 3.3. The peptide 
mass of CK1 delta and SUMO-1 were estimated using PeptideMass on the ExPASy 
server. 
The mass spectrometry peptide dataset was first used to search for the potential 
SUMO-modified CK1 sequences and if the peptide sequence was absent, then it was a 
good indication for it being potentially modified. When the mass spectrometer checks 
the peptide sequence and the mass of the peptide, it realises that there is too much 
mass for that peptide and the data is automatically discarded. 
All the potential charges and masses of the SUMO-modified CK1 delta peptides were 
calculated (Table 3.4) and checked in the mass spectrometry dataset. The following 
CK1 peptides were found to be modified by SUMO-1: K38, K130, K140, K224 and 
K294 (shown in bold in Table 3.4).  
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Figure 3.68. Expression of SUMO-modified CK1 delta 1-317 for mass spectrometry analysis 
BL21-Gold(DE3) cells transformed with pET-28a CK1 delta 1-317 and pT-Trx-AU(E1)-Ubc9(E2)-
SUMO-1, induced with 0.2 mM IPTG and left to grow overnight at 22 ˚C. Protein was purified and 
two fractions were loaded onto a 4-20% polyacrylamide gradient gel and stained with Coomassie Blue. 
Bands marked with an arrow were cut out for mass spectrometry analysis. 
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Table 3.2. Peptide mass of CK1 delta 
SUMO site in 
CK1 delta 1-
317 
Peptide sequence Theoretical Mass 
(monoisotopic mass) 
K14 LGRKIGSGSFGDIYLGTDIAAGEEVAIK 2837.5043 
K38 IGSGSFGDIYLGTDIAAGEEVAIKLECVK 3012.5233 
K130 DVKPDNFLMGLGK 1433.7457 
K140 DVKPDNFLMGLGKK 1561.8406 
K154 GLNVYIIDFGLAKK 1550.8940 
K155 GNLVYIIDFGLAKKYR 1870.0585 
K217 DDLESLGYVLMYFNLGSLPWQGLKAATK 3129.5965 
K221 AATKR 546.3358 
K224 QKYER 723.3784 
K263 FDDKPDYSYLR 1418.6586 
K294 QGFSYDYVFDWNMLKFGASR 2431.1175 
 
Table 3.2. The peptide mass of CK1 delta 1 was estimated using PeptideMass on the ExPASy 
server 
The following conditions were selected for the estimation:  
Selected enzyme: Trypsin 
Two missed cleavages 
All cysteines have been treated with Iodoaceamide to form carbamidomethyl-cysteine (Cys_CAM) 
Methionines have not been oxidized 
Using monoisotopic masses of the occurring amino acid residues and peptide masses as [M+H]+. 
 
Table 3.3. Peptide mass of SUMO-1 
Lysine in SUMO-1 
where trypsin is 
cleaving 
Peptide sequence Theoretical Mass 
(monoisotopic mass) 
K78 ELGMEEEDVIEVYQEQTGG 2154.9383 
 
Table 3.3. The peptide mass of the SUMO-1 peptide was estimated using PeptideMass on the 
ExPASy server 
The following conditions were selected for the estimation:  
Selected enzyme: Trypsin 
Zero missed cleavages 
All cysteines have been treated with Iodoaceamide to form carbamidomethyl-cysteine (Cys_CAM) 
Methionines have not been oxidized 
Using monoisotopic masses of the occurring amino acid residues and peptide masses as [M+H]+. 
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Table 3.4. Theoretical mass of SUMO-modified CK1 delta peptides 
SUMO 
site  
Theoretical 
mass of 
CK1/ 
SUMO 
peptide 
Mass/charge 
(m/z) 
2 charges 
Mass/charge 
(m/z) 
3 charges 
Mass/charge 
(m/z) 
4 charges 
Mass/charge 
(m/z) 
5 charges 
K14 4973.4426 n/a 1658.481 1244.111 995.488 
K38 5148.4616 n/a 1716.821 1287.865 1030.492 
K130 3569.6840 n/a 1190.561 893.171 714.737 
K140 3697.7789 n/a 1233.259 925.195 740.356 
K154 3686.8323 n/a 1229.611 922.458 738.166 
K155 4005.9968 n/a 1335.999 1002.249 801.999 
K217 5265.5348 n/a 1755.844 1317.132 1053.907 
K221 2938.4276 1469.714 980.143 735.357 588.485 
K224 2859.3167 n/a 953.772 715.579 572.663 
K263 3554.5969 n/a 1185.532 889.399 711.719 
K294 4567.0558 n/a 1523.019 1142.514 914.211 
 
 
Table 3.4. The theoretical mass of the different SUMO-modified CK1 delta peptides 
The mass was done using the following calculation. Mass of CK1 peptide + mass of SUMO-1 peptide -
1 (1 charge) -18 (H2O) = the theoretical mass of the CK1 delta/SUMO-1 peptide. 
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The mass spectra of the peptides can be found in Figures 3.69-71 and an overview of 
the modified peptides is shown at the bottom of each spectra. These results confirmed 
some of the SUMO-modification sites using the SUMOplot prediction server from 
Abgent and it looked very promising together with the results from Figure 3.67. All 
the lysines were checked in the CK1 delta structure (PDB: 4jjr) and found to be on the 
outside of the protein, except for K38, and therefore available for modification 
(Figures 3.72 and 3.73). K38 is in the active site, K130 is in front of the active site or 
in the catalytic loop and K224 in the docking site for p53.  
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Figure 3.69. Mass spectra of SUMO-modified CK1 delta peptide K38 and K130 
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Figure 3.70. Mass spectra of SUMO-modified CK1 delta peptide K140 and K224 
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Figure 3.71. Mass spectrum of the SUMO-modified CK1 delta K294 peptide 
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Figure 3.72. Highlighting the lysines in CK1 delta 1-317 which can be SUMO-modified according 
to the mass spectrometry results  
UCSF Chimera was used for the analysis (UCSF- a visualization system for exploratory research and 
analysis. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. J 
Comput Chem. 2004 Oct; 25(13):1605-12). PDB reference: Casein kinase 1d, 4jjr.  
Lysines are marked in red. The aspartic acid D128 important for proton transfer is marked in orange in 
A. The potential SIMs are marked in purple in B and C. With kind help from Dr Rajeka Perera. 
 
K38 conserved in all CK1 isoforms (α,γ,δ,ε)       K38 is in the active site 
K130 conserved in all CK1 isoforms       K130 in front of the active site/in the catalytic loop 
K140 conserved in CK1 γ, δ and ε              K140 ? 
K224 conserved in α, δ and ε        K224 is in the docking site for p53 
K294 conserved in α, δ and ε        K294 ? 
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Figure 3.73. Highlighting the lysines in CK1 delta 1-317 which can be SUMO-modified according 
to the mass spectrometry results 
UCSF Chimera was used for the analysis (UCSF- a visualization system for exploratory research and 
analysis. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. J 
Comput Chem. 2004 Oct; 25(13):1605-12). PDB reference: Casein kinase 1d, 4jjr.  
Lysines are marked in red. K46 is not on the surface but might still be available to SUMO-modification 
because of the C-terminal GG-finger in SUMO. With kind help from Dr Rajeka Perera. 
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3.5.9 Kinase activity of CK1 delta and SUMO-modified CK1 delta 
Kinase activity studies of CK1 delta 1-317 were performed in parallel to mapping the 
lysines involved in SUMO-modification. Because some of the SUMO-modified 
lysines in CK1 delta could provide some potential inhibition of the kinase activity and 
therefore be involved in the regulation of the kinase activity, kinase assay experiments 
were performed. 
The ADP-Glo kinase assay from Promega was used and an overview of the principles 
employed in the assay method is shown in Figure 3.74.  
A preliminary experiment was performed and the results can be seen in Figure 3.75. 
As expected, the activity of SUMO-modified CK1 delta 1-317 was lower than the 
unmodified kinase when used at a concentration of 20 ng. A purified CK1 delta 1-317 
from NEB was used as a positive control. Two different concentrations of the purified 
proteins were tested in the assay. For unmodified CK1 delta there was no difference 
in activity between 20 ng and 100 ng of protein. For the modified version of the 
kinase the activity went up when 100 ng was used, which was expected. Several 
experiments followed to optimise the conditions for the assay. The length of the 
kinase assay was varied from 20-40 minutes. The length of the assay depends on the 
ATP concentration used in the assay and the amount of ATP was varied from 50-150 
µM (Supplementary Figures 6.2, 6.3 and 6.4). The optimised conditions chosen were 
13 ng protein + 240 µM substrate + 150 µM ATP. It was important to make sure that 
nothing was limiting the assay. These experiments were done in parallel to mapping 
the SUMO-modified lysines in CK1 delta 1-317, so the protein purification 
optimisation also influenced the kinase assay. In Figure 3.76 it can be seen that the 
activity of the purified proteins went down compared to the bought kinase. This was 
due to changes in the purification protocol and taking out the Triton X-100. It did not 
appear to be a problem as the difference between the unmodified and the modified 
CK1 kinase was the important point of interest and the tendency remained the same. 
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Figure 3.74. Overview of ADP-Glo assay (figure adapted from Promega) 
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Figure 3.75. Kinase assay with CK1 delta 1-317 and SUMO-1 modified CK1 delta 1-317 
Kinase reaction: 13/26 ng CK1 + 240 µM CK1 peptide substrate [pS7} + 40 µM ATP 
Kinase reaction 30 minutes at room temperature 
ADP-Glo added 
Incubated 40 minutes at room temperature 
Kinase detection reagent added 
Luminescense measured for 23 minutes 
 
A: Standard curve 
B: Calibration curve created using the standard curve 
C: Kinase activity measured as luminescence 
D: ATP converted by the kinase - calibration curve (B) used to convert luminescence from (C) into 
ATP concentrations  
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Figure 3.76. Kinase assay with CK1 delta 1-317 and SUMO-1 modified CK1 delta 1-317 
Kinase reaction: 13 ng CK1 + 240 µM CK1 peptide substrate [pS7} + 150 µM ATP 
Kinase reaction 30 minutes at room temperature 
ADP-Glo added 
Incubated 40 minutes at room temperature 
Kinase detection reagent added 
Luminescense measured for 40 minutes 
 
A: Standard curve 
B: Calibration curve created using the standard curve 
C: Kinase activity measured as luminescence 
D: ATP converted by the kinase - calibration curve (B) used to convert luminescence from (C) into 
ATP concentrations  
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Because it proved difficult to map the modified lysines in the CK1 delta 1-317 kinase 
in the E.coli system, the planned experiments were slightly altered. It had been 
intended to mutate all the lysines important for SUMO-modification in CK1 delta 1-
317, then check the kinase activity and after that add the SUMO site back into the 
protein sequence, modify the kinase and check the activity again. That way it would 
have been possible to see how much each modified lysine inhibits the activity of CK1 
delta. It proved to be difficult not only because one of the modified lysines was in the 
active site in CK1 delta but also because SUMO modified other lysines in the E.coli 
system when CK1 delta 1-317 was mutated. 
The next step was to take the purified and modified CK1 kinase and use a purified 
SUMO protease to de-modify it and then to measure the activity before and after in 
the kinase assay. Some optimisation experiments were performed to find the length of 
time for the de-modification but also to see if the SUMO protease would cleave in the 
buffer needed for the following kinase experiment. It was even possible to see the 
cleavage in a Coomassie Blue stain although only faintly (Supplementary Figure 
6.5A). Another experiment was performed and this time the cleavage was checked in 
a western blot (Supplementary Figure 6.5B). 
For the final experiment the unmodified and modified CK1 delta 1-317 protein was 
purified again, then checked in a western blot (Figure 3.77A). The fractions marked 
with an arrow were concentrated and a SUMO protease assay performed (Figure 
3.77B). The protein before and after protease cleavage was used in the kinase assay 
(Figure 3.78). Again, as observed in all kinase experiments, the activity of the 
modified kinase was lower than the unmodified kinase. Surprisingly and very 
unexpectedly the activity went up for both the modified and unmodified kinase after 
treatment with SUMO protease. Another experiment was done to see if that would be 
the case for CK1 delta kinase from NEB as well. As can be seen in Figure 3.79, this 
was not the case. Here the activity went down after treatment with the SUMO 
protease. This is due to dilution of the kinase when adding the protease. One possible 
explanation could be that the purified kinase was not folded so well after taking away 
the Triton X-100 in the elution buffer. 
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Figure 3.77. SUMO protease cleavage of SUMO-modified CK1 delta 1-317 
BL21-Gold(DE3) cells co-transformed with pET-28a CK1 delta 1-317 SUMO mutant and pT-Trx-
AU(E1)-Ubc9(E2)-SUMO-1 were induced with 0.2 mM IPTG and left to grow overnight at 22 ˚C. 
Proteins were purified and several fractions were loaded onto a 4-20% polyacrylamide gradient gel, 
transferred onto a nitrocellulose membrane and the expressed proteins were detected using an anti-His 
mAb (A) or polyclonal rabbit anti-SUMO-1 antibodies after 4 hours’ cleavage with the SUMO 
protease at room temperature (B). 
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Figure 3.78. Kinase assay with CK1 delta 1-317,  SUMO-1 modified CK1 delta 1-317 and SUMO-
1 modified CK1 delta treated with SUMO protease 
Kinase reaction: 13 ng CK1 + 240 µM CK1 peptide substrate [pS7} + 150 µM ATP 
Kinase reaction 30 minutes at room temperature 
ADP-Glo added 
Incubated 40 minutes at room temperature 
Kinase detection reagent added 
Luminescense measured for 40 minutes 
 
A: Standard curve 
B: Calibration curve created using the standard curve 
C: Kinase activity measured as luminescence 
D: ATP converted by the kinase - calibration curve (B) used to convert luminescence from (C) into 
ATP concentrations  
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Figure 3.79. Activity of CK1 delta from NEB before and after treatment with the SUMO 
protease 
Kinase reaction: 13 ng CK1 + 240 µM CK1 peptide substrate [pS7} + 150 µM ATP 
Kinase reaction was left 20 minutes at room temperature  
ADP-Glo added 
Incubated 40 minutes at room temperature 
Kinase detection reagent added 
Luminescense measured for 35 minutes 
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3.5.10 Summary 
• SuPr-1 colocalised with DEFs where it hydrolysed SUMO from the 
filaments 
• SuPr-1 did not colocalise with the DEFs formed by the FADD 
phosphorylation mutants 
• The CK1 alpha LS protein has a very short half life in mammalian 
cells and mapping of the lysines necessary for SUMO modification 
was not possible 
• CK1 alpha LS and CK1 alpha splice variants were insoluble when 
expressed in E.coli 
• Lysines important for SUMO modification in CK1 alpha are 
conserved in CK1 delta and mapped in this isoform 
• Mass spectrometry analysis showed that CK1 delta 1-317 was 
SUMO-modified at K38, K130, K140, K224 and K294. 
• SUMO modification of CK1 delta inhibited its kinase activity and 
could potentially regulate the localisation of the kinase 
 
 
3.5.11 Conclusion and hypothesis  
CK1 alpha was insoluble when expressed in E.coli and instead the necessary lysines 
for SUMO-modification were mapped in CK1 delta, which is 76% identical to the 
amino acid level of CK1 alpha. The important and highly predicted lysines important 
for SUMO-modification are conserved in the isoforms. Mass spectrometry analysis 
was used to map the SUMO-modified lysines in CK1 delta 1-317. SUMO-
modification of the kinase inhibited its kinase activity and could potentially regulate 
the localisation of the kinase. 
 
3.5.12 Summary of the of the colocalisation studies 
DEFs were formed by overexpressed FADD and were used here to mimic interactions 
and functionality. DEFs localised to the ICD where they colocalised with NLS-
vimentin. PML NBs also localise to the ICD. Soon after the transfection of FADD 
and during early stages of the formation of the DEFs they colocalised with the PML 
NBs without disrupting them. At a later stage the results showed that a protein, which 
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could potentially be CK1 alpha, was recruited to the filaments and  SUMO-modified. 
CK1 might be recruited there already modified, although the results indicated that it 
occurs at a later time point. Early after transfection of FADD, CK1 was observed 
localising to the DEFs without colocalisation of SUMO. The colocalisation of CK1 
alpha and SUMO increased over time. This led to SUMO colocalising with the DEFs 
in the nucleus, which again led to other SUMO-modified proteins leaving the PML 
NBs all at different time points. When a SUMO-specific protease colocalised to DEFs 
there was no disruption of the PML NBs. This suggested that SUMO is needed for the 
disruption of the PML NBs. 
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4 Discussion 
4.1 The role of PML and PML NBs in FADD-mediated apoptosis 
4.1.1 Introduction  
In the following chapter all the results retrieved during my PhD are considered and 
used to try to explain the role of PML and PML NBs in FADD-mediated apoptosis. 
The FADD protein is involved in death receptor-mediated apoptosis and when 
overexpressed forms DEFs which are used here to mimic interactions and 
functionality. Phosphorylation of FADD, which is involved in cell cycle arrest, is 
highly regulated by the CK1 alpha kinase. A new role for PML and PML NBs in 
regulating kinase activity and therefore phosphorylation of proteins is proposed. 
 
4.1.2 Signal transduction pathways as part of a PML regulatory cascade 
As a part of functional studies of the PML protein done by Boddy et al., 1996, TFAF-
1 was identified as an interacting partner with PMLVI in a yeast two-hybrid assay. 
Nothing else had been published about TFAF-1 at the time and it was only when I 
started my project that this interaction began to be investigated further. 
Only a partial coding sequence of TFAF-1 was available at the beginning of my PhD 
studies and it is tempting to think that this clone was identified as a yeast two-hybrid 
interaction partner with TRAF4, hence the name ‘TRAF4-associated factor 1’ (TFAF-
1). However, this has not been corroborated experimentally. An anti-peptide antibody 
was generated against the TFAF-1 protein and used in colocalisation studies with 
PML. Neither endogenous nor overexpressed TFAF-1 colocalised with PML at PML 
NBs. TFAF-1 showed a diffuse distribution in the nucleus and the cytoplasm. A small 
fraction of PML is soluble in the nucleoplasm and this might be that fraction 
interacting with TFAF-1. The TFAF-1 protein contains a coiled-coil domain and this 
is probably the domain interacting with the coiled-coil domain in the PML protein. 
An interesting observation is that the domain structure of PML is very similar to the 
domain structure of TRAF4 and the family of TRAF proteins (Arch et al., 1998). All 
proteins contain the RING finger, several zinc finger motifs and a coiled-coil domain. 
When TFAF-1 was expressed as a fusion protein with the DsRed protein it formed 
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cytoplasmic filaments. These filaments were shown to be a part of the microtubule 
cytoskeleton and co-localised in the cytoplasm with DEFs formed by the FADD 
protein. This suggested that TFAF-1 could be involved in Fas-mediated apoptosis. 
The DsRed protein has strong oligomerisation properties and has been shown to form 
at least a tetramer or even a weak octamer (Baird et al., 2000). This could be the 
reason, together with TFAF-1 probably also being able to homo-oligomerize through 
its coiled-coil domain, for the DsRed/TFAF-1 filament formation. TFAF-1 
oligomerisation is unlikely on its own to form the filaments. The filament formation 
should then be observed when TFAF-1 is expressed with the FLAG-tag as well, yet 
this was not the case. Because the main interest was to investigate PML and PML 
nuclear bodies involved in apoptosis – and especially death receptor-mediated 
apoptosis – the colocalisation studies with the DEFs were investigated further. 
 
During the course of this study other publications have reported on TFAF-1, which 
now has alternate names such as FLJ14502, HSD11, chromosome 15 open reading 
frame 23 and SKAP (for Small Kinetochore Associated Protein). TFAF-1/SKAP is 
shown to be a microtubule-associated protein and localises to kinetochores and the 
mitotic spindle during mitosis. This localisation suggests a function in mitosis (Fang 
et al., 2009; Schmidt et al., 2010; Dunsch et al., 2011). Depletion of TFAF-1/SKAP 
delays the metaphase to anaphase transition, causes elongated spindle and partial 
segregation of chromosomes, and in some cells multipolar spindles are observed 
(Fang et al., 2009; Schmidt et al., 2010; Dunsch et al., 2011). 
It could be interesting to go back to the PML/TFAF-1 interaction studies, especially 
because it has been shown that PML -/- cells show abrogation in the mitotic entry and 
in the response to spindle depolymerisation (Daniels et al., 2004).  
 
4.1.3 PML nuclear bodies and death-effector filaments 
It was observed that pDsRed/TFAF-1 filaments colocalise in the cytoplasm with 
DEFs formed by FADD. Although the DsRed/TFAF-1 filaments were shown to be 
cytoplasmic filaments, the PML NB formation seemed to be altered in some of the 
pDsRed/TFAF-1-expressing cells. It was also observed that the DEFs formed by 
FADD changed the pattern of PML NBs, in that the DEFs took PML into small 
tracks. It was shown that DEFs are not only cytoplasmic filaments as published earlier 
(Siegel et al., 1998) but also went through the nucleus, where they localised to the 
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interchromosomal domains (ICD). PML has been shown to localise to the ICD 
together with other nuclear body components like Cajal bodies (Bridger et al., 1998). 
The DEFs did not disrupt Cajal bodies, HIPK2 bodies or nucleoli and the disruption 
seemed to be specific for PML NBs. 
Many different cell lines were tested after transfection of FADD but it did not seem to 
make any obvious difference to the formation of DEFs or track/filament formation of 
PML NBs. No difference was observed between U2OS and Saos-2 (p53 null cell line) 
cells. This suggested that p53 was not involved in the filament formation of DEFs and 
in the track/filament formation of PML NBs. A third cell line, HT1080 cells, were 
used in the studies but also here no difference was observed in the formation of DEFs 
or track/filament formation of PML NBs. 
Other major PML NB constituents such as SUMO, Sp100 and Daxx were also taken 
into the DEFs. SUMO associated with the DEFs in longer filaments and is probably 
the first member of the constituents to change from bodies to filaments. SUMO was 
already disrupted 24 hours after tranfection of FADD and so was PML, whereas 
Sp100 and Daxx followed later, around 48 hours after transfection. PML tracks and 
SUMO filaments colocalised in DEFs and PML NB disruption increased over time. 
Shortly after the transfection of FADD the DEFs formed along the ICD and PML 
NBs associated with them before disruption. DEFs were formed by overexpressing 
the FADD protein and were used here to mimic functionality. 
It was important to know if not only overexpressed FADD but also endogenous levels 
could disrupt the PML NBs. When cells were treated with apoptotic inducers FADD 
formed some kind of filaments which could be DEFs, but they did not disrupt the 
PML NBs. These filaments appeared to localise to the cytoplasm and therefore would 
be unable to disrupt the PML NBs.  
Caspase-8 has been shown to be recruited to the DEFs (Siegel et al., 1998). Full-
length caspase-8 cannot form DEFs; only the caspase-8 DED-AB and caspase-8 
DED-B are able (Siegel et al., 1998). It was interesting to see whether the PML NB 
disruption was dependent on the recruitment of caspases. This did not seem to be the 
case as filament/track formation of SUMO and PML was still observed in FADD-
transfected cells after treatment with caspase inhibitor z-VAD-fmk. When caspase-8 
DED-AB was overexpressed as a fusion protein with GFP it formed DEFs localising 
to the cytoplasm and therefore did not disrupt the PML NBs. Another observation 
made to confirm that the formation of DEFs and disruption of PML NBs was 
 185 
independent of caspases was when FADD transfections were done with CrmA. CrmA 
is a serpin-like protease inhibitor and blocks the activities of many caspases. Also 
here there was no difference in the formation of DEFs or in the disruption of PML 
NBs.  
Many viral proteins also disrupt PML NBs and the disruption observed here by the 
DEFs reminded one of the PML track formation caused by Ad5 E4 Orf3. DEFs and 
filaments/tracks formed by Ad5 E4 Orf3 showed a partial colocalisation, which meant 
PML tracks formed by the aforementioned proteins could be the same. PML II has 
been shown to interact with Ad5 E4 Orf3 (Hoppe et al., 2006) and maybe there was a 
possible but as yet unidentified interaction between the FADD DED and PML II.  
DEFs seemed to target the PML NBs specifically. PML -/- cells did not have PML 
NBs and in these cells the DEF formation appeared a little different. The DEFs were 
shorter and non-continuous and it was almost as if the formation was disrupted, which 
could suggest that PML or PML NBs are needed for the formation. Co-transfection of 
FADD and SUMO did not change the formation of DEFs in PML -/- cells, which 
suggested that it was not SUMO alone that was needed for the DEF formation. 
Phosphorylation of FADD has been shown to be involved in the non-apoptotic 
properties of FADD (Alappat et al., 2005) and PML -/- cells are protected from 
apoptosis induced by Fas and TNF (Wang et al., 1998b). It was therefore interesting 
to look at phosphorylation of FADD in PML -/- cells. Surprisingly, there was less 
phosphorylated FADD found in PML -/- cells compared to NIH/3T3 cells. This 
experiment might not be conclusive because two different cell lines from two 
different mouse strains were used. This was done because the PML wild type cell line 
was not available to us at the time when the experiments were performed. 
Phosphorylated FADD localises to the nucleus and not at the death receptors and is 
usually associated with its non-apoptotic properties (Zhang et al., 2008). As 
mentioned above, it was difficult to draw any conclusion from the experiment here. 
Another experiment was conducted in a PMLIII-inducible cell line but there was no 
difference detected in phosphorylation of transfected FADD before and after 
induction of PML. There was only one PML isoform expressed in the inducible cell 
line and a much better experiment would have been to deplete PML and then observe 
whether there was a difference in FADD phosphorylation and formation of DEFs 
before and after depletion. It was attempted to make a stable cell line where PML was 
depleted but it was not achieved during the studies.  
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4.1.4 PML nuclear bodies and FADD 
PML -/- KO mice and cells have an altered response to death receptor ligands so it 
was very interesting to observe that DEFs change the pattern of PML NBs. It was 
tempting to think that it was a direct interaction between PML and FADD. PML could 
associate with the DEFs and because PML is needed for the NB formation the other 
constituents could co-associate with PML. But this did not seem to be the case, at 
least not for the PML isoform tested here. No interaction was found between FADD 
and PML IV (personal communication with T.G. Hofmann). A better option would 
probably have been to test for an interaction between the isoform PML II and FADD 
after finding a partial colocalisation of the the DEFs and the filaments formed by Ad5 
E4 Orf3. 
Truncated FADD constructs and FADD mutants were made to try to map the domain 
in FADD necessary for the disruption of the PML NBs. The FADD DED was 
sufficient to change the localisation of PML and Sp100. The pattern of PML and 
Sp100 looked very much like the PML tracks formed by Ad5 E4 Orf3. The dominant 
negative mutant FADD-DN containing the death domain (DD) and the C-terminus of 
FADD showed a diffuse distribution and did not change the localisation of PML NBs. 
These results suggesed that the DED and the formation of DEFs were necessary for 
the disruption of the PML NBs. Earlier results suggested that caspase activation was 
not important for PML NB disruption. This was confirmed again by transfecting the 
mutant FADD F25G. This mutant has a mutation in the DED and reduced binding to 
caspase-8. It was able to form DEFs in some of the transfected cells and to disrupt the 
PML NBs. Again, caspase activation did not seem to be necessary for the disruption 
of the PML NBs.  
Because SUMO colocalised to the DEFs in the nucleus it was conjectured that it 
could be FADD getting SUMO-modified. Two potential lysines, K35 which is a part 
of a potential NLS, and K125, were mutated to arginines but no change in the PML 
NB track/filament formation was detected. Nuclear fractions from FADD-transfected 
cells were loaded onto a polyacrylamide gel and a western blot was done using anti-
FADD antibodies, but also here no SUMO-modified FADD was observed. This 
concurs with the literature where no interaction or SUMO-modification of FADD has 
 187 
been reported and suggested that another protein was being recruited to the DEFs and 
then SUMO-modified, or that it could be recruited already SUMO-modified.  
Independent studies using only the C-terminus of FADD containing the DD result in 
the dominant negative mutant FADD-DN which can bind the death receptor but not 
caspase-8 because of the missing DED. It is possible to disrupt this interaction with 
the death receptor Fas by mutating the alanine A174 in the DD to a proline. A174P is 
still able to bind to two other interacting partners, TRADD and RIP, but is unable to 
induce apoptosis (Morgan et al., 2001). This mutation is also in the kinase-binding 
domain of FADD and the mutant FADD-DN A174P has been shown to be less 
phosphorylated compared to wild-type FADD (Alappat et al., 2005). Interestingly this 
mutant FADD A174P localised partially to PML NBs. A possible explanation could 
be that FADD might be recruited to PML NBs under certain conditions where it 
interacts with CK1 alpha before getting phosphorylated. FADD A174P could still be 
recruited to PML NBs but the phosphorylation is disrupted and FADD stays in the 
PML NBs. 
Phosphorylation of FADD is mapped to the serine 194 (Scaffidi et al., 2000). 
Phosphorylation of FADD is important for cell cycle arrest in G2/M and thereby in 
regulating the apoptotic properties of FADD (Alappat et al., 2003). The serine was 
mutated to an alanine to create a phospho-dead mutant. Two other two mutants were 
made as well, serine to glutamic acid or aspartic acid, to mimic phosphorylation. The 
interesting results showed that FADD had to be phosphorylated to disrupt the PML 
NBs. The DEFs formed by the phospho-mutants were still nuclear and the PML NBs 
colocalised with the filaments but they were not disrupted. No obvious difference 
between phosphorylated and unphosphorylated DEFs was detected. Phosphorylation 
of the DEFs seemed to be necessary for the disruption of the PML NBs. These results 
also suggested that the disruption of the PML NBs is specific and is not just the DEFs 
penetrating the nucleus. Had the latter been the case one would have expected it to 
occur with the unphosphoryltated DEFs as well. The DEFs mimic interactions and 
functionality but filament formation probably only occurs when FADD is 
overexpressed and not with endogenous levels of the FADD protein.  
 
4.1.5 The role of PML in FADD phosphorylation 
HIPK3 was the first kinase published to phosphorylate FADD (Rochat-Steiner et al., 
2000). HIPK3 is shown to partially colocalise with PML and also phospho-FADD. 
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This was the perfect candidate to phosphorylate FADD maybe even at the PML NBs, 
but unfortunately it was not possible to reproduce the original results.  
The focus was therefore on casein kinase 1 alpha (CK1 alpha), a serine/threonine 
kinase and the second candidate to be published to phosphorylate FADD (Alappat et 
al., 2005). CK1 alpha is expressed as four different splice variants with or without two 
inserts, L and S. The L insert contains a potential NLS and the longest isoform LS 
was chosen for this study. All four splice variants have been shown to phosphorylate 
FADD. CK1 alpha LS localises to splicing speckles when overexpressed (Gross et al., 
1999). The CK1 family of proteins is highly conserved and has been shown to be 
involved in cell cycle progression, cell differentiation and proliferation, DNA repair 
and chromosome segregation (Knippschild et al., 2005). 
Both overexpressed and endogenous CK1 alpha was recruited to the DEFs where it 
colocalised with SUMO in many of the transfected cells. SUMO was not always 
detected in the filaments and this suggested that it could be a cell cycle-dependent 
phenomenon or that SUMO could be recruited later, after phosphorylation of FADD. 
Interestingly, CK1 alpha was not recruited to any of the DEFs formed by the 
phospho-FADD mutants. It was expected that CK1 alpha LS would colocalise with 
the phospho-mutant DEFs but just not phosphosrylate FADD. The serine 194 is not 
localised in the kinase binding domain so why would it interrupt the binding? These 
results were consistent with the observation that FADD had to be phosphorylated to 
disrupt the PML NBs and further strengthened the enquiry. Is it SUMO-modified 
CK1 alpha observed in the DEFs? SUMO modification of the kinase, potentially at 
PML NBs, could regulate the localisation and the activity of the kinase. 
 
4.1.6 SUMO-modification of CK1 alpha LS in mammalian cells 
By using servers to predict SUMO-modification sites in the CK1 alpha LS protein, 
several potential sites were found. SUMO-modification of CK1 alpha LS can be 
another way of regulating localisation and activity of CK1 just as autophosphorylation 
has been shown to regulate the activity of several CK1 family members (Budini et al., 
2009; Rivers et al., 1998). A SUMO-specific protease named SuPr-1 is recruited to 
the DEFs and the colocalisation of SuPr-1 and DEFs resulted in no disruption of the 
PML NBs. This suggested that SUMO is needed for the disruption of PML NBs. It is 
probably a case of SUMO leaving the PML NBs first and then all other NB 
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components following. The inactive mutant SuPr-1 C466S colocalised to the DEFs 
but it did not hydrolyse SUMO from them and the PML NB disruption was still 
observed. As expected, neither the active SUMO protease nor the inactive form were 
recruited to the DEFs formed by the phospho-FADD mutants. 
From all the colocalisation studies it was clear that the colocalisation of the DEFs and 
the PML NBs increased over time. The DEFs are forming in the ICD and the PML 
NBs are colocalising with the DEFs. A protein is recruited to the DEFs, which might 
be CK1 alpha, and is being SUMO-modified. This causes SUMO to leave the bodies 
and all the other SUMO-modified PML NB components follow at different times 
(Summary in Figure 4.1). 
 
 
 
 
Figure 4.1. Overview of DEF formation and PML NB disruption 
A: DEFs are forming in the ICD. 
B: DEFs colocalise with PML NBs in the ICD. 
C: A protein, possibly CK1 alpha, is recruited to the DEFs and is being SUMO-modified. This results 
in colocalisation of SUMO and DEFs. 
D: SUMO is recruited away from the PML NBs and other PML NB components follow. This results in 
colocalisation of other SUMO-modified PML NB components and DEFs. 
 
CK1 alpha LS was overexpressed with or without SUMO in different mammalian cell 
lines to try and confirm the predicted SUMO-modification of CK1 alpha. SUMO-1,2 
and 3 were tested together with eleven CK1 alpha LS SUMO mutants, but the results 
were inconclusive. Higher migrating bands, which could be SUMO-modified CK1 
alpha, were detected after cotransfection of CK1 alpha LS and either EGFP-SUMO-1 
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or MLV-SUMO-1. It proved to be very difficult to map the lysines involved in the 
SUMO modification of CK1 alpha LS using mammalian cells because the CK1 alpha 
LS splice variant has a very short half-life of only 100 minutes (Burzio et al., 2002). 
This resulted in very little difference observed between the many mutants tested with 
and without SUMO in western blots. Only one mutant showed any difference in 
immunofluorescence studies. CK1 alpha LS K138R caused an increase in SUMO 
filaments after co-transfection with FADD. This could be due to the mutant being 
more active and phosphorylating FADD more efficiently and then following that, 
becoming SUMO-modified.  
These experiments could possibly be repeated with inhibitors of deSUMOylases. This 
could lead to a more conclusive result. Another experiment, such as co-
immunoprecipitation studies between CK1 and SUMO, could also lead to more 
specific results. Inhibitors of deSUMOylases were not used routinely when the 
experiments were conducted for this study. 
 
4.1.7 Expression and SUMO-modification of CK1 alpha LS in E.coli 
A new SUMO-modification system using E.coli was set up to try to map the 
necessary lysines in CK1 alpha LS. In this system the SUMO-modification machinery 
is expressed from one plasmid and the protein of interest from another plasmid. Full-
length CK1 alpha LS and three other shorter constructs – CK1 alpha aa 1-325 (the 
shortest splice variant); a mutant CK1 alpha aa 1-325 S313G; and a truncated CK1 
alpha aa 1-301 – were all tested under many different conditions. Cell-free expression 
systems were tested to avoid potential degradation or toxicity. Different temperatures 
were tested for better protein folding, but no matter what changes were made the CK1 
alpha isoform stayed mainly insoluble and therefore unable to be SUMO-modified.  A 
mutant strain of BL21 which has been optimised for expression of insoluble proteins 
in a soluble form was tested but also here the CK1 alpha remained insoluble. 
CK1 alpha is known to be 76% identical to the amino acid level of CK1 delta (Gross 
and Anderson, 1998) and most of the lysines important for SUMO modification are 
conserved through the CK1 family as well. CK1 delta has been used for 
crystallisation studies and this isoform was chosen for the SUMO-modification 
studies (Longenecker et al., 1996; Zeringo et al., 2013). 
In the meantime it is possible to buy purified CK1 alpha S protein. The CK1 alpha S 
protein is expressed in insect cells, which suggest that the CK1 protein needs post-
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translational modification that is not available in E.coli for proper protein folding and 
solubility.  
 
4.1.8 Expression and SUMO-modification of CK1 delta in E.coli 
CK1 delta 1-317 was soluble and SUMO-modified by SUMO-1 and SUMO-3 in the 
E.coli expression system. SUMO-1 was chosen for the expression and SUMO-
modification studies as SUMO-1 does not make SUMO-chains (Bayer et al., 1998), 
and the higher molecular bands would each count for one SUMO attachment. 
Optimisation of expression and SUMO-modification of CK1 delta 1-317 was 
conducted and a better purification was seen using a Cobalt-affinity column, which 
has a very low non-specific binding. After adding a C-terminal His-tag to the protein 
as well as having the N-terminal His-tag, a much better binding to the affinity column 
was found. This could be due to folding of the CK1 delta protein and the N-terminal 
His-tag not being properly exposed. The protocol used from (Burzio et al., 2002) uses 
1 % Triton X-100 in the elution buffer. This caused the purified protein to produce an 
indisctict band pattern when run on a polyacrylamide gel and made it very difficult to 
distinguish between the higher-migrating SUMO-modified bands. Therefore the 
elution buffer was used without Triton X-100. This causes the protein to be more 
likely to aggregate and all assays were carried out on the same day of purification or 
on the day after.  
Several CK1 delta 1-317 SUMO mutants were created in the hope of being able to 
map the lysines involved in the modification. Many overnight expression and 
modification experiments were performed but it became clear from the western blots 
that as soon as mutations were introduced into CK1 delta 1-317, SUMO started to 
modify other non-specific lysines in the CK1 delta 1-317 protein. Because of this, 
mass spectrometry of the SUMO-modifed CK1 delta protein was used to identify the 
crucial lysines. In parallel, expression and SUMO-modifications studies were 
continued at shorter time points as this made it less likely to force-modify the protein 
and SUMO less likely modify other unspecific lysines. After 5-6 hours’ expression 
instead of overnight, (as described by Uchimura et al., 2004 and Saitoh et al., 2009) it 
looked far more promising, although it was still not exactly clear which lysines are 
modified. It was only after analysis of the mass spectrometry data was performed that 
a much clearer result appeared. 
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4.1.9 Mass spectrometry of SUMO-modified CK1 delta 1-317 from E.coli 
The mass spectrometry of SUMO-modifed CK1 delta 1-317 was undertaken by Dr 
Paul Hitchen in the CISBIO Mass Spectrometry Core Facility at Imperial College 
London, but all the data analyses calculating potential charges and masses I conducted 
manually and checked them in the mass spectrometry dataset. CK1 delta was found to 
be SUMO-modified at K38, which is the active site and involved in binding of ATP. 
When looking at the surface structure of the CK1 delta protein in Figure 3.73 (p. 171) 
it is clear that this lysine is hidden in the active site, but because the GG-finger in 
SUMO-1 is quite long and flexible it still appears to be possible to modify K38. K38 
is a SUMO consensus site and will probably be modified if the lysine is exposed and 
available to the SUMO-modification machinery. This was the only lysine that was 
easily mapped as SUMO-modified in the E.coli system using western blotting. The 
other lysines detected in the mass spectrometry analysis are all exposed and on the 
surface of the CK1 delta protein. K130 is located in the catalytic pocket and very 
close to the aspartic acid D128 (Figure 3.72A, p. 170), which is the catalytic base 
(Longenecker et al., 1996; Hanks, 2003). SUMO-modification at K130 could regulate 
the activity of the kinase by interfering with the catalytic domain. This is consistent 
with the observation of the CK1 alpha LS K138R mutant where more SUMO 
filaments are formed after co-transfection of FADD, likely due to higher activity of 
this mutant. Absence of SUMO modification at this lysine in CK1 results in less 
inhibition of the catalytic loop and therefore higher kinase activity. K224 is next to a 
region that is disordered (Figure 3.72, p. 170) and this region is thought to be able to 
adopt conformation to unphosphorylated substrates (Longenecker et al., 1996). 
Interestingly, this region has been mapped as a docking site for p53 (Venerando et al., 
2010). Both CK1 delta and CK1 alpha phosphorylate p53 at the N-terminus 
(Venerando et al., 2010). CK1 phosphorylation of p53 stabilises p53 through 
inhibition of MDM2 (Bode and Dong, 2004). This SUMO-modification site, K224, 
could potentially regulate the phosphorylation of p53 and therefore its activity. 
Interestingly, K224 is an arginine in the CK1 gamma isoform and this isoform does 
not phosphorylate p53 (Venerando et al., 2010) and therefore does not need this 
regulation. Another interesting observation is that K224 is a part of a potential NLS. 
Lysines involved in SUMO-modification are often part of a NLS, as shown for K490 
in PML (Duprez et al., 1999). SUMO modification of the last two lysines, K140 and 
K294, do not show any obvious regulation, yet these sites could potentially under 
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certain conditions be modified by SUMO-2/3 and thus potentially be targeted for 
degradation. This is similar to PML, which is modified by SUMO-2/3 at K160 after 
arsenic treatment and targeted for degradation (Lallemand-Breitenbach et al., 2008). 
RNF4 was found to bind to and ubiquitinate SUMO-2 chains (Tatham et al., 2008). 
This could be another way of regulating the kinase activity and therefore protein 
phosphorylation. 
All 11 potential SUMO-modifications sites in CK1 delta were checked in the mass 
spectrometry dataset but only five were found. These five sites are all predicted using 
the SUMOplot analysis program from Abgent. The sites K38, K130 and K224 are 
sites that correspond to the sites predicted in the isoform CK1 alpha.  
CK1 delta contains three potential SIMs, two of them overlapping. CK1 delta could 
interact with SUMO and at the same time be covalently modified, as suggested for the 
yeast kinase SNF1 (Simpson-Lavy and Johnston, 2013). SUMO could potentially 
interact with CK1 delta and at the same time covalently modify a lysine in another 
CK1 protein and thereby inactivate the kinase. The CK1 alpha protein also contains a 
SIM and the proposed regulation could be the same for this isoform. 
 
4.1.10 Kinase activity of CK1 delta and SUMO-modified CK1 delta. 
Kinase activity of CK1 delta and SUMO-modified CK1 delta was tested using the 
ADP-Glo kinase assay from Promega. A purified CK1 delta protein bought from NEB 
was used as a positive control. As expected, the SUMO-1-modified CK1 delta kinase 
showed less activity compared to the unmodified kinase. It was not possible to modify 
CK1 delta fully. Usually around 50 % of the kinase is modified by SUMO but only 
two out of the six sites detected in MS interfere with the active site. This correlates 
with the inhibition measured in the kinase assay where a reduction in Figure 3.75 (p. 
174) was detected from 35 µM ATP for CK1 delta 1-317 to 29 µM ATP for CK1 
delta 1-317/SUMO-1. SUMO-modification varied slightly between each purification 
but the tendency was always consistent. The inhibition by SUMO of the kinase 
activity varied from 17% to 35%. It would have been preferable to purify 100% 
SUMO-modified CK1 delta and measure it together with the unmodified kinase in the 
assay, perhaps by expressing a His-tagged SUMO protein. However, this is not 
possible because SUMO modifies a large variety of proteins and the purification 
would end up with not only SUMO-modified CK1 delta but also many others being 
purified. 
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It would have been ideal to mutate every single lysine detected in the mass 
spectrometry analysis as a SUMO-modification site and then test the activity of the 
kinase with and without this lysine modified to see how much SUMO-modification at 
each particularly lysine inhibits the activity of the kinase. This was unfortunately not 
possible as SUMO started modifying other lysines in the mutated CK1 delta kinase in 
the E.coli system. The activity was therefore tested with the SUMO-modified kinase 
and compared to the unmodified kinase and then compared again after treatment with 
a SUMO-specific protease to de-modify the kinase. The activity of the modified CK1 
delta kinase was then expected to rise to the level of the unmodified kinase after de-
modification. This was the case for the modified CK1 delta kinase: the activity went 
up after protease treatment by 25%. The problem was that the activity also went up by 
32% for the unmodified kinase when the protease was added. This was probably due 
to the purified CK1 kinases not being absolutely folded or more likely aggregating 
due to the exclusion of Triton X-100 from the elution buffer. Another experiment was 
performed to see if the activity increases for the bought CK1 delta after treatment 
with the SUMO protease as well, but this was not the case. After adding the protease 
to the bought CK1 delta the activity went down by 10%, probably due to dilution of 
the kinase by adding the protease. Further experiments are planned to optimise the 
protein purification for the kinase assay to ensure that the purified protein is well-
folded and not aggregating. The protease treatment of the SUMO-modified kinase can 
then be repeated under optimal conditions. 
Preliminary data showed that CK1 delta is SUMO-modified and the modification 
alters the activity. Because the protein sequence is highly conserved throughout the 
CK1 family it is tempting to assume that the lysines modified in CK1 delta could be 
modified in CK1 alpha as well. SUMO-modification might alter not only the activity 
of the kinase but also the localisation. SUMO modification could potentially also 
regulate autophosphorylation of the kinases and thus also regulate the kinase activity. 
These results add an entirely new level to the regulation of the CK1 kinase activity. 
Further mass spectrometric experiments are planned which will select for the peptides 
of interest identified in the first round of MS experimentation. The peptides will be 
selected for tandem mass spectrometry (MS/MS) in order to obtain sequence 
information on the peptides of interest, thus confirming the presence of any SUMO 
modification on the peptide, as predicted by the observed peptide molecular mass in 
the first round of experimentation. 
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Futher in vivo studies should be done to confirm the SUMO modification of CK1. 
Colocalisation studies in different mammalian cell lines should be performed and co-
immunoprecipitations should be conducted using overexpressed and endogenous CK1 
and SUMO. Again, these experiments could possibly be repeated with inhibitors of 
deSUMOylases. 
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5 Conclusion 
Preliminary data showed CK1 delta is modified by SUMO-1 in the E.coli system. The 
crucial lysines are conserved in the CK1 alpha isoform as well. SUMO-modification 
alters the activity of the kinase, and PML NBs might be where SUMO modification 
takes place. FADD is phosphorylated by CK1 alpha. CK1 alpha might be modified by 
SUMO to regulate the activity of the kinase. The SUMO-modification of CK1 alpha 
might be altered in PML -/- cells because of the missing PML NBs and this could 
result in a deregulation of phosphorylated FADD. This again could potentially lead to 
the altered Fas-mediated apoptosis in PML -/- cells. Another factor which could 
contribute to the altered response in PML -/- cells is that the missing PML is not 
interacting with the Fas receptor and is thereby destabilising the 
Fas/FADD/Procaspase-8 complex, as speculated by (Tao et al., 2011). Another 
possibility is an unidentified interaction between PML II and FADD DED, which is 
consistent with the speculation above. The B-box in PML could interact with the Fas 
receptor and the C-terminus of PML II could interact with the DED in FADD, 
stabilising the Fas/FADD/Procaspase-8 complex. 
It could potentially be two separate events observed when the DEFs are disrupting the 
PML NBs: one where CK1 alpha is SUMO-modified after phosphorylation of FADD 
causing the other PML NB component to leave the bodies as well. The other event 
could potentially be FADD DED interacting with the C-terminus of PML II causing 
the disruption of the bodies. 
Another positive aspect of the results here is that PML has been shown to interact 
with CK1 delta in cells after treatment with the DNA damage-inducing reagent 
Doxorubicin. CK1 delta is recruited to the PML NBs upon DNA damage where it 
interacts with PML and p53, facilitating phosphorylation of p53 and protecting p53 
from inhibition by Mdm2 (Alsheich-Bartok et al., 2008). Also here it could be 
speculated that CK1 delta might be SUMO-modified after phosphorylation of p53 or 
that CK1 is SUMO-modified first and is then taken to the PML NBs. SUMO might 
potentially modify not only the active site K38 but also the active pocket K130 as 
well as K224 in the p53 docking site, which could play very important roles here and 
regulate phosphorylation of p53 and p53 activity. 
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The overall conclusion is that preliminary results show an unexplored area where the 
SUMO-modification of kinases adds a new regulation and therefore alters 
phosphorylation of proteins. This regulation might take place at PML NBs and this 
also adds another interesting aspect to the already very complex story of PML NBs 
and PML NB constituents. (SUMO-modification of CK1 isoforms and proposed 
regulations summarised in Figure 5.1.) 
 
 
 
Figure 5.1. SUMO-modification of CK1 members and proposed regulations 
A: SUMO-modification of CK1 alpha might take place at PML NBs. This could potentially regulate 
phosphorylation of FADD and therefore cell cycle arrest and apoptosis. 
B: SUMO-modification of CK1 delta might take place at PML NBs. This could potentially regulate the 
phosphorylation of p53 and therefore cell cycle arrest, senescence, DNA repair and apoptosis. 
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6 Supplementary material 
 
 
Supplementary Figure 6.1. Testing wash and elution conditions of SUMO-modified CK1 delta 1- 
317 
BL21-Gold(DE3) cells transformed with pET-28a CK1 delta 1-317 with or without pT-Trx-AU(E1)-
Ubc9(E2)-SUMO-1, induced with 0.2 mM IPTG and left to grow overnight at 15 ˚C. Protein was 
purified and several fractions were loaded onto a 4-20% polyacrylamide gradient gel and stained with 
either Coomassie Blue (A) or proteins were transferred onto a nitrocellulose membrane and detected 
using a rabbit anti-SUMO-1 antibody (B).  
 199 
 
 
Supplementary Figure 6.2. Testing protein concentrations with CK1 delta 1-317 and SUMO-1 
modified CK1 delta 1-317 
Kinase reaction: 13/26 ng CK1 + 240 µM CK1 peptide substrate [pS7} + 40 µM ATP 
Kinase reaction 30 minutes at room temperature 
ADP-Glo added 
Incubated 40 minutes at room temperature 
Kinase detection reagent added 
Luminescense measured for 40 minutes 
 
A: Standard curve 
B: Calibration curve created using the standard curve 
C: Kinase activity measured as luminescence 
D: ATP converted by the kinase - calibration curve (B) used to convert luminescence from (C) into 
ATP concentrations  
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Supplementary Figure 6.3. Testing the length of the  kinase reaction and concentration of ATP in 
a kinase assay with CK1 delta 1-317 (NEB) 
Kinase reaction: 13 ng CK1 + 240 µM CK1 peptide substrate [pS7} + 50, 100, 150 µM ATP 
Kinase reaction 20 or 30 minutes at room temperature 
ADP-Glo added 
Incubated 40 minutes at room temperature 
Kinase detection reagent added 
Luminescense measured for 35 minutes 
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Supplementary Figure 6.4. Kinase assay with CK1 delta 1-317 and SUMO-1 modified CK1 delta 
1-317 
Kinase reaction: 13 ng CK1 + 240 µM CK1 peptide substrate [pS7} + 80 µM ATP 
Kinase reaction 15 minutes at room temperature 
ADP-Glo added 
Incubated 40 minutes RT 
Kinase detection reagent added 
Luminescense measured for 31 minutes 
 
A: Standard curve 
B: Calibration curve created using the standard curve 
C: Kinase activity measured as luminescence 
D: ATP converted by the kinase - calibration curve (B) used to convert luminescence from (C) into 
ATP concentrations  
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Supplementary Figure 6.5. SUMO protease cleavage of SUMO-modified CK1 delta 1-317 
BL21-Gold(DE3) cells co-transformed with pET-28a CK1 delta 1-317 SUMO mutant and pT-Trx-
AU(E1)-Ubc9(E2)-SUMO-1 were induced with 0.2 mM IPTG and left to grow overnight at 22 ˚C.  (A) 
Proteins were purified and several fractions were concentrated (A: lane 1 and 2). SUMO protease 
cleavage of the purified proteins was performed (A: lane 3 and 4) and loaded onto a 4-20% 
polyacrylamide gradient gel and stained with Coomassie Blue. (B) A time course was done to find the 
optimal time needed for full cleavage of the SUMO-modified CK1 delta 1-317. Uncleaved and cleaved 
protein was loaded onto a 4-20% polyacrylamide gradient gel, transferred onto nitrocellulose and 
proteins were detected using rabbit anti-SUMO-1 antibodies.  
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